An LC-MS/MS-based approach for analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using the biomarker prostate-specific antigen (PSA) as example by Lang, Robert
Aus dem Institut für Laboratoriumsmedizin 
 
der Ludwig-Maximilians-Universität München 
 
 
Direktor: Univ. Prof. Dr. med. Daniel Teupser 
 
 
 
An LC-MS/MS-based approach for analysis of site-specific 
core-fucosylation of low-concentrated glycoproteins in 
human serum using the biomarker prostate-specific 
antigen (PSA) as example 
 
 
 
Dissertation 
 
zum Erwerb des Doktorgrades der Humanbiologie 
 
an der Medizinischen Fakultät der 
 
Ludwig-Maximilians-Universität zu München 
 
 
 
 
 
 
 
 
 
 
 
 
 
vorgelegt von 
 
Robert Lang 
 
aus 
 
Leipzig 
 
 
2018 
  
  
 
Mit Genehmigung der Medizinischen Fakultät der Universität München 
 
 
 
 
 
 
Berichterstatter:   Prof. Dr. med. Michael Vogeser   
 
     
 
 
Mitberichterstatter:   Prof. Dr. rer. nat. Thomas Carell 
 
    Prof. Dr. med. Raphaela Waidelich 
  
    Prof. Dr. med. Jürgen Ruland 
 
 
 
Dekan:     Prof. Dr. med. dent. Reinhard Hickel   
 
 
Tag der mündlichen Prüfung:  19.12.2018  
 
  
  
 
Eidesstattliche Versicherung 
 
 
Robert Lang 
 
 
 
Ich erkläre hiermit an Eides statt,  
dass ich die vorliegende Dissertation mit dem Thema 
 
 
„An LC-MS/MS-based approach for analysis of site-specific core-fucosylation of low-
concentrated glycoproteins in human serum using the biomarker prostate-specific antigen 
(PSA) as example“ 
 
 
selbstständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und alle 
Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als solche kenntlich 
gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle einzeln nachgewiesen habe. 
 
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in ähnlicher Form 
bei einer anderen Stelle zur Erlangung eines akademischen Grades eingereicht wurde. 
 
Robert Lang 
 
München, den 08.06.2018  
  
 
Acknowledgements 
First of all, I would like to thank Prof. Dr. Michael Vogeser from the University Hospital at the Ludwig-
Maximilians-Universität in Munich for the external supervision. I am very grateful for his academic 
guidance and support. Equally, I would like to thank Dr. Andreas Leinenbach for giving me the 
opportunity to perform my PhD in his working group and for the great technical support during the last 
three years. I also want to thank Dr. Uwe Kobold for offering the PhD position in the “Instrumental 
analytics” division. I kindly thank Dr. Johann Karl and Dr. Magdalena Swiatek-de Lange for the 
financial support and their input in many lively discussions in the late afternoons.  
 
I am very grateful to my colleagues Andreas Huber and Thomas Duelffer for introducing me into the 
LC-MS instrumentation in our group and for extremely valuable advices in the daily laboratory routine. 
Special thanks also go to Dr. Eirini Frylingou for her assistance in LTQ-FTICR measurements as well 
as to Michael Kampe and Marie Steger for their guidance in several MALDI-TOF tasks. My sincere 
thanks go to Monika Briechle und Gertrud Freisl. Without their, the everyday life in the laboratory 
would not be so comfortable. I also thank Ekkehard Rudy and Jo Anne Wright for their support in the 
procurement of laboratory equipment and reagents. Of course, I warmly thank Lisanne Grund, Robert 
Gossmann, Stefanie Schedlbauer, Manuela Collins, Katrin Gradl, Milou van Rooij, Sandra Fleischer, 
Angela Puhlmann, Ulrike Schauer, Pia Eberhardt, Korbinian Huber, Thomas Hausler, Christine 
Wintterle-Roehm, Tahira Abubaker, Matthias Metz, Ingrid Munk, Rupert Schmid, Dr. Martin Rempt, 
Dr. Christian Geletneky, Dr. Judith Taibon, Dr. Holger Busskamp, Stephan Pongratz, Dr. Frank 
Wedekind, and Dr. Julian Hofmann for the very friendly working atmosphere in our division.  
 
My sincere thanks go to Dominic Knoblauch from the group of Dr. Glòria Tabarés for his MS support 
in intact protein measurements. I also thank Dr. Tobias Oelschlaegel for providing the lectin-
separated PSA material and Dr. Markus Haberger for the LC-MS-based N-glycan analysis of PSA. 
I thank Leopold von Proff for surface plasmon resonance measurements. Many thanks go to 
Dr. Heike Wegmeyer for providing clinical and pathological information of patient samples. I thank 
Peter Stegmueller and Dagmar Knodel for the Elecsys® measurement of total and free PSA levels in 
PSA spiked-in serum samples and human specimens. Thanks to Dr. Sandra Rutz for her good 
advices during the method optimization phase. I also thank Dr. Lars Hillringhaus for the synthesis of 
several peptide standards. 
 
Last, my hearty thanks go to my mother, Kerstin, and my friends for their joyful and constant support. 
 
   Table of contents 
5 
 
Table of contents 
 
Table of contents...................................................................................................... 5 
Table of abbreviations ............................................................................................. 9 
Abstract ................................................................................................................... 13 
Zusammenfassung ................................................................................................. 15 
 
Chapter I: Aim of the thesis ................................................................................... 17 
 
Chapter II: Theoretical part .................................................................................... 19 
1. Biological samples – Focus on blood and its fractions ................................ 20 
2. Structure of proteins ........................................................................................ 22 
2.1. Amino acids – Building blocks of proteins ............................................................................. 22 
2.2. The peptide bond .................................................................................................................. 23 
2.3. Levels of protein structures ................................................................................................... 24 
3. N-linked glycosylation of proteins .................................................................. 25 
3.1. Biosynthesis of N-glycans and their major structural types .................................................. 25 
3.2. Strategies for analysis of protein N-glycosylation ................................................................. 26 
3.2.1. Analysis of intact glycoproteins ..................................................................................... 26 
3.2.2. Analysis of glycopeptides .............................................................................................. 28 
3.2.3. Analysis of glycans ........................................................................................................ 29 
4. Hybrid immunoaffinity mass spectrometry (IA-MS) ...................................... 32 
4.1. Immunoassays (IA) ............................................................................................................... 32 
4.2. Triple quadrupole mass spectrometry (TQMS) ..................................................................... 33 
4.3. Opportunities of hybrid IA-MS-based assays ........................................................................ 35 
 
Chapter III: Development of an LC-MS/MS-based strategy for analysis of site-
specific core-fucosylation of prostate-specific antigen (PSA) in the low ng/mL 
range in human serum ........................................................................................... 37 
1. Introduction ...................................................................................................... 38 
1.1. The role of human protein glycosylation ............................................................................... 38 
1.2. Prostate-specific antigen (PSA) ............................................................................................ 38 
1.3. Approaches for the analysis of core-fucosylated proteins .................................................... 39 
2. Experimental section ....................................................................................... 41 
2.1. Reagents and materials ........................................................................................................ 41 
2.2. Instruments and equipment ................................................................................................... 41 
2.3. PSA spiked-in serum samples and human specimen .......................................................... 42 
   Table of contents 
6 
 
2.4. Endoglycosidase selection .................................................................................................... 43 
2.5. Protease and surrogate peptide selection ............................................................................ 44 
2.6. Analyte-specific MS parameter tuning .................................................................................. 47 
2.6.1. Tuning of surrogate peptides generated by protease Arg-C digestion ......................... 47 
2.6.2. Tuning of surrogate peptides generated by tryptic digestion ........................................ 49 
2.7. Immunoaffinity enrichment .................................................................................................... 50 
2.7.1. MSIA tip-based approach .............................................................................................. 50 
2.7.2. Magnet bead-based approach ...................................................................................... 50 
2.8. Partial deglycosylation and digestion .................................................................................... 50 
2.8.1. Protease Arg-C-assisted approach using MSIA tips (in solution protocol) ................... 50 
2.8.2. Trypsin-assisted approach using MSIA tips (on tip protocol) ........................................ 51 
2.8.3. Trypsin-assisted approach using magnet beads (on bead protocol) ............................ 51 
2.9. LC-MS/MS analysis ............................................................................................................... 51 
2.9.1. RPLC-MS/MS analysis of protease Arg-C derived PSA peptides ................................ 51 
2.9.2. HILIC-MS/MS analysis of tryptic PSA peptides ............................................................ 52 
2.9.3. Multiple reaction monitoring cubed (MRM³) .................................................................. 53 
2.10. Data acquisition and analysis ................................................................................................ 53 
3. Results and discussion ................................................................................... 54 
3.1. Endoglycosidase selection .................................................................................................... 54 
3.2. Protease and surrogate peptide selection ............................................................................ 57 
3.2.1. In silico digestion of PSA ............................................................................................... 57 
3.2.2. In vitro digestion of PSA ................................................................................................ 58 
3.3. Protease Arg-C-based approaches ...................................................................................... 60 
3.3.1. Surrogate peptide selection and MRM parameter optimization .................................... 60 
3.3.2. Overview of the experimental workflow using MSIA tips .............................................. 63 
3.3.3. Determination of core-fucosylated and total PSA in serum samples ............................ 64 
3.3.4. Optimization approaches .............................................................................................. 65 
3.3.4.1. Antibody type ............................................................................................................. 65 
3.3.4.2. Antibody and enzyme amount ................................................................................... 66 
3.3.4.3. Order of digestion and elution steps ......................................................................... 67 
3.3.4.4. Multiple reaction monitoring (MRM) compared to selected ion monitoring (SIM) ..... 68 
3.4. From reversed phase to hydrophilic interaction liquid chromatography ............................... 70 
3.5. Trypsin-based approaches .................................................................................................... 75 
3.5.1. Surrogate peptide selection and analyte-specific MS parameter optimization ............. 75 
3.5.2. Overview of the experimental workflow using MSIA tips .............................................. 76 
3.5.3. Determination of partially deglycosylated and total PSA in spiked serum samples ..... 76 
3.5.4. Feasibility of the method in native serum samples ....................................................... 79 
3.5.5. Optimization approaches .............................................................................................. 80 
3.5.5.1. Transitions ................................................................................................................. 80 
3.5.5.2. Differential ion mobility mass spectrometry (DMS) ................................................... 82 
   Table of contents 
7 
 
3.5.5.3. Multiple reaction monitoring cubed (MRM³) .............................................................. 83 
3.5.5.4. Derivatization using tandem mass tags (TMT) ......................................................... 84 
3.5.6. Overview of the experimental workflow using magnet beads ....................................... 87 
3.5.7. Development of the magnet bead-based workflow ....................................................... 87 
3.5.7.1. Optimization of immunoaffinity enrichment ............................................................... 87 
3.5.7.2. Optimization of partial deglycosylation and tryptic digestion .................................... 89 
3.5.8. Comparison of streptavidin-coated solid support materials for immunoaffinity 
enrichment ..................................................................................................................................... 91 
3.5.9. Characterization of the final workflow using magnet beads .......................................... 92 
3.5.9.1. Linearity, LLOD, LLOQ and imprecision of the magnet bead-based workflow ......... 92 
3.5.9.2. Analysis of serum samples containing different amounts of fucosylated PSA ......... 94 
3.5.9.3. Analysis of human specimens ................................................................................... 95 
4. Conclusions ...................................................................................................... 96 
 
Chapter IV: A case study: Is core-fucosylated prostate-specific antigen (PSA) a 
refined biomarker for differentiation of benign prostate hyperplasia (BPH) and 
prostate cancer of different aggressiveness? ..................................................... 97 
1. Introduction ...................................................................................................... 98 
2. Experimental section ..................................................................................... 101 
2.1. Reagents and materials ...................................................................................................... 101 
2.2. Preparation of calibrators and control samples ................................................................... 101 
2.3. Patient samples ................................................................................................................... 101 
2.4. Quantification of total and free PSA by ECLIA .................................................................... 102 
2.5. LC-MS/MS-based analysis of total PSA and core-fucosylated PSA................................... 102 
2.6. Study design........................................................................................................................ 104 
2.7. Data analysis and statistics ................................................................................................. 104 
3. Results ............................................................................................................ 105 
4. Discussion ...................................................................................................... 110 
5. Conclusions .................................................................................................... 113 
 
Chapter V: References ......................................................................................... 115 
 
Appendix ............................................................................................................... 127 
 

   Table of abbreviations 
9 
 
Table of abbreviations 
ABC   Ammonium bicarbonate buffer 
ACN   Acetonitrile 
AFP-L3   α-fetoprotein-L3 
AUC   Area under the curve 
BPH   Benign prostatic hyperplasia 
CAM   Carbamidomethylation 
CE   Collision energy 
CID   Collision-induced dissociation 
cps   Counts per second  
CV   Coefficient of variation 
CXP   Cell exit potential 
DRE   Digital rectal examination  
DMS   Differential ion mobility mass spectrometry 
DP   Declustering potential 
DTT   Dithiothreitol 
ECLIA   Electrochemiluminescence immunoassay 
ELISA   Enzyme-linked immunosorbent assay 
ELLA   Enzyme-linked lectin assay 
EP   Entrance potential 
EPI   Enhanced product ion scan 
ER   Endoplasmic reticulum 
ESI   Electrospray ionization 
FA   Formic acid 
FDA   Food and Drug Administration 
Fuc   Fucose 
fuc-PSA  core-fucosylated PSA 
GlcNAc   N-acetylglucosamine 
GS   Gleason score 
HILIC   Hydrophilic interaction chromatography 
   Table of abbreviations 
10 
 
HPLC   High-performance liquid chromatography 
HRMS   High-resolution mass spectrometry 
IAM   Iodoacetamide 
IA-MS   Immunoaffinity mass spectrometry 
IgG   Immunoglobulin G 
ISF   In-source fragmentation 
KLK3   Kallikrein-3 
LLOD   Lower limit of detection 
LLOQ   Lower limit of quantification 
MALDI   Matrix-assisted laser desorption/ionization 
MRM   Multiple reaction monitoring 
MS   Mass spectrometry 
MSIA   Mass spectrometric immunoassay 
n/a   not applicable 
NP   Normal phase 
OX   Oxidation 
PBS   Phosphate buffered saline 
PCa   Prostate cancer 
PCA3   Prostate Cancer Antigen 3 
PHI   Prostate Health Index 
PSA   Prostate-specific antigen 
PTM   Post-translational modification 
ROC   Receiver operating characteristic 
RP   Reversed phase 
Sia   Sialic acid 
SIL   Stable isotope labeled 
SIM   Selected ion monitoring 
SISCAPA  Stable isotope standards and capture by anti-peptide antibodies 
SRM   Selective reaction monitoring 
TFA   Trifluoroacetic acid 
   Table of abbreviations 
11 
 
TMT   Tandem mass tag 
TOF   Time of flight 
TQMS   Triple quadrupole mass spectrometry 
TRUS   Transrectal ultrasound 
TURP   Transurethral resection of the prostate

  Abstract 
 
13 
 
Abstract 
Recently, certain glycan structures of glycoproteins such as site-specific core-fucosylation have 
attracted attention as they can be associated with several diseases, including cancer. For example, 
changes in prostate-specific antigen (PSA) glycosylation pattern have been described in prostate 
cancer (PCa), which is among the most frequently diagnosed cancer types in men worldwide. 
However, sensitive and selective methods for analysis of very low-concentrated individual 
glycoproteins in complex matrices, such as serum, are rare and defined glycan structures, which 
might serve as potential cancer markers, are hard to detect by common methods, including 
immunoassays.  
In the first part of this work, a mass spectrometry-based strategy for the simultaneous analysis of 
core-fucosylated and total PSA in the low ng/mL concentration range in human serum was developed. 
The final sample preparation workflow comprised an immunoaffinity capture step to enrich total PSA 
from human serum using anti-PSA antibody coated magnetic beads followed by consecutive two-step 
on bead partial deglycosylation with endoglycosidase F3 and tryptic digestion prior to LC-MS/MS 
analysis. The method was shown to be linear from 0.5 to 60 ng/mL total PSA concentrations and 
allows the simultaneous quantification of core-fucosylated PSA down to 1 ng/mL and total PSA lower 
than 0.5 ng/mL. The imprecision of the method over two days ranged from 9.7-23.2 % for 
core-fucosylated PSA and 10.3-18.3 % for total PSA depending on the PSA level. The feasibility of 
the method in native sera was shown using three human specimens making it a useful tool for the 
analysis of comprehensive patient cohorts in order to study if core-fucosylated PSA may serve as a 
more specific biomarker compared to conventional total and free PSA. Furthermore, the described 
strategy could be used to monitor potential changes in site-specific core-fucosylation of other 
low-concentrated glycoproteins, which could serve as improved markers (“marker refinement”) in 
cancer research. 
In the second part of this work, the previously developed LC-MS/MS-based strategy was used for 
multiplex analysis of core-fucosylated PSA and total PSA levels in sera from 50 benign prostatic 
hyperplasia (BPH) and 100 PCa patients of different aggressiveness (Gleason scores 5-10) covering 
the critical grey area (2-10 ng/mL) in PCa diagnosis. The objective of this study was to evaluate 
whether the core-fucosylation determinant of serum PSA may serve as refined marker for 
differentiation between non-aggressive from aggressive PCa and identification of BPH. The data 
showed that the ratio core-fucosylated PSA to total PSA (%-fuc-PSA) was decreased in aggressive 
PCa (Gleason score > 6) in comparison to non-aggressive PCa (Gleason score ≤ 6) and yielded a 5 
to 8 % increase in the area under the curve (AUC = 0.60) than the currently used total PSA 
(AUC = 0.52) and %-free PSA (AUC = 0.55) tests. In contrast, both core-fucosylated PSA and 
%-fuc-PSA had no diagnostic value for differentiation of BPH from PCa. In summary, a higher 
tendency for differentiation of non-aggressive and aggressive PCa was obtained using %-fuc-PSA 
compared to conventional diagnostic PCa markers. Therefore, %-fuc-PSA should be further 
investigated e.g. in larger patient cohorts or by more precise methods whether it could be clinically 
used in PCa diagnosis.  
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Zusammenfassung 
Bestimmte Glykanstrukturen von Glykoproteinen, wie z.B. spezifische Fucosylierung am Glykankern 
(Kern-Fucosylierung), haben unlängst das Interesse geweckt, da sie mit verschiedenen Krankheiten, 
u.a. Krebs, in Verbindung gebracht werden können. So wurden beispielsweise für Prostatakrebs, eine 
der weltweit am häufigsten diagnostizierten Krebsarten bei Männern, veränderte 
Glykosylierungsmuster des Prostata-spezifischen Antigens (PSA) beschrieben. Sensitive und 
selektive Methoden zur Bestimmung von sehr niedrig konzentrierten, individuellen Glykoproteinen aus 
komplexen Matrices wie Serum sind jedoch selten und definierte Strukturen von Glykanen, die als 
mögliche Krebsmarker dienen könnten, sind mit bekannten Methoden, wie immunologischen Tests, 
schwer nachzuweisen. 
Im ersten Teil dieser Arbeit wurde eine massenspektrometrische Methode für die simultane Analyse 
von Kern-Fucosyliertem und gesamt PSA (total PSA) im niedrigen ng/mL Konzentrationsbereich in 
humanem Serum entwickelt. Der finale Probenvorbereitungsablauf umfasste einen 
Immunoaffinitätsschritt mit anti-PSA Antikörper beschichteten magnetischen Partikeln, um total PSA 
aus humanem Serum anzureichern. Anschließend wurden zwei nacheinander folgende Schritte auf 
den mit PSA beladenen magnetischen Partikeln durchgeführt. Einer kontrollierten 
Teildeglykosylierung mit Endoglykosidase F3 folgte ein tryptischer Verdau vor der eigentlichen 
LC-MS/MS Messung. Die Methode ist in einem Konzentrationsbereich von 0,5-60 ng/mL total PSA 
linear und erlaubt die simultane Quantifizierung von bis zu 1 ng/mL Kern-Fucosyliertem PSA und 
weniger als 0,5 ng/mL total PSA. Die Präzision der Methode, gemessen über zwei Tage, lag 
abhängig vom PSA Level bei 9,7-23,2 % für Kern-Fucosyliertes PSA und 10,3-18,3 % für total PSA. 
Die Eignung der Methode zur Anwendung in nativen Seren wurde anhand von drei Patientenproben 
gezeigt. Dies macht die Methode zu einem nützlichen Hilfsmittel für die Analyse von größeren 
Patientenkohorten, um zu untersuchen, ob Kern-Fucosyliertes PSA als Marker mit höherer Spezifität 
als konventionelles total PSA und freies PSA fungieren könnte. Außerdem könnte die beschriebene 
Methode genutzt werden, um mögliche Veränderungen in der spezifischen Kern-Fucosylierung von 
anderen, niedrig konzentrierten Glykoproteinen zu erforschen, die als verbesserte Marker dienen 
könnten („marker refinement“).  
Im zweiten Teil dieser Arbeit wurde die vorher entwickelte LC-MS/MS Methode zur simultanen 
Konzentrationsbestimmung von Kern-Fucosyliertem und total PSA in Patientenproben angewendet. 
Die Proben stammten dabei von 50 Patienten mit Benigner Prostatahyperplasie (BPH) und 
100 Patienten mit unterschiedlich stark differenziertem Prostatakarzinom (Gleason Scores 5-10). Die 
total PSA Level der Probanden lagen im kritischen Grau-Bereich (2-10 ng/mL) für die Diagnose von 
Prostatakrebs. Ziel dieser Studie war es zu evaluieren, ob Kern-Fucosyliertes PSA in Serum als 
verbesserter Marker zur Differenzierung von nicht-aggressivem und aggressivem Prostatakrebs bzw. 
zur Identifizierung von BPH dienen könnte. Die Ergebnisse zeigten, dass das Verhältnis von Kern-
Fucosyliertem und total PSA (%-fuc-PSA) bei aggressivem Prostatakrebs (Gleason score > 6) 
gegenüber nicht-aggressivem Prostatakrebs (Gleason score ≤ 6) erniedrigt war. Zudem wurde mit 
%-fuc-PSA eine Steigerung der Fläche unter der Kurve (Englisch: Area under the curve, AUC = 0,60) 
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von 5-8 % im Vergleich zu gegenwärtig verwendeten Tests wie total PSA (AUC = 0,52) und %-freies 
PSA (AUC = 0,55) beobachtet. Im Gegensatz dazu hatten sowohl Kern-Fucosyliertes PSA als auch 
%-fuc-PSA keinen diagnostischen Wert zur Differenzierung zwischen BPH und Prostatakrebs. 
Zusammenfassend lässt sich sagen, dass im Vergleich zu konventionellen Prostatakrebsmarkern mit 
%-fuc-PSA tendenziell eine etwas höhere Unterscheidung von aggressivem und nicht-aggressivem 
Prostatakrebs erzielt wurde. Daher sollte weiter untersucht werden, ob %-fuc-PSA einen klinischen 
Nutzen in der Prostatakrebsdiagnose hat, sei es z.B. in größeren Patientenkohorten oder mithilfe von 
präziseren Methoden. 
  
   
   Chapter I: Aim of the thesis 
17 
 
 
Chapter I 
  
 
Aim of the thesis 
  
   Chapter I: Aim of the thesis 
18 
 
Chapter I: Aim of the thesis 
Glycoproteins are functional molecules in organisms involved in several biological processes such as 
cell-signaling, cell-cell interaction, immune recognition, cell proliferation and differentiation [1]. 
Dysfunctions in these processes are frequently associated with altered glycoproteins, hence making 
them excellent biomarker candidates for disease monitoring. However, glycoprotein analysis in 
complex biological fluids such as serum is challenging as they often possess very low concentrations 
compared to numerous other high-abundant matrix proteins such as albumin or immunoglobulin 
(IgG). The extensive glycan heterogeneity of glycoproteins represents an additional challenge and 
leads to the requirement for specialized set of tools for their study. In this work, the glycoprotein 
prostate-specific antigen (PSA) served as an ideal example as its native serum concentrations usually 
are in the low ng/mL concentration range which in fact is approximately 6-8 orders of magnitude lower 
than the most abundant proteins in serum. Moreover, alterations in PSA glycosylation pattern such as 
terminal sialylation or site-specific core-fucosylation have been reported in prostate cancer (PCa) cell 
lines, prostate tissue, seminal fluid, urine, and serum samples with elevated PSA levels, frequently by 
means of lectin-based assays [2-5].  
 
The aim of the first part of this work was to develop a mass spectrometry (MS)-based strategy for the 
simultaneous analysis of both site-specific core-fucosylated and total PSA in the low ng/mL 
concentration range in human serum. For this purpose, several sub-goals were pursued including 
(1) evaluation of various enzymes for protein cleavage and selective glycan trimming, (2) testing of 
different solid support materials and capture reagents for immunoaffinity enrichment to ensure 
purification of the sample, (3) selection of suitable high-performance liquid chromatography (HPLC) 
columns for retention of target peptides and separation of interfering compounds generated during the 
sample preparation process, (4) identification of suitable surrogate peptides and their respective mass 
transitions representing the target analytes, and (5) tuning of analyte-specific MS parameters in order 
to achieve the maximum sensitivity. Following method development and optimization, the final 
workflow was characterized in terms of linear range, lower limit of detection (LLOD), lower limit of 
quantification (LLOQ), and assay imprecision, and the feasibility of the method in native sera was 
shown using three human specimens. 
 
The aim of the second part of this work was to evaluate whether core-fucosylated PSA might serve as 
potential biomarker for differentiation of non-aggressive and aggressive PCa and for identification of 
other prostatic diseases such as benign prostatic hyperplasia (BPH). For this purpose, a large number 
of patient samples (n = 150) was analyzed applying the previously developed LC-MS/MS method. 
Patient samples were classified into three groups according to their clinical diagnosis and the Gleason 
score (GS) grading system: (1) BPH, (2) non-aggressive PCa (GS ≤ 6), and (3) aggressive PCa 
(GS > 6). Total PSA levels obtained in this refinement study were compared to results from 
electrochemiluminescence immunoassay (ECLIA) using a Bland Altman plot and Deming regression. 
Statistical data evaluation was performed by receiver operating characteristic (ROC) curves and box 
plot diagrams.  
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Chapter II: Theoretical part 
1. Biological samples – Focus on blood and its fractions 
A wide variety of biological sample types may be collected from human origin including blood, tissue, 
urine, saliva, semen, bone marrow, cell lines, exhaled air, feces, and hair. Of particular interest for 
routinely analysis are those sample types that can be collected most conveniently and efficiently, and 
at the lowest cost for large population-based studies. The most common sample types for these 
studies are blood, tissue, urine, and saliva [6]. In this work, serum which was previously isolated from 
whole blood was used as sample matrix. Hence, basic information such as functions, composition, 
processing, and storage of blood and its fractions is given below.  
 
Blood, which is circulated by the heart through the vascular system, has several major functions. It 
transports oxygen, nutrients (such as amino acids, fatty acids, glucose) and cells to and removes 
waste materials (such as carbon dioxide, urea, lactic acid) away from body tissues. Blood is 
responsible for the regulation of pH, temperature and water content of cells. Tissue damages are 
indicated by transport of hormones through the blood serving as a messenger system. Immune 
defense and coagulation are stimulated by biochemical cascades and complex coagulation pathways 
initiated by blood compounds. The average human adult has a blood volume of roughly 5 L, which 
accounts for 6-8 % of the human body weight. Whole blood consists of plasma and blood cells in a 
composition of approximately 55 to 45 % in healthy conditions. Blood plasma is composed of nearly 
92 % water and 7 % plasma proteins by volume and contains trace amounts of glucose, electrolytes, 
hormones, and gases. The total plasma protein concentration usually ranges from 60 to 85 g/L [7]. 
However, individual protein concentrations can differ by 10 orders of magnitude with interleukin-6 
(0-5 pg/mL) at the low abundance and albumin (35-50g/L) at the high abundance end of the protein 
landscape (Figure 1) [8].  
 
Figure 1: Reference intervals for 29 plasma proteins plotted on a log(10) scale spanning 12 orders of 
magnitude. Reproduced and modified from [8]. 
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Blood cells, also known as corpuscles or formed elements, represent mainly red blood cells 
(erythrocytes), white blood cells (leukocytes) and platelets (thrombocytes). The proportion of blood 
occupied by red blood cells is referred to as the hematocrit, and is normally within the range of 
36-48 % in females and 40-53 % in males [9]. These values can be changed in diseases such as 
anemia (depressed hematocrit) or polycythemia (elevated hematocrit). Whole blood is often 
fractionated by centrifugation before being analyzed and stored. While plasma is obtained from an 
anticoagulated blood sample, serum isolation requires no anticoagulants. After centrifugation of 
anticoagulated blood, white blood cells and platelets build the so-called buffy coat (<1 %) between the 
upper, straw yellow plasma layer and the lower, bright red layer consisting of red blood cells. If 
coagulated blood is processed, the buffy coat forms a cell clot with red blood cells and is not 
amenable to separate analysis (Figure 2). Therefore, depending on the intended analysis and the 
required blood fraction, it should be considered whether blood is collected anticoagulated or 
coagulated. In addition, anticoagulant effects need to be respected to avoid certain problems in 
laboratory applications. For example, EDTA as anticoagulant is preferred for hematology testing but 
interferes with calcium assays due to its chelating character [10]. Blood fractions can serve for 
different intended uses. Whole blood, buffy coat and cell clots representing suitable sources for DNA 
are preferably used in genomic studies whereas serum and plasma are the preferred sample types in 
proteomics, although analytical results may be different in both specimen [11]. This could probably be 
due to protein binding to the cell clot formed during coagulation which causes a decrease in free 
protein serum concentration. Improper storage conditions can also lead to coagulation and protein 
precipitation and therefore affect blood stability. To reduce these effects, repetitive freeze-thaw cycles 
should be avoided, the temperature at which blood is collected may be important and stabilizing 
agents might be necessary to preserve distinct analytes.  
 
Figure 2: Preparation of plasma (upper path) and serum (lower path) by centrifugation of whole blood 
previously treated with or without anticoagulants, respectively.  
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2. Structure of proteins 
2.1. Amino acids – Building blocks of proteins 
Proteins are linear biopolymers constituted of monomer subunits known as amino acids. As the name 
indicates, each amino acid contains an amine (–NH2) and a carboxyl (–COOH) functional group 
attached to one central carbon atom, the α-carbon. The remaining two bonds of this α-carbon atom 
are generally satisfied by a hydrogen (–H) atom and a side chain (–R group) specific to each amino 
acid. Depending on the –NH2 and –COOH functional groups’ positions, α-, β-, γ- or δ-amino acids 
exist. In nature, α-amino acids are of particular importance. Therefore, in the following context the 
term amino acid is used to refer specifically to the α-form. According to the polarity of their side chains 
amino acids can be classified into four groups: (1) non-polar, (2) polar/uncharged, (3) acidic, and (4) 
basic amino acids. Among these groups a broad variety of residues including aliphatic, aromatic, 
heterocyclic, hydroxylic, carboxylic, amidic, and sulfur containing side chains can be distinguished 
which leads to the unique and manifold functionality of proteins. Twenty amino acids encoded by the 
universal genetic code are occurring in natural proteins. These so-called proteinogenic amino acids 
are abbreviated by three-letter or single-letter notations as depicted in Table 1 [12, 13]. All 
proteinogenic amino acids are chiral molecules due to the configuration of the α-carbon atom with four 
different ligands, except glycine as it contains two hydrogen atoms on the α-carbon atom. The 
absolute stereochemistry can be indicated by (L) and (D) designators in which only (L)-amino acids 
are present in human proteins.  
 
Table 1: Name, three-letter, single-letter and structure of the 20 proteinogenic amino acids classified 
according to their polarity. 
1. Non-polar amino acids 
Alanine Ala A 
 
Phenylalanine Phe F 
 
Glycine Gly G 
 
Proline Pro P 
 
Isoleucine Ile I 
 
Tryptophan Trp W 
 
Leucine Leu L 
 
Valine Val V 
 
Methionine Met M 
 
    
  
 
 
O H
NH
O
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Table 1 continued: Name, three-letter, single-letter and structure of the 20 proteinogenic amino acids 
classified according to their polarity. 
2. Polar/uncharged amino acids 
Asparagine Asn N 
 
Serine Ser S 
 
Cysteine Cys C 
 
Threonine Thr T 
 
Glutamine Gln Q 
 
Tyrosine Tyr Y 
 
3. Acidic amino acids 
Aspartic acid Asp D 
 
Glutamic acid Glu E 
 
        
4. Basic amino acids 
Lysine Lys K 
 
Histidine His H 
 
Arginine Arg R 
 
    
 
 
2.2. The peptide bond 
When the α-carboxyl group of one amino acid reacts with the α-amine group of a second amino acid, 
a covalent bond, the peptide bond, is formed thereby releasing a molecule of H2O (condensation 
reaction). Depending on the number of amino acids linked together one can distinguish oligopeptides 
(2-20 amino acids), polypeptides (21-50 amino acids), and proteins (> 50 amino acids). However, the 
boundary is not well defined and can overlap in meaning. Due to resonance effects the peptide bond 
possesses partial double bond characteristics resulting in a very stable, planar geometry in which two 
amino acids are fixed in either cis- or trans-conformation. Most peptides are in trans-conformation, 
where the two α-carbon atoms are on opposite sides of the peptide bond, as there is less steric 
hindrance between side chains attached to α-carbon atoms. Even though the geometry of the peptide 
bond is fixed, single bonds on either side of the α-carbon atoms can rotate allowing for flexibility in 
protein folding.  
 
 
 
 
OH
NH2
O H
O
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2.3. Levels of protein structures 
Generally four levels of protein structures are differentiated: primary, secondary, tertiary and 
quaternary structures. The primary structure is the amino acid sequence assembled in a particular 
order in a protein. The sequence of a protein is written from the amino terminus (N-terminus, left) to 
the carboxyl terminus (C-terminus, right). For instance, the amino acid sequence of prostate-specific 
antigen (PSA, Uni-ProtKB P07288) starts with methionine (M) at the N-terminus and ends with 
proline (P) at the C-terminus (Figure 3).  
 
Figure 3: Amino acid sequence of prostate-specific antigen (PSA, Uni-ProtKB P07288) illustrated as 
single-letter code. 
 
The secondary structure corresponds to local folded structures within the protein due to interactions 
between amino hydrogen and carboxyl oxygen atoms of the backbone. The most common types of 
secondary structures are alpha helices and beta sheets. In alpha helices, a helical structure is formed 
by hydrogen bonds in which each turn contains around 3.6 amino acids [14]. Side chains are directed 
to the outside of the helix where they are free to interact. In beta sheets, segments of the polypeptide 
chain line up parallel or anti-parallel to each other, forming a sheet-like structure by hydrogen bond 
interactions. Side chains protrude below or above the sheet’s plane. Different secondary structure 
elements, also known as protein domains, can be present in a single protein molecule linked by turns 
and flexible loops. The tertiary structure refers to the overall, three-dimensional structure of a protein. 
The spatial arrangement is maintained by different interactions between the side chains of the amino 
acids. Both non-covalent interactions such as hydrophobic interactions, dipole-dipole interactions, 
hydrogen bonds, and ionic bonding as well as covalent disulfide bridges, established between two 
cysteine residues, contribute to the tertiary structure. The conformational structure of proteins is also 
affected by the surrounding medium. For instance, in aqueous medium non-polar residues will cluster 
in the inside of a protein, whereas polar amino acids as presented on the outside to interact with 
water molecules. Some proteins possess multiple polypeptide chains with defined tertiary structures, 
which are also called subunits. These subunits can interact together by similar interactions that were 
mentioned for tertiary structures forming the quaternary structure.  
 
  
        10         20         30         40         50 
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3. N-linked glycosylation of proteins 
3.1. Biosynthesis of N-glycans and their major structural types 
After protein biosynthesis by ribosomes, proteins may undergo post-translational modification (PTM) 
such as acetylation, phosphorylation, lipidation, amidation, methylation, and glycosylation which 
further increase the structural complexity of proteins. This section describes only N-linked 
glycosylation of proteins including steps in their synthesis and processing, potential N-glycosylation 
sites, and their major structural classes. Strategies for analysis of N-glycosylated proteins including 
their isolation, purification, separation and detection is reserved for the next section.  
 
In the first phase, N-glycan synthesis of all eukaryotes begins on the cytoplasmic side of the 
endoplasmic reticulum (ER) membrane by the transfer of 2-N-acetylglucosamine-1-phosphate 
(GlcNAc-1-P) from uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) to the membrane-bound 
precursor dolichol phosphate (Dol-P), forming dolichol pyrophosphate N-acetylglucosamine (GlcNAc-
P-P-Dol). Subsequently, a second N-acetylglucosamine (GlcNAc) and five mannose (Man) residues 
are transferred step-by-step to GlcNAc-P-P-Dol by specific glycosyltransferases to generate 
Man5GlcNAc2-P-P-Dol on the cytoplasmic side of the ER. By a mechanism that is not fully 
understood, the Man5GlcNAc2-P-P-Dol precursor flips across the ER membrane bilayer. The glycan 
structure, which is now exposed to the lumen of the ER, is further extended by addition of four Man 
and three glucose (Glc) residues. In total, fourteen sugars were sequentially added to the Dol-P 
precursor. Next, the entire glycan structure (Glc3Man9GlcNAc2) is transferred by 
oligosaccharyltransferase (OST) to asparagine (GlcNAcβ1-Asn linkage) in nascent protein regions 
that have translocated into the ER [15]. It must be noted that not all asparagine residues can accept 
an N-glycan but only those within the receptive NXT/S motifs where X is a variable amino acid except 
proline. However, the presence of the consensus tripeptide is not always sufficient to conclude that an 
asparagine residue is N-glycosylated, as protein folding plays an important role in the regulation of 
N-glycosylation. Sometimes, unfolding of the polypeptide chain might be required in order to expose 
respective sequons for carbohydrate attachment [16]. 
 
In the second phase, a series of processing reactions trims the 14-N-glycan. In the ER, Glc residues 
are removed by α-glucosidases I and II to give Man9GlcNAc2Asn. The majority of glycoproteins exits 
the ER towards the Golgi apparatus with either eight or nine Man residues, depending on whether 
they were processed by ER α-mannosidase I. Mature glycoproteins, which are not processed in the 
following cis-Golgi compartment, possess N-glycans referred to the oligomannose N-glycan type. In 
the cis-Golgi compartment, glycan trimming continues in which three Man residues are removed by 
α-mannosidases IA and IB forming Man5GlcNAc2Asn, which is a key intermediate for the biosynthesis 
of hybrid and complex N-glycans initiated in the medial-Golgi compartment. Here, 
N-acetylglucosaminyltransferase GlcNAc-TI adds an GlcNAc residue to the core of Man5GlcNAc2Asn. 
Next, terminal Man residues are removed by α-mannosidase II to form GlcNAcMan3GlcNAc2Asn. 
Hybrid N-glycans will be formed, if this step does not occur. A second GlcNAc residue is added to the 
Man core by the action of N-acetylglucosaminyltransferase GlcNAc-TII to yield 
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GlcNAc2Man3GlcNAc2Asn, the precursor for all biantennary, complex N-glycans. Additional branches 
can be added at the core mannoses to yield tri- and tetra-antennary N-glycans. Further modifications, 
such as addition of fucose (Fuc) to the core, elongation of branching with galactose (Gal), or capping 
of branches by sialic acid (Sia), mostly occur in the trans-Golgi compartment. Biosynthesis of 
N-glycans leads to a myriad of oligosaccharides, as this process is non-template-driven involving the 
availability of several enzymes and substrates without any proofreading machinery. Three major 
structural classes of N-glycans attached to mature proteins at the NXT/S motifs can be distinguished 
(Figure 4). (1) Oligomannose-type glycans contain only two GlcNAc and a variable number of Man 
and sometimes also Glc residues, (2) complex-type glycans are composed of GlcNAc, Gal, Fuc, Sia 
and sometimes also GalNAc residues in addition to the pentasaccharide core, and (3) hybrid-type 
glycans combine the characteristics of both oligomannose- and complex-type glycans [17]. 
 
Figure 4: Three major structural classes of N-glycans in mature proteins: (1) Oligomannose-, (2) 
complex-, and (3) hybrid-type oligosaccharides and their specific linkages. Each N-glycan type 
contains the common pentasaccharide core Man3GlcNAc2Asn. Reproduced and modified from [15]. 
 
3.2. Strategies for analysis of protein N-glycosylation 
Analysis of protein N-glycosylation can be performed at the levels of intact glycoproteins, 
glycopeptides and free oligosaccharides. A general overview of the wide landscape of methods and 
tools aiming for these targets is given in this section.  
 
3.2.1. Analysis of intact glycoproteins 
One of the first steps in isolation and analysis of intact glycoproteins is the usage of gel 
electrophoresis such as sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). In 
gel electrophoresis, glycoproteins are separated according to their size and/or charge depending on 
the utilized gel conditions. Although complete separation is often not feasible due to the 
heterogeneous glycan patterns, gel electrophoresis may be used as preparative technique prior to the 
use of other methods. For instance, subsequent application of lectins, which are highly specific for 
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carbohydrates moieties, may enable improved detection and characterization of glycosylation patterns 
of electro-blotted proteins [18]. Several lectins exist with different selectivities such as Fuc-binding 
lectins e.g. Aleuria aurantia lectin (AAL), Ulex europaeus agglutinin (UEA), Sia-binding lectins e.g. 
elderberry lectin from Sambucus nigra (SNA), Maackia amurensis hemoagglutinin (MAH), 
Man-binding lectins e.g. Concanavalin A (ConA), and GlcNAc-binding lectins e.g. Wheat germ 
agglutinin (WGA). A higher resolving power of glycoforms can be provided by capillary 
electrophoresis (CE) whereas CE does not allow per se elucidation of attached glycan structures [19]. 
Mass spectrometric detection of individual glycoproteins is difficult due to the extensive 
microheterogeneity of their glycan moieties. Resolution of small glycoproteins with a limited number of 
glycans has been achieved by the use of matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectrometry (MS) [20]. Larger proteins with multiple glycosylation sites and 
heterogeneous glycosylation patterns usually lead to broad and unresolved peaks as shown in 
Figure 5 using the example of prostate-specific antigen (PSA). Normally, electrospray ionization 
(ESI)-MS is also faced with severe problems in intact glycoprotein analysis including less efficient 
ionization, adduct formation and data complexity due to multiple ion species. In this context, the use 
of lectins bound to appropriate supporting materials like magnet beads, micro-columns or membranes 
also allows for isolation, fractionation and separation of glycoproteins according to their glycan 
structures [5, 21, 22]. Additional information on the number of glycosylation sites and attached glycan 
types can be obtained by combining MS- or lectin-based approaches with previous treatment of target 
glycoproteins using specific endo- and exo-glycosidases. 
 
 
Figure 5: Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrum of the 
native glycoprotein prostate-specific antigen (PSA) leading to a broad and unresolved peak in the 
mass range of 26-29 kDa. Aldolase (m/z 39,112 Da) was used as internal mass calibrator.  
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3.2.2. Analysis of glycopeptides 
Prior to glycopeptide analysis, specific or non-specific cleavage of glycoproteins is required which 
yields a mixture of different peptides and glycopeptides. The resulting peptide length depends on the 
glycoprotein’s amino acid sequence and the specificity of the cleavage reagent. Different proteolytic 
enzymes and chemical reagents for specific protein cleavage together with their preferred cleavage 
sites are summarized in Table 2. One of the most common proteases in protein digestion for 
MS-based applications is trypsin, which offers some major advantages such as good availability, high 
specificity, an optimal average peptide length of ~14 amino acids, and typically the presence of at 
least two defined positive charges at the N-terminus as well as at the C-terminal Arg or Lys residues, 
rendering tryptic peptides well suited for ESI-MS [23]. Non-specific cleavage e.g. by pronase provides 
glycans only containing one amino acid or very short peptide backbones [17]. Alternatively, chemical 
reagents such as cyanogen bromide (CNBr) or hydroxylamine may be used as important tools for 
selective cleavage of proteins. In contrast to enzymatic cleavage, chemical treatment usually targets 
residues and speciﬁc dipeptide linkages that occur at low frequencies in proteins resulting on average 
in fewer peptides being larger in size compared to those produced by standard protease 
treatment [24]. Glycoproteins can be completely denatured by reduction e.g. with dithiothreitol (DTT) 
and alkylation e.g. with iodoacetamide (IAM) to ensure accessibility of cleavage reagents. However, it 
has to be considered that protein cleavage might be sterically hindered in highly glycosylated 
proteins. 
 
Table 2: Proteolytic and chemical cleavage reagents for specific protein digestion and their respective 
cleavage sites. 
Cleavage Reagent Preferred cleavage site* 
Proteolytic Trypsin C-terminus of arginine and lysine residues 
 Chymotrypsin C-terminus of tryptophan, tyrosine, phenylalanine, 
leucine, methionine, and histidine residues 
 Pepsin (pH = 1.3) C- and N-terminus of phenylalanine, leucine, 
tyrosine, and tryptophan residues 
 Protease Arg-C  C-terminus of arginine residues 
 Protease Glu-C  C-terminus of glutamic acid residues 
 Protease Lys-C C-terminus of lysine residues 
 Protease Asp-N N-terminus of aspartic acid residues 
Chemical Cyanogen bromide (CNBr) C-terminus of methionine residues 
 2-Iodosobenzoic acid (IBA) C-terminus of tryptophan residues 
 Hydroxylamine Asparagine-glycine peptide bonds 
 Formic acid (FA) Aspartic acid-proline peptide bonds 
* Enzyme specific exceptions not considered 
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After glycoprotein cleavage, glycopeptide identification is still challenging for several reasons. First, 
glycopeptides usually represent only a minor proportion within the generated total peptide mixture. 
Second, glycopeptides often possess lower signal intensities than non-glycosylated peptides, mainly 
because glycopeptide signals are distributed across several species carrying different glycan 
structures. Third, glycopeptides may suffer from low ionization efficiency and ion suppression in the 
presence of other peptides, especially if glycans are capped by negatively charged sialic acid 
residues [25]. To avoid these challenges, several additional techniques can be applied in parallel or 
sequentially. As mentioned before, the use of lectin-affinity capture enables discrimination between 
glycosylated and non-glycosylated peptides. Depending on their specificity, lectins can function as 
structure-specific selectors or allow for binding of multiple glycan types [26, 27]. Hydrophilic 
interaction chromatography (HILIC) can also be applied for separation of hydrophilic glycopeptides 
from more hydrophobic peptides [28]. Furthermore, size exclusion chromatography (SEC) may be 
useful for fractionation of peptide mixtures according to their size [29]. Carbohydrate residues, 
previously oxidized with periodate, can be coupled to hydrazine beads followed by peptide release 
using peptide-N-glycosidase F (PNGaseF) [30]. This method could serve as additional strategy in 
glycopeptide analysis, although information on the oligosaccharide structure is lost. Glycopeptides 
may be identified in samples measured before and after enzymatic release of either the whole glycan 
or defined carbohydrate moieties [31]. The latter can also be used for elucidation of the carbohydrate 
constitution by calculation of mass differences if the glycopeptide contains only one glycoslyation site. 
Most commonly used glycosidases are shown in Figure 6. Different MS fragmentation techniques can 
be employed to determine glycan structures, glycan attachment sites and peptide sequences. For 
instance, collision-induced dissociation (CID) in triple quadrupole MS instruments leads predominantly 
to fragmentation of glycosidic linkages which are more labile compared to peptide bonds, hence 
primarily revealing information on the glycan composition [32]. In contrast, applying electron capture 
dissociation (ECD) in Fourier transform (FT)-MS or electron transfer dissociation (ETD) in ion trap 
instruments, the peptide backbone is preferably fragmented leaving glycan structures intact [33, 34]. 
Thus, a combination of these fragmentation techniques leads to complementary information.  
 
3.2.3. Analysis of glycans 
Similar to protein cleavage, glycan release can be accomplished by enzymatic and chemical methods 
in which different reagents are employed compared to proteolysis. The usage of peptide-
N-glycosidase F (PNGaseF) enables complete N-glycan removal, except for those containing 
α(1,3)-linked Fuc attached to the reducing terminal GlcNAc residue [35]. In contrast, this type of 
glycan can be removed by PNGaseA. Both amidases cleave the linkage between GlcNAc and Asn 
which converts Asn into Asp. The resulting mass shift of +0.98 Da can be used to identify respective 
attachment sites in glycoproteins or -peptides with a single N-glycosylation site. 
Endo-β-N-acetylglucosaminidases cleave the glycosidic bond between the first and the second 
GlcNAc residue of the chitobiose core, leaving a single GlcNAc residue still bound to the peptide 
backbone. Glycosidases of this enzyme classification possess different substrate specificities [36]. 
Endo H and F1 preferably cleave oligomannosidic and most hybrid-type chains, while Endo F2 and 
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F3 liberate certain complex-type glycans. Exoglycosidases such as sialidase, α-fucosidase, 
α/β-mannosidase, β-N-acetylhexoaminidase, and β-galactosidase cleave non-reducing terminal Sia, 
Fuc, Man, GlcNAc, and Gal residues, respectively, and can be used for enzymatic glycan sequencing. 
Hence, information can be obtained on the glycan composition, on the anomeric linkages and, at least 
with certain available enzymes, on the monomeric linkage positions [17]. An overview of suitable 
endo- and exoglycosidases for glycan analysis is illustrated in Figure 6. The enzymatic release of 
glycans is applicable to glycoproteins in solution, in gel after gel electrophoresis, directly on the 
MALDI-target plate or bound to affinity reagents [37-39]. For chemical release, hydrazinolysis and 
β-elimination under harsh conditions are the most common procedures producing intact N-glycans 
with a free reducing terminus, but disruption of the peptide chain has to be considered as an 
inevitable drawback [40, 41]. 
 
 
Figure 6: A biantennary N-glycan is shown with different exoglycosidases (black) only acting on 
terminal sugars and endoglycosidases (red) removing intact N-glycans. Reproduced and modified 
from [15]. 
 
As glycan detection is hampered by interconversion of anomeric forms of the reducing sugar, the lack 
of chromophores and low ionization efficiency by MS, several possible labeling reactions generating 
respective glycan derivatives have been developed such as reductive amination, Michael addition, 
and hydrazide labeling [42-44]. By reductive amination of the reducing end-aldehyde group, 
amine-based labels such as 2-aminopyridine (PA) and 2-aminobenzamide (2-AB) can be incorporated 
into the glycan structure. For Michael addition, the active methylene group of a label reagent like 
1-phenyl-3-methyl-5-pyrazolone (PMP) reacts with the reducing end of a glycan, followed by a 
reversible 1,4-Michael addition of a second label molecule under basic conditions [45]. The 
considerable risk of loss of sialic acids in acidic medium in case of reductive amination reactions can 
be avoided [46]. In hydrazide labeling, the hydrazine label such as benzohydrazide is attached to the 
end-aldehyde group of a glycan forming a hydrazone under weak acidic conditions [47]. Glycans may 
be not only derivatized by chromophores and fluorophores facilitating detection after chromatographic 
separation but also by ionizable functional groups, thus improving sensitivity in MS-based detection.  
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Glycan derivatization may be also required as saccharides are very hydrophilic structures primarily 
due to numerous hydroxyl groups, and thus analysis by reversed phase (RP) high-performance liquid 
chromatography (HPLC) is challenging. In order to achieve retention on hydrophobic stationary 
phases, glycans can be permethylated or are often labeled with hydrophobic tags such as 
2-AB [48, 49]. For analysis of complex glycan mixtures, several other techniques have been 
employed enabling separation of isobaric and isomeric glycan species, of which MS-based 
differentiation is still a cumbersome task. Ion exchange chromatography (IEC) has been used for 
many years for separation of glycans based on the number of charged groups and to a minor extent 
on the glycan size [50]. The widely used mode of IEC for the analysis of glycans is high-performance 
anion-exchange chromatography (HPAEC) coupled with pulsed amperometric detection (PAD) and 
MS [51-53]. In normal phase (NP)-HPLC, glycan elution times generally increase with sugar size due 
to elevated hydrophilic interactions between glycans and the stationary phase [54]. HILIC is 
considered as a variant of NP-HPLC as it also utilizes a stationary phase which is more polar than the 
initial mobile phase. When this type of separation system is applied, glucose oligomers (dextran 
ladder) are often utilized for the calibration of retention time relying on certain conditions such as pH, 
salt concentration, and temperature. Porous graphitized carbon (PGC) columns fractionate 
oligosaccharides mainly due to hydrophobic interactions and are widely employed for efficient 
separation of glycan isomers and closely related compounds [55]. As described before, lectin affinity 
chromatography also offers a tool for fractionation of complex glycan mixtures into structurally subsets 
according to the lectin specificity. Lastly, capillary electrophoresis (CE) separates charged analytes 
according to their migration velocity in an electric field placed across the ends of a capillary 
column [17]. All of the aforementioned separation techniques differ partially or complete in their 
separation mechanism, and thus represent complementary methodologies which can be used in 
conjunction helping to provide substantial information on N-glycan structures. Advancements of mass 
spectrometry in terms of sensitivity, together with the capability for direct coupling to many separation 
methods mentioned above, has made MS a key technology for analysis of N-linked glycosylation. 
Understanding of N-glycan composition and its structural features is important as N-glycosylation 
influences glycoprotein properties such as protein folding, solubility, antigenicity, and recognition by 
other proteins. Consequently, alterations in glycosylation patterns affect a variety of biological 
processes and may lead to human diseases [15]. However, protein N-glycosylation analysis in low 
concentration ranges in biological samples is often impeded by the small amounts of sample available 
and the enormous structural glycan heterogeneity.  
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4. Hybrid immunoaffinity mass spectrometry (IA-MS) 
The aforementioned challenges accompanied with the analysis of protein N-glycosylation in biological 
samples might be tackled by combining the advantages of traditional immunoassays (IA) with latest 
MS-based technology, called hybrid immunoaffinity mass spectrometry (IA-MS). In this section, first 
the principles of IA and triple quadrupole mass spectrometry (TQMS) are briefly described together 
with their pros and cons for large biomolecule analysis. Then, the main drivers and opportunities of 
hybrid IA-MS-based assays are discussed. 
 
4.1. Immunoassays (IA) 
IA are widely used for bioanalysis of large molecules through the use of antibodies specific to an 
analyte (antigen-capture). Numerous variations of IA have been developed which can be classified 
into heterogeneous and homogeneous assays, respectively. While heterogeneous IA contain multiple 
steps such as binding, separation, and washing, homogeneous IA are operated simply by mixing the 
reagents and sample without additional steps prior to detection of the analyte of interest. Both assay 
types can be performed in either competitive or non-competitive mode depending on nature of the 
analyte, availability of antibodies and label reagents, and analytical requirements. In the competitive 
mode, the sample analyte and a labeled analyte compete for the binding to a limited amount of 
anti-analyte antibody bound to a solid support such as test tubes or 96-well plates. After equilibration 
and separation, the label activity on the solid phase is measured e.g. by radiation, fluorescence or 
enzymes. The obtained signal is inversely proportional to the analyte concentration in the sample 
(Figure 7a) [56]. In the non-competitive mode, also called sandwich assay, two antibodies are 
required which bind to non-overlapping epitopes on the analyte molecules. One of the two antibodies 
is used as analyte capture antibody, whereas the second one is labeled and used for detection. The 
analyte in the sample is allowed to specifically bind to the capture antibody which is immobilized onto 
a solid phase. After washing away of other sample constitutes, the analyte-antibody-complex is 
incubated with an excess of the labeled detection antibody, which binds to another epitope on the 
analyte molecule. After washing, the label activity can be measured directly or indirectly by means of 
substrates depending on the label type linked to the detection antibody (Figure 7b) [56]. Among a 
variety of different signal generating labels including radioactive isotopes, DNA reporters, 
electrochemiluminescent tags, fluorescent probes or metal chelates, enzymes are the most common 
labels employed in IA-based methods, frequently called enzyme-linked immunosorbent assays 
(ELISA) [57-62]. The major advantages of these assays in large biomolecule analysis are the ease of 
use, the possibility to fully automate the method, high throughput, and very low limits of detection. 
However, the development of antibodies specific to different epitopes of the antigen is often 
time-consuming and expensive. Moreover, IA have narrow dynamic ranges and suffer from limited 
selectivity due to antibody cross-reactivity which may result in lack of specificity from interferences 
and high-background levels [63].  
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Figure 7: Schematic representation of two different immunoassay designs:  
a) Competitive immunoassay including (1) solid support coating with capture antibodies, (2) sample 
loading and competitive reaction of sample analyte and labeled analyte, (3) capture of sample analyte 
and labeled analyte after washing, and (4) reading label activity and relating signal to analyte 
concentration.  
 
b) Non-competitive immunoassay including (1) solid support coating with capture antibodies, (2) 
sample loading and capture of analyte, (3) addition of detection antibody and binding to analyte, and 
(4) reading label activity and relating signal to analyte concentration. 
 
 
4.2. Triple quadrupole mass spectrometry (TQMS) 
With the introduction of electrospray ionization (ESI) in the late 1980’s, it has become possible to 
hyphenate high-performance liquid chromatography with mass spectrometry for the analysis of 
biological macromolecules such as proteins, peptides, and nucleic acids because ESI does not 
induce their fragmentation [64]. After ionization, quantitative analysis of generated ions has been 
dominated by triple quadrupole mass spectrometry (TQMS) due to its broad dynamic range and 
superior sensitivity over other MS analyzers including high-resolution mass spectrometers (HRMS) or 
time of flight (TOF) instruments [65-67]. A TQMS analyzer consists of two quadrupole mass filters (Q1 
and Q3) in tandem, separated by a quadrupole collision region (Q2), and can be operated in different 
scan modes allowing for simple MS or MS/MS data collection. The most selective scan mode is 
referred to as multiple reaction monitoring (MRM) or selected reaction monitoring (SRM). In MRM the 
first quadrupole (Q1) selects ions of interest, so called precursor ions, previously generated in the ion 
source. The second quadrupole (Q2) filled with a collision gas e.g. nitrogen is used as a collision cell 
to fragment precursor ions into product ions. The third quadrupole (Q3) is set to allow only specified 
product ions to pass. Hence, defined precursor/product ion pairs (mass transitions) are conducted to 
the MS detector, which typically is an electron multiplier. A schematic overview of a TQMS analyzer 
operating in MRM mode is illustrated in Figure 8.  
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Figure 8: Schematic overview of a triple quadrupole mass spectrometer (TQMS) operating in multiple 
reaction monitoring (MRM) scan mode. 
 
While TQMS instruments exhibit excellent sensitivity in MRM mode, they tend to be limited in mass 
resolution and possess low mass detection ranges. The upper mass limit of state-of-the-art 
instruments is approximately at 2000 m/z [68]. For the measurement of protein targets, thus, a 
bottom-up approach is commonly used in which intact proteins are subjected to proteolytic cleavage 
and resulting surrogate peptides are analyzed by tandem MS. Using collision-induced dissociation 
(CID) characteristic peptide fragments can be observed which are denoted as a-, b-, and c-ions, when 
the charge is retained on the N‐terminal side of the fragmented peptide, and x-, y-, and z-ions when 
the charge is retained on the C‐terminal side [69]. The most common peptide fragments observed in 
low energy collisions (collision energy < 200 eV) are a-, b- and y-ions, as depicted in Figure 9. In 
comparison to traditional IA-based methods, LC-MS-based assays benefit from less method 
development time, wider dynamic ranges, ability of multiplex analysis, and improved specificity, 
whereas the expertise to operate complex LC-MS instrumentation and the low throughput limits wider 
adoption of the technique [63]. In addition, with LC-MS, analysis of large molecules at low ng/mL 
levels in biosamples is challenging without pre-enrichment, mainly due to ion suppression from 
high-abundant proteins in the sample [70].  
 
 
Figure 9: Characteristic fragmentation pattern of a tetrapeptide observed in collision-induced 
dissociation (CID)-MS. 
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4.3. Opportunities of hybrid IA-MS-based assays 
 
Both traditional IA and latest LC-MS/MS are essential technologies being used in large molecule 
bioanalysis but each technique is associated with individual pros and cons as mentioned before. 
Major limitations in specificity or sensitivity can be tackled by combining both technologies allowing for 
efficient sample purification and immunoaffinity enrichment of large molecules prior to highly selective 
LC-MS/MS-based analysis. For this purpose, different formats of immunoaffinity enrichment methods 
have been developed in which antibody-coated microbeads such as agarose or magnetic beads have 
been the most widely applied tools [71]. Affinity capturing has also been performed in 96-well plates, 
on chips, on columns, and on pipette tips [72-75]. Antibodies can be immobilized onto solid support 
materials using different strategies including simple physical adsorption, covalent binding, 
biotin-streptavidin interaction, DNA directed orientation, or protein A/G capturing [76]. Another driver 
for hybridizing IA with MS may be that only one specific antibody is needed to enrich target proteins 
compared to ELISA which requires two antibodies against different epitopes. Moreover, the antibody 
selectivity is of less priority due to the final selection by MS [70]. This significantly reduces time and 
costs in assay development. Besides antibodies against intact proteins, another approach uses 
anti-peptide antibodies together with stable isotope standards (SIS), known as stable isotope 
standards and capture by anti-peptide antibodies (SISCAPA) workflow. An alternative option for 
protein capturing complementary to antibodies represents the use of aptamers which are chemically 
synthesized, single-stranded oligonucleotides forming a complex three-dimensional structure [77]. If 
affinity enrichment is conducted on protein level, proteolytic digestion can be performed either after 
elution of captured proteins in solution or directly on the solid support material where the target 
protein is still immobilized. As LC-MS/MS possess the ability of multiplex analysis, simultaneous 
detection of multiple peptides and even biotransformation products including metabolites is 
feasible [78, 79]. Assay automation has enabled the screening of large number of samples, which is a 
required step in biomarker evaluation due to the large variations across populations [80]. This might 
offer the adoption of hybrid IA-MS from early biomarker discovery to high throughput clinical 
applications. As shown, hybrid IA-MS provides new opportunities to keep up with the increasing 
demand for selective and very sensitive analysis of biologicals such as therapeutic monoclonal 
antibodies, antibody drug conjugates (ADC), fusion proteins, and biomarkers with specific isoforms or 
post-translational modifications (PTMs).  
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Chapter III: Development of an LC-MS/MS-based strategy for 
analysis of site-specific core-fucosylation of prostate-specific 
antigen (PSA) in the low ng/mL range in human serum 
 
1. Introduction 
1.1. The role of human protein glycosylation 
Among protein post-translational modifications (PTMs), glycosylation is a frequently occurring and 
functionally important one involved in many physiological processes including cell adhesion, receptor 
activation, protein folding and immune response [81-84, 108]. Estimates suggest that approximately 
half of all mammalian proteins are glycosylated [85, 108]. Protein glycosylation is not a template-
driven process such as DNA, RNA or protein synthesis, but is rather controlled by complex enzymatic 
pathways during protein passage through the endoplasmic reticulum and Golgi compartments. The 
activity of those enzymes depends on factors including their quantity, localization and substrate 
availability, which can largely vary based on differences in tissue, cell type and disease state [86-88, 
108]. Even under non-malignant conditions this greatly increases the complexity of protein 
glycosylation, resulting in extensive molecular micro- and macroheterogeneity of glycoproteins. The 
disturbance of this equilibrium in disease often leads to altered glycosylation of individual 
glycoproteins expanding the degree of heterogeneity beyond their natural forms [89, 108]. This offers 
the potential for glycoproteins to serve as markers for a variety of biological processes. Fucose (Fuc), 
galactose (Gal), glucose (Glc), mannose (Man), N-acetylglucosamine (GlcNAc), N-
acetylgalactosamine (GalNac) and sialic acid (Sia) are the primary building blocks of a diverse set of 
human N- and O-glycan structures. Core-fucosylation, consisting of an α(1,6)-Fuc modification on the 
innermost GlcNAc residue of the N-glycan core structure, has attracted attention, because it can be 
linked to various types of cancers such as hepatocellular carcinoma, pancreatic cancer, lung cancer 
and prostate cancer (PCa) [4, 90-92, 108]. 
  
1.2. Prostate-specific antigen (PSA) 
Prostate-specific antigen (PSA), also known as Kallikrein-3 (KLK3), is a 28-32 kDa glycoprotein 
composed of 237 amino acids. According to the NXT/S motif for N-glycosylation (if X is not proline), 
PSA possesses a single N-glycosylation site at Asn-69. In blood, PSA circulates in two predominant 
forms, either as free PSA or complexed to α1-antichymotrypsin and α2-macroglobulin [93, 108]. PSA 
is almost exclusively secreted by epithelial cells of the prostate gland, which makes PSA a highly 
organ-specific biomarker [2, 108]. PSA blood levels of 10 ng/mL or higher indicate the risk of cancer, 
and prostate biopsy is usually recommended [94, 108]. However, PSA is not a cancer-specific 
biomarker because PSA blood levels do not efficiently distinguish between PCa and other prostatic 
diseases, such as benign prostatic hyperplasia (BPH) and prostatitis, especially in the so called “grey 
area” ranging from 4-10 ng/mL [95, 108]. In addition, PSA serum levels cannot differentiate between 
indolent and aggressive PCa [96, 108]. As a consequence, PSA screening resulted in tremendous 
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over-diagnosis and over-treatment during the last decades [97, 108]. Several groups proposed that 
altered glycosylation might increase the diagnostic potential of PSA [98, 108]. Defined changes in the 
fucosylation degree of PSA in cancer samples have been described using different lectin-based 
approaches. For example, Fukushima et al. showed in a 40-sample cohort that α(1,2)-fucosylated 
total PSA levels were higher in sera of PCa patients than in sera of BPH patients with more than 95 % 
probability [99, 108]. The α(1,2)-fucosylated form of free PSA was shown by Dwek et al. to be 
increased in sera of cancer patients with 92 % specificity and 69 % sensitivity for PCa over BPH [93, 
108]. In contrast, a significant decrease with 90 % sensitivity and 95 % specificity in α(1,6)-core-
fucosylated total PSA was found by Llop et al. in high-risk PCa that differentiated BPH and low-risk 
PCa from high-risk PCa patients in a 73-sample cohort in which total PSA concentrations ranged from 
4.14 to 109.7 ng/mL [4, 108].  
 
1.3. Approaches for the analysis of core-fucosylated proteins  
Although glycoprotein research has been improved by advancements in mass spectrometry (MS), 
core-fucosylation analysis in complex matrices remains challenging as concentrations of individual 
glycoproteins are usually very low due to glycan microheterogeneity at multiple glycosylation sites. 
Furthermore, representative glycopeptides have decreasing ionization efficiencies with glycan 
branching and sialylation and notably suffer from ion suppression from co-eluting non-glycopeptides 
during electrospray ionization (ESI) [100, 108]. Several methods have been applied to overcome 
these challenges using large scale glycoprotein or glycopeptide enrichment steps, for example, lectin 
affinity chromatography, peroxidase oxidation prior to hydrazide coupling or hydrophilic interaction 
chromatography [30, 90, 108]. In contrast, specific enrichment of individual glycoproteins using IgG 
depletion followed by immunoprecipitation has been performed on high-abundance glycoproteins 
such as ceruloplasmin and α2-macroglobulin [91, 101, 108]. Enriched and purified glycoproteins or 
glycopeptides are commonly enzymatically treated by endoglycosidases for complete or partial 
cleavage of their glycans and are analyzed by tandem MS with or without previous labeling [102, 103, 
108]. Core-fucosylation analysis at the glycan level is usually achieved by using peptide-N-
glycosidase F (PNGaseF) cleaving N-glycans from purified proteins or from biological mixtures [104, 
108]. This enzymatic release additionally allows for indirect identification of N-glycosylation sites of 
glycoproteins by deamidation of asparagine to aspartic acid providing a mass shift of +0.98 Da. 
However, information linking multiple glycosylation sites to its respective glycan structures is lost. 
Other enzyme-based strategies using galactosidases, sialidases or endo-β-N-acetylglucosaminidases 
retain site-specific information as these enzymes do not remove the complete glycan [105, 108]. In 
addition, glycan microheterogeneity of partially truncated glycopeptides is simplified and ionization 
efficiency is increased compared to intact glycopeptides, making partial deglycosylation a useful tool 
in core-fucosylation analysis.  
 
All of the examples mentioned above have been limited to the core-fucosylation analysis of high-
abundance and highly purified glycoproteins or applied large scale screenings of core-fucosylated 
serum proteomes. By applying glycoproteome-wide studies, disease-specific modifications of a single, 
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low-concentrated glycoprotein cannot be monitored. The analysis of individual modifications may be a 
more effective biomarker refinement strategy as the discovery of the core-fucosylated α-fetoprotein 
(AFP-L3) approved for the early diagnosis of hepatocellular carcinoma by the Food and Drug 
Administration (FDA) recently showed [106, 108]. Alternative, non-MS-based strategies for core-
fucosylation analysis use enzyme-linked lectin assays (ELLA). These types of assays are based on a 
similar principle to the common enzyme-linked immunosorbent assay (ELISA) technique, in which the 
capture or detection antibody or both are replaced by a lectin. Approaches involving antibody-based 
capture of low-concentrated glycoproteins and subsequent detection of their fucosylation by lectins 
have been employed [4, 93, 108]. Major challenges with ELLA are the inherent glycosylation of the 
capture/ detection antibody or non-specific binding by high-abundance glycoproteins from human 
matrices, which can cause a non-specific background signal by lectin detection, obscuring the analyte 
signal of interest. Furthermore, simultaneous measurement of total glycoprotein levels and 
corresponding core-fucosylated subpopulations is not feasible. Outside the biological context, lectins 
have low affinity for their target glycans as multivalent interactions are missing [107, 108]. This makes 
glycosylation analysis in the low concentration range more difficult.  
 
In this chapter, a hybrid immunoaffinity mass spectrometry (IA-MS) based approach for the 
simultaneous quantification of total PSA levels and its core-fucosylated subpopulation in the low 
ng/mL concentration range in human serum was developed [108]. Challenges in lectin-based 
approaches including weak affinity for low-concentrated targets could be tackled by combining the 
sensitivity of immunoassays with the specificity of mass spectrometric detection. Here, the 
glycoprotein PSA served as an ideal example as its native serum concentrations usually are very low. 
The heart of the method was a magnetic bead-based immunoaffinity enrichment step followed by 
consecutive partial deglycosylation and proteolytic digestion while PSA was still captured by the 
immunoaffinity complex. Following, surrogate peptides of total PSA and core-fucosylated PSA were 
analyzed by LC-MS/MS. Based on calibration curves of total and core-fucosylated PSA, the linear 
range, lower limit of detection (LLOD), lower limit of quantification (LLOQ) and imprecision expressed 
as coefficient of variation (CV) were evaluated [108].   
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2. Experimental section 
2.1. Reagents and materials  
Streptavidin-coated magnetic particles (Ref. 11641786001), biotinylated monoclonal antibodies 
PSA30 against free PSA, PSA10, PSA36 and PSA66 against total PSA (= free and complexed PSA), 
total PSA CalSet II (Ref. 04485220190), sialidase from Clostridium perfringens (Ref. 11585886001), 
protease Arg-C from Clostridium histolyticum (Ref. 11370529001), protease Arg-C activation solution 
(Ref.11370529001), proteinase K from Pichia pastoris (Ref. 03115887001), 2-Amino-2-
(hydroxymethyl)propane-1,3-diol (TRIS, Ref. 10708976001) and universal diluent (Ref. 11732277122) 
were obtained from Roche Diagnostics GmbH (Mannheim, Germany). Endoglycosidase F3 (Endo F3) 
from Elizabethkingia meningosepticum and endoglycosidase F2 (Endo F2) from Elizabethkingia 
miricola were obtained from Ludger Ltd (Oxfordshire, UK). IgGZERO® Endo S from Streptococcus 
pyogenes AP1 and GlycINATOR® Endo S2 from Streptococcus pyogenes M49 were obtained from 
Genovis Inc. (Cambridge, USA). Remove-iT® Endo S from Streptococcus pyogenes was purchased 
from New England Biolabs (Ipswich, USA). Thermolysin and elastase were received from Promega 
(Madison, USA). Phosphate buffered saline (PBS), triethylammonium bicarbonate buffer (TEAB), 
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), trypsin from porcine pancreas, 
α-chymotrypsin from bovine pancreas, pepsin from pig gastric mucosa, tween 20, 1,4-dithiothreitol 
(DTT), iodoacetamide (IAM) and ammonium bicarbonate (ABC) were purchased from Sigma-Aldrich 
(St. Louis, USA). TMT duplex isobaric label reagent set containing TMT-126 and TMT-127 label 
reagent was purchased from Thermo Fisher Scientific (Waltham, USA). Di-sodium hydrogen 
phosphate, sodium dihydrogen phosphate, di-potassium hydrogen phosphate, potassium dihydrogen 
phosphate, sodium chloride and calcium chloride, anhydrous sodium acetate, potassium hydroxide 
and glacial acetic acid were obtained from Merck (Darmstadt, Germany). Acetonitrile (ACN), 
trifluoroacetic acid (TFA) and formic acid (FA) were all ULC/MS grade and purchased from Biosolve 
(Dieuze, France). Hydrochloric acid (HCl) was obtained from Bernd Kraft GmbH (Duisburg, Germany). 
Deionized water (18.2 mΩ cm) was prepared with a Milli-Q® Plus integral water purification system for 
ultrapure water from Merck Millipore (Darmstadt, Germany). PSA purified from human seminal fluid 
was purchased from Scripps Laboratories (San Diego, USA). Peptides LSEPAELTDAVK (single-letter 
amino acid code), SVILLGR and a mixture of glycopeptides N(GlcNAc)K and N(GlcNAc+Fuc)K were 
synthesized in house at Roche Diagnostics GmbH (Penzberg, Germany). MS tune solutions including 
2.0 e-7 M polypropylene glycol and ES tuning mix were obtained from AB Sciex (Darmstadt, 
Germany). 
 
2.2. Instruments and equipment  
Microcon® centrifugal filter were purchased from Merck Millipore (Carrigtwohill, Ireland). Protein 
LoBind tubes, 96-deepwell plates, pipette tips and combitips advanced were obtained from Eppendorf 
(Hamburg, Germany). Mass spectrometric immunoassay disposable automation research tips 
(MSIATM D.A.R.T.'STM) coated with streptavidin were purchased from Thermo Fisher Scientific 
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(Waltham, USA). HPLC vials and 0.1 mL micro inserts were obtained from VWR (Radnor, USA). 
0.35 mL micro inserts were obtained from WICOM (Heppenheim, Germany).  
 
Unless stated otherwise, the following instruments and equipment were used. Samples were 
incubated on a ThermoMixer C from Eppendorf (Hamburg, Germany) or in a drying oven Typ B 6030 
from Heraeus instruments (Hanau, Germany). For sample drying a vacuum concentrator 5301 from 
Eppendorf was used. Samples were weighed with a Research RC 210 P MC1 analytical scale from 
Sartorius (Utting, Germany). MSIA tip-based experiments were performed using a FinnpipetteTM 
Novus i Multichannel Electronic Pipette from Thermo Fisher Scientific (Waltham, USA). Magnet 
particle separation was achieved using a DynaMag™-2 Magnet from Thermo Fisher Scientific. 
Samples were centrifuged using a centrifuge 5417R from Eppendorf. Multipette® stream and pipettes 
Reference® 2 were also from Eppendorf. LC-MS/MS analysis was performed using an Infinity 1290 
UHPLC from Agilent Technologies (Santa Clara, USA) equipped with a G4220A binary pump, a 
G4226A autosampler, a G1316C thermostatted column compartment and a G1330B thermostat. The 
MS instrument was a QTRAP 6500 equipped with TurboVTM Ion Source from AB Sciex (Darmstadt, 
Germany) which was initially tuned and calibrated according to the manufacturer’s instructions using 
polypropylene glycol, ES Tuning Mix and Tuning Mix Solvent from AB Sciex. Q1 and Q3 resolution 
was set to 0.7 ± 0.1 amu full width at half height at a scan rate of 10 Da/s, referred to as unit 
resolution in MRM mode. Chromatographic separation of tryptic surrogate peptides was performed 
using an XBridge Amide column (130 Å, 3.5 µm, 2.1 x 100 mm). Surrogate peptides generated by 
digestion of PSA using protease Arg-C were separated using an Acquity UPLC BEH C18 column 
(130 Å, 1.7 µm, 2.1 x 150 mm). Both columns were obtained from Waters (Milford, USA).  
 
2.3. PSA spiked-in serum samples and human specimen 
For method optimization and characterization, total PSA CalSet II was used containing calibrator 
1 and 2 consisting of human PSA (Scripps Laboratories) in female serum matrix at 0 ng/mL and 
60 ng/mL, respectively. Both calibrators were mixed and spiked if applicable with PSA purified from 
human seminal fluid (Scripps Laboratories) resulting in different concentrations of total PSA. Prior to 
preparing PSA spiked-in serum samples, N-glycans of human PSA from Scripps Laboratories were 
analyzed by LC-MS to give a rough estimation about the fucosylation degree of this material. 
N-glycan analysis revealed two major N-glycan peaks corresponding to a biantennary complex 
structure (A2G2S2, Oxford notation name) with and without core-fucose in a proportion of 78 % and 
32 %, respectively. Furthermore, non-fucosylated and fucosylated PSA previously separated by lens 
culinaris agglutinin (LCA) lectin affinity chromatography using PSA from Scripps Laboratories as raw 
material were diluted in universal diluent and combined accordingly, resulting in different ratios of 
non-fucosylated to fucosylated PSA. These solutions were spiked into PSA-free female serum 
resulting in final total PSA concentrations of 10 ng/mL and different ratios of non-fucosylated to 
fucosylated PSA (100:0, 75:25, 50:50, 25:75 and 0:100). Three anonymized human specimen with 
total PSA concentrations of 2.35, 7.20 and 7.30 ng/mL and three PSA-free female sera were provided 
in-house by Roche Diagnostics GmbH (Penzberg, Germany) for feasibility studies. Total PSA 
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concentrations of PSA spiked-in serum samples and human specimen were measured using 
commercially available Elecsys® total PSA electrochemiluminescence immunoassay (ECLIA) assays 
on the cobas e 601 system (Roche Diagnostics GmbH, Penzberg, Germany) as described previously 
[59]. All procedures in this study involving human sera were conducted according to the Declaration of 
Helsinki [108].  
 
2.4. Endoglycosidase selection 
Endoglycosidase selection was performed based on partial deglycosylation of intact PSA according to 
the following protocols:  
 
IgGZERO® Endo S: 
10 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories), 38 µL of a 10 mM sodium phosphate 
buffer containing 150 mM sodium chloride at pH 7.4 and 2 µL (80 units) IgGZERO® Endo S were 
mixed and incubated at 37 °C overnight. 
 
GlycINATOR® Endo S2: 
10 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories), 38 µL of a 10 mM sodium phosphate 
buffer containing 150 mM sodium chloride at pH 7.4 and 2 µL (80 units) GlycINATOR® Endo S2 were 
mixed and incubated at 37 °C overnight.  
 
GlycINATOR® Endo S2 and Sialidase: 
10 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories), 30 µL of a 2 mM potassium phosphate 
buffer at pH 6.1 and 5 µL (0.1 units) Sialidase were mixed and incubated at 37 °C overnight. Next, 
3 µL 20 mM potassium hydroxide, 2 µL H2O and 2 µL (80 units) GlycINATOR® Endo S2 were added, 
mixed and incubated at 37 °C overnight.  
 
Remove-iT® Endo S:  
10 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories), 5 µL of a 500 mM sodium phosphate 
buffer at pH 7.5, 34 µL H2O and 1 µL (200 units) Remove-iT® Endo S were mixed and incubated at 
37 °C overnight.  
 
Remove-iT® Endo S and Sialidase: 
10 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories), 5 µL of a 500 mM sodium acetate 
buffer containing 50 mM CaCl2 at pH 5.5, 29 µL H2O, 5 µL (0.1 units) Sialidase and 1 µL (200 units) 
Remove-iT® Endo S were mixed and incubated at 37 °C overnight.  
 
Endo F2: 
10 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories), 10 µL of a 250 mM sodium acetate 
buffer at pH 4.5, 28 µL H2O and 2 µL (0.01 units) Endo F2 were mixed and incubated at 37 °C 
overnight.  
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Endo F3: 
10 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories), 10 µL of a 250 mM sodium acetate 
buffer at pH 4.5, 28 µL H2O and 2 µL (0.01 units) Endo F3 were mixed and incubated at 37 °C 
overnight.  
 
Endo F2 and Endo F3:  
10 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories), 10 µL of a 250 mM sodium acetate 
buffer at pH 4.5, 26 µL H2O, 2 µL (0.01 units) Endo F2 and 2 µL (0.01 units) Endo F3 were mixed and 
incubated at 37 °C overnight.  
 
Endo F3 and Sialidase: 
10 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories), 25 µL of a 100 mM sodium acetate 
buffer at pH 5.0, 8 µL H2O, 5 µL (0.1 units) Sialidase and 2 µL (0.01 units) Endo F3 were mixed and 
incubated at 37 °C overnight.  
 
Endo F3 in TRIS/HCl buffer: 
10 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories), 25 µL of a 100 mM TRIS/HCl buffer 
containing 10 mM CaCl2 at pH 7.8, 28 µL H2O and 2 µL (0.01 units) Endo F3 were mixed and 
incubated at 37 °C overnight. 
 
All endoglycosidase treated PSA solutions were separated on an Acquity UHPLC system (Waters, 
Milford, USA) equipped with a Zorbax C8 column (Agilent Technologies, Santa Clara, USA) and 
analyzed on a LCT Premier (Waters, Milford, USA) in-house at Roche Diagnostics GmbH (Penzberg, 
Germany).   
 
2.5. Protease and surrogate peptide selection 
In silico digestion of PSA (Uni-ProtKB P07288) was performed by the PeptideMass tool [109] which is 
available online at the ExPASy Bioinformatics Resource Portal. PSA cleavage was simulated using 
different enzymes including trypsin, Lys-C, protease Arg-C, Asp-N, Glu-C, chymotrypsin, pepsin, 
proteinase K, elastase and thermolysin using the following settings: no missed cleavages and 
cysteines in reduced form.  
 
For in vitro digestion, 50 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories) were partially 
deglycosylated by adding 10 µL (0.05 units) Endo F3 and 140 µL of a 50 mM sodium actetate buffer 
at pH 4.5. The mixture was incubated overnight at 37 °C. Following partial deglycosylation, 10 µL of 
the Endo F3 treated PSA solution were pipetted on a 10 kDa cut-off Microcon® centrifugal filter and 
50 µL of a 100 mM ABC buffer at pH 8.0 were added. After centrifugation at 12,500 rpm for 30 min, 
50 µL of a 100 mM ABC buffer at pH 8.0 containing 50 µg PPS and 5 µL of a 10 mM DTT solution 
were added. The mixture was incubated at 50 °C for 30 min. After cooling to RT, reduced PSA was 
carboxymethylated by adding 5 µL of a 55 mM IAM solution and mixed at 37 °C for 30 min in the dark. 
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The mixture was centrifuged at 12,500 rpm for 30 min and the Microcon® vial, containing the flow 
through, was replaced by a new Microcon® vial. In total, fourteen preparations were executed in this 
way in order to test seven different enzymes each at two different PSA-to-enzyme ratios (10:1 and 
100:1) according to the following protocols: 
 
Trypsin  
50 µL of a 50 mM ABC buffer at pH 8.0 containing 50 µg PPS and 5 µL of a 0.05 µg/µL trypsin 
solution (PSA-to-enzyme ratio 10:1) or 5 µL of a 0.005 µg/µL trypsin solution (PSA-to-enzyme ratio 
100:1), respectively, were added and incubated overnight at 37 °C.  
 
Elastase 
50 µL of a 50 mM TRIS/HCl buffer at pH 9.0 and 5 µL of a 0.05 µg/µL elastase solution (PSA-to-
enzyme ratio 10:1) or 5 µL of a 0.005 µg/µL elastase solution (PSA-to-enzyme ratio 100:1), 
respectively, were added and incubated overnight at 37 °C.  
 
Proteinase K 
50 µL of a 50 mM TRIS/HCl buffer at pH 9.0 and 5 µL of a 0.05 µg/µL proteinase K solution (PSA-to-
enzyme ratio 10:1) or 5 µL of a 0.005 µg/µL proteinase K solution (PSA-to-enzyme ratio 100:1), 
respectively, were added and incubated overnight at 37 °C.  
 
Thermolysin 
50 µL of a 50 mM TRIS/HCl buffer at pH 8.0 containing 0.5 mM CaCl2 and 5 µL of a 0.05 µg/µL 
thermolysin solution (PSA-to-enzyme ratio 10:1) or 5 µL of a 0.005 µg/µL thermolysin solution (PSA-
to-enzyme ratio 100:1), respectively, were added and incubated overnight at 37 °C.  
 
Protease Arg-C 
45 µL of a 100 mM TRIS/HCl buffer at pH 7.8 containing 10 mM CaCl2, 5 µL activation solution 
containing 50 mM DTT and 5 mM EDTA, and 5 µL of a 0.05 µg/µL protease Arg-C solution (PSA-to-
enzyme ratio 10:1) or 5 µL of a 0.005 µg/µL protease Arg-C solution (PSA-to-enzyme ratio 100:1), 
respectively, were added and incubated overnight at 37 °C.  
 
Pepsin (pH = 1.3) 
48 µL of a 50 mM ABC buffer at pH 8.0 containing 50 µg PPS, 2 µL 2M HCl and 5 µL of a 0.05 µg/µL 
pepsin solution (PSA-to-enzyme ratio 10:1) or 5 µL of a 0.005 µg/µL pepsin solution (PSA-to-enzyme 
ratio 100:1), respectively, were added and incubated overnight at 37 °C.  
 
Chymotrypsin 
50 µL of a 100 mM TRIS/HCl buffer at pH 7.8 containing 10 mM CaCl2 and 5 µL of a 0.05 µg/µL 
chymotrypsin solution (PSA-to-enzyme ratio 10:1) or 5 µL of a 0.005 µg/µL chymotrypsin solution 
(PSA-to-enzyme ratio 100:1), respectively, were added and incubated overnight at 37 °C.  
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After incubation, all samples were centrifuged at 12,500 rpm for 30 min. 2 µL FA were added to the 
flow through to stop digestion and incubated for 1 h at 37 °C, except of samples containing pepsin, 
which were heated to 90 °C for 15 min to stop digestion. Prior to LC-MS/MS analysis, 5 µL of the 
samples were diluted with 25 µL H2O containing 0.1 % FA (v/v). Diluted samples were separated 
using a Dionex UltiMate 3000 nano LC system equipped with NanosprayTM Flex ion source, a 
FLM-3300B flow manager, a LPG-3300MB micro pump, a WPS-3000TPL RS autosampler (all 
devices from Thermo Fisher Scientific, Waltham, USA) and a temperature controller ET1312 (Enda, 
Istanbul, Turkey) used as external column oven. The column used was a PepSwiftTM monolithic 
polymer column (200 µm x 5 cm, Polystyrene/Divinylbenzol) and operated at a flow of 2 µL/min. The 
mobile phase A was 0.05 % TFA in H2O (v/v) and mobile phase B was 0.05 % TFA in acetonitrile 
(v/v). The analytical gradient lasted for 45 min where solvent B was held for 3 min at 0 %. The 
composition of solvent B was increased from 0 to 30 % in 30 min, followed by washing where solvent 
B was increased to 80 % in 1 min and held for 5 min. For column re-equilibration, solvent B was 
decreased to 0 % in 1 min and held for 5 min. The injection volume was 1 µL, the flush volume was 
7 µL and the loop overfill was 2 µL. Full loop injection mode was applied. Prior to sample injection the 
loop was washed twice with 100 µL 50 % acetonitrile in H2O (v/v). MS analysis was performed using a 
LTQ/FT Ultra mass spectrometer (Thermo Fisher Scientific, Waltham, USA) operated in positive 
ionization mode. The nano ESI (NSI) spray voltage and capillary voltage were set to 3.5 kV and 48 V, 
respectively. Collision-induced dissociation (CID) fragmentation was applied at 35 % of the 
normalized collision energy. Mass spectra were acquired in data-dependent manner using a full scan 
in the mass range of m/z 300 to 2000 and a resolution of 100,000 followed by CID MS/MS which was 
performed on the three most intensive ions using dynamic exclusion.  
 
Spectra of two enzymatic preparations (PSA-to-enzyme ratio 10:1 and 100:1) were combined and 
searched automatically by Proteome DiscovererTM software (Version 1.3, Thermo Fisher Scientific) 
with SEQUEST using the following settings: (1) two maximum missed cleavage sites were allowed, 
(2) precursor mass tolerance was 10 ppm and fragment mass tolerance was 0.8 Da, (3) dynamic 
modifications i.e. methionine oxidation (+15.995 Da), asparagine glycosylation with GlcNAc 
(+203.079 Da) and with GlcNAc + Fuc (+349.137 Da), (4) static modification i.e. cysteine 
carbamidomethylation (+57.021 Da), (5) an in-house database was used containing PSA 
(Uni-ProtKB P07288), (6) trypsin, elastase, thermolysin, proteinase K, protease Arg-C, pepsin or 
chymotrypsin were selected as digestion enzymes. Peptide identification data was assessed manually 
using XCaliburTM software (Version 2.2, Thermo Fisher Scientific) and compared to in silico data. 
Based on these results, surrogate peptides suitable for quantification of total and core-fucosylated 
PSA were chosen prior to analyte-specific MS parameter optimization.  
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2.6. Analyte-specific MS parameter tuning 
Suitable surrogate peptides, generated by protease Arg-C and trypsin digestion of PSA, were 
selected for quantification of total and core-fucosylated PSA. For this purpose, analyte-specific MS 
parameters i.e. transitions, declustering potential (DP), entrance potential (EP), collision energy (CE) 
and cell exit potential (CXP) were optimized. In this work, surrogate peptides generated by protease 
Arg-C were not available as synthetic standard peptides whereas tryptic surrogate peptides were 
synthesized in-house. Thus, two different procedures were used for analyte-specific MS parameter 
optimization. Both procedures are described below. 
 
2.6.1. Tuning of surrogate peptides generated by protease Arg-C digestion 
10 µL of a 1 µg/µL PSA solution in H2O (Scripps Laboratories) were partially deglycosylated using 
GlycINATOR® Endo S2 followed by protease Arg-C digestion similar to the procedures described in 
the previous chapter. Prior to LC-MS/MS analysis, digested PSA was diluted in H2O containing 0.1 % 
FA (v/v) to a final concentration of 1.48 µg/mL relating to the initial PSA weight. Chromatographic 
separation was performed using the Infinity 1290 UHPLC equipped with an Acquity UPLC BEH C18 
column. The column oven temperature was set to 50 °C and the injection volume was 5 µL. The flow 
rate was set to 0.4 mL/min and mobile phases consisted of water containing 0.1 % FA (v/v) as eluent 
A and acetonitrile containing 0.1 % FA (v/v) as eluent B. The gradient started with 100 % eluent A for 
2 min and was then decreased to 65 % eluent A within 30 min. Then, the percentage of eluent A was 
decreased to 5 % linearly within 1 min and held for 2 min. Afterwards eluent A was increased again to 
100 % within 0.1 min and the column was re-equilibrated for 4.9 min at this percentage. In total, each 
run took 40 min taking into account the column re-equilibration time. 
 
Using a QTRAP 6500 MS, enhanced product ion (EPI) scans of different precursor ions were 
performed and product ions were monitored in the mass range from 200 to 1000 Da as shown in 
Table 3. The scan rate was set to 10,000 Da/s and measurements were performed in positive 
ionization mode. The pause time between mass ranges was 1.5 ms, resolution in Q1 was set to unit 
resolution and a dynamic fill time of the linear ion trap was applied. Source parameters were adjusted 
as follows: curtain gas = 30 psi; collision gas = 12 psi; ion spray voltage = 3500 V; 
temperature = 450 °C; gas 1 = 50 psi; gas 2 = 70 psi. Analyte-specific MS parameters were uniform 
for each precursor: DP = 100 V, EP = 10 V and CE = 7 V. After each LC-MS/MS run, the CE was 
increased by 3 V, while the other parameters were held constant. This resulted in nine different 
LC-MS/MS runs applying CE values of 7, 10, 13, 16, 19, 22, 25, 28 and 31 V.  
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Table 3: Peptide sequences generated by protease Arg-C digestion of total PSA and their respective 
precursor ions with charge states. 
Peptide generated by protease Arg-C 
digestion 
Precursor ion [Da] Charge state 
KWIKDTIVANP 642.9 2+ 
KWIKDTIVANP 428.9 3+ 
PSLYTKVVHYR 681.9 2+ 
PSLYTKVVHYR 454.9 3+ 
N(GlcNAc)KSVILLGR 1202.7 1+ 
N(GlcNAc)KSVILLGR 601.9 2+ 
N(GlcNAc)KSVILLGR 401.6 3+ 
N(GlcNAc+Fuc)KSVILLGR 674.9 2+ 
N(GlcNAc+Fuc)KSVILLGR 450.3 3+ 
 
For multiple reaction monitoring (MRM), a MRM method was created based on the most sensitive 
precursor/product ion pairs and their respective CE values identified in the EPI scan experiments 
(Table 9). The dwell time of each transition was 100 ms and the pause time between single transitions 
was set to 5 ms. Q1 and Q3 resolution was set to 0.7 ± 0.1 amu full width at half peak height at a scan 
rate of 10 Da/s, which is referred to as unit resolution in MRM mode. Source parameters were used 
as described in the EPI scan experiments. The initial analyte-specific MS parameters were as follows: 
DP = 100 V, EP = 10 V and CXP = 20. The CE values were analyte-specific as shown in Table 4. 
Chromatographic settings were similar as described in the EPI scan experiments but this time using 
an improved gradient which started with 90 % eluent A for 2 min and was then decreased to 70 % 
eluent A within 30 min. Then, the percentage of eluent A was decreased to 5 % linearly within 1 min 
and held for 2 min. Afterwards eluent A was increased again to 100 % within 0.1 min and the column 
was re-equilibrated for 4.9 min at this percentage. For this experiment, 5 µL of a 1.48 µg/mL digested 
PSA solution were injected, which was the same solution as used in the EPI scan experiments. 
Several LC-MS/MS runs were performed based on the described MRM method, but each time one of 
the initial analyte-specific MS parameters was varied (CE ± 2 V, CXP ± 5 V, DP set to 25, 50, 75 or 
125 V, EP set to 7, 8 or 9 V), resulting in several slightly differing LC-MS/MS runs. This procedure 
was repeated using further parameter variations in order to obtain final optimized analyte-specific MS 
parameters of PSA peptides generated by protease Arg-C (Table 10). 
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Table 4: Most sensitive transitions and their respective CE values identified in EPI scan experiments. 
Peptide generated by 
protease Arg-C digestion 
Charge 
state 
Precursor ion 
[Da] 
Product ion 
[Da] 
Collision 
energy [V] 
KWIKDTIVANP 2+ 642.9 585.3 19 
KWIKDTIVANP 3+ 428.9 528.3 10 
KWIKDTIVANP 3+ 428.9 585.3 10 
PSLYTKVVHYR 2+ 681.9 574.3 28 
PSLYTKVVHYR 3+ 454.9 589.3 13 
PSLYTKVVHYR 3+ 454.9 633.4 13 
N(GlcNAc)KSVILLGR 2+ 601.9 757.5 25 
N(GlcNAc+Fuc)KSVILLGR 2+ 674.9 601.9 22 
N(GlcNAc+Fuc)KSVILLGR 2+ 674.9 757.5 22 
 
 
2.6.2. Tuning of surrogate peptides generated by tryptic digestion 
Analyte-specific MS parameters of tryptic PSA peptides, including transitions, DP, EP, CE and CXP, 
were automatically tuned in terms of signal intensity carrying out the compound optimization feature of 
the Analyst software (Version 1.6.2, AB Sciex) scanning for the ten most intensive transitions. For this 
purpose, pure peptide solutions of LSEPAELTDAVK, SVILLGR and a mixture of glycopeptides 
N(GlcNAc)K and N(GlcNAc+Fuc)K were directly infused into the QTRAP 6500 MS via T-fitting at a 
concentration of 1 µg/mL solved in 70 % acetonitrile in H2O containing 0.1 % FA (v/v) accompanied 
by a constant LC flow consisting of 70 % acetonitrile in H2O containing 0.1 % FA (v/v) at a flow rate of 
0.3 mL/min. DMS and MS3 parameters as well as source parameters were optimized manually using 
the same T-Fitting arrangement as mentioned before. Furthermore, 10 µg of peptide 
LSEPAELTDAVK as well as 10 µg of the glycopeptides N(GlcNAc)K and N(GlcNAc+Fuc)K were 
labeled using 20 µg TMT-126 and incubated overnight at RT. Analyte-specific MS parameters of 
TMT-labeled peptides at concentrations of 4 µg/mL were automatically tuned in the same manner as 
unlabeled peptides. 
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2.7. Immunoaffinity enrichment 
2.7.1. MSIA tip-based approach  
Initially, streptavidin-coated MSIA tips were prewashed with 200 µL PBS buffer by repetitive up and 
down pipetting (175 µL pipetted volume, 20 cycles) using a FinnpipetteTM Novus i Multichannel 
Electronic Pipette (Thermo Fisher Scientific, Waltham, USA). A volume of 125 µL of biotinylated 
PSA36 antibody solution at 10 µg/mL was loaded into a 500 µL Protein LoBind 96-deepwell plate. 
100 µL of that solution were drawn through the streptavidin-coated pipette tip for enrichment 
(400 cycles). Afterwards, a washing step using 200 µL PBS was incorporated to remove unbound 
anti-PSA antibodies (175 µL pipetted volume, 20 cycles). 100 µL of serum samples were loaded into 
the 96-deepwell plate prior to immunoaffinity capture. The PSA enrichment was performed by 
repeatedly aspirating and dispensing 75 µL of serum sample through the antibody-bound streptavidin-
coated pipette tips (1000 cycles). Following, the tips were rinsed stepwise with 200 µL PBS buffer 
containing 0.1 % Tween 20 followed by 200 µL PBS in order to remove unbound serum contaminants 
(175 µL pipetted volume, 20 cycles each).  
 
2.7.2. Magnet bead-based approach 
By means of a magnet separator 100 µg (100 µL) streptavidin-coated magnetic particles were washed 
with 10 mM (100 µL) PBS buffer in order to remove storage buffer containing 50 mM HEPES, 0.1 % 
BSA, 0.1 % chloracetamide and 0.01 % methyl-isothiazolone. Next, supernatant was removed, 1 µg 
(100 µL) biotinylated anti-PSA antibody PSA36 was added to washed streptavidin-coated magnetic 
particles and incubated for 10 min at 25 °C. Again, the supernatant was removed and streptavidin-
coated magnetic particles were washed with 10 mM (100 µL) PBS buffer in order to remove 
unspecific-bound antibodies. 100 µL of serum samples were added to antibody-bound streptavidin-
coated magnetic particles and incubated for 10 min at 25 °C. Supernatant was removed. After 
incubation, magnetic particles were washed with 10 mM (100 µL) PBS containing 0.05 % Tween 
followed by 10 mM (100 µL) PBS [108].  
 
2.8. Partial deglycosylation and digestion  
2.8.1. Protease Arg-C-assisted approach using MSIA tips (in solution protocol) 
Following immunoaffinity capture, enriched PSA was eluted manually into a clean 0.5 mL Protein 
LoBind tube by repetitive (20 cycles) up and down pipetting of 25 μl elution buffer consisting of 40 % 
acetonitrile and 0.4 % TFA in H2O (v/v). Next, a volume of 40 µL of a 200 mM TRIS/HCl buffer at pH 
7.5 containing 10 mM CaCl2 was added to the 0.5 mL Protein LoBind tube and mixed. Afterwards, 
2 µL (0.01 units) Endo F3 in 20 mM TRIS-HCl buffer at pH 7.5 were added and incubated at 37 °C 
overnight. The next day, 60 µL of 200 mM TRIS/HCl buffer at pH 7.5 containing 10 mM CaCl2 and 
10 µL protease Arg-C solution containing 1.4 ng/µL protease Arg-C, 200 mM TRIS/HCl, 10 mM CaCl2, 
25 mM DTT and 2.5 mM EDTA were added and incubated at 37 °C overnight. Finally, samples were 
dried in a vacuum concentrator for 3.5 h at 45 °C and redissolved in 25 µL 10 % acetonitrile in H2O 
containing 0.1 % FA (v/v) prior to LC-MS/MS analysis. 
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2.8.2. Trypsin-assisted approach using MSIA tips (on tip protocol) 
Following immunoaffinity enrichment, 2 µL (0.01 units) Endo F3 and 8 µL 100 mM sodium acetate 
buffer at pH 4.5 were pipetted into a 0.5 mL LoBind tube. The entire mixture was loaded onto the 
emptied streptavidin-coated pipette tip, still capturing the antibody-PSA complex. The pipette tip was 
placed into the 0.5 mL LoBind tube and incubated in a drying oven at 37 °C overnight. Next, the 
Endo F3 containing solution was discarded and the pipette tip was washed automatically with 200 µL 
ABC buffer at pH 8.0 (175 µL pipetted volume, 20 cycles). Then, 10 µL of a 0.1 µg/µL trypsin solution 
in 100 mM ABC buffer at pH 8.0 were loaded onto the emptied pipette tip. The pipette tip was placed 
into a 0.35 mL HPLC micro insert (WICOM) and incubated in a drying oven at 37 °C overnight. The 
trypsin solution containing on tip digested proteins including PSA was discarded and the pipette tip 
was washed with 20 µL of acetonitrile containing 0.1 % FA (v/v) kept in a separate 0.5 mL LoBind 
tube (10 µL pipetted volume, 20 cycles). The eluate of the separate 0.5 mL LoBind tube was added to 
the volume of the HPLC Micro Insert prior to LC-MS/MS analysis. 
 
2.8.3. Trypsin-assisted approach using magnet beads (on bead protocol) 
Following immunoaffinity enrichment, partial deglycosylation and proteolytic digestion were performed 
stepwise while PSA was still captured by the immunoaffinity complex. First, 0.01 units (50 µL) 
Endo F3 in 100 mM sodium acetate buffer at pH 4.5 were added to the washed magnetic particles 
and incubated for 3 h at 37 °C. Supernatant was removed and magnetic particles were washed with 
100 mM (100 µL) ABC buffer at pH 8.0. Secondly, 1 µg (50 µL) trypsin in 100 mM ABC buffer at 
pH 8.0 was added and incubated overnight (20.5 h) at 37 °C. Finally, supernatant was transferred to a 
new vial, dried for 2.5 h at 45 °C in a vacuum concentrator, and redissolved in 30 µL 70 % acetonitrile 
in H2O containing 0.1 % FA (v/v) prior to LC-MS analysis [108].  
 
2.9. LC-MS/MS analysis 
2.9.1. RPLC-MS/MS analysis of protease Arg-C derived PSA peptides 
After sample preparation, samples were analyzed by LC-MS/MS using an Infinity 1290 UHPLC. The 
MS instrument was a QTRAP 6500 MS equipped with TurboVTM Ion Source. MS measurements were 
carried out in positive ionization mode using the following source parameters: curtain gas = 30 psi; 
collision gas = medium; ion spray voltage = 3500 V; temperature = 450 °C; gas 1 = 50 psi; 
gas 2 = 70 psi. Q1 and Q3 resolution was set to 0.7 ± 0.1 amu full width at half peak height at a scan 
rate of 10 Da/s, which is referred to as unit resolution in MRM mode. Analyte-specific MS parameters 
i.e. transitions, dwell time, DP, EP, CE, and CXP were optimized and are listed in Table 10. One 
MRM transition of each of the two peptides N(GlcNAc+Fuc)KSVILLGR (m/z 674.9/601.9) and 
KWIKDTIVANP (m/z 428.9/585.3) was selected to quantify fucosylated PSA and total PSA, 
respectively. Pause time between single MRM transitions was set to 5 ms. Chromatographic 
separation was performed using the Acquity UPLC BEH C18 column at a flow rate of 0.4 mL/min. The 
injection volume was 20 µL and the column oven temperature was set to 50 °C. The mobile phases 
consisted of water containing 0.1 % FA (v/v) as eluent A and acetonitrile containing 0.1 % FA (v/v) as 
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eluent B. The gradient started with 90 % eluent A for 2 min and was then decreased to 84 % eluent A 
within 13 min. Then, the percentage of eluent A was decreased to 5 % linearly within 1 min and held 
for 2 min. Afterwards eluent A was increased again to 90 % within 0.1 min and the column was 
re-equilibrated for 4.9 min at this percentage. In total, each run took 23 min taking into account the 
column re-equilibration time [108]. 
 
2.9.2. HILIC-MS/MS analysis of tryptic PSA peptides  
After sample preparation, samples were analyzed by LC-MS/MS using an Infinity 1290 UHPLC. The 
MS instrument was the QTRAP 6500 MS equipped with TurboVTM Ion Source. MS measurements 
were carried out in positive ionization mode using the following source parameters: curtain 
gas = 30 psi; collision gas = high; ion spray voltage = 4500 V; temperature = 450 °C; gas 1 = 50 psi; 
gas 2 = 70 psi. Q1 and Q3 resolution was set to 0.7 ± 0.1 amu full width at half peak height at a scan 
rate of 10 Da/s, which is referred to as unit resolution in MRM mode. Analyte-specific MS parameters 
i.e. transitions, dwell time, DP, EP, CE, and CXP were optimized and are listed in Table 13. One 
MRM transition of each of the two peptides N(GlcNAc+Fuc)K (m/z 464.2/261.2) and LSEPAELTDAVK 
(m/z 636.9/943.4) was selected to quantify core-fucosylated PSA and total PSA, respectively. Pause 
time between single MRM transitions was set to 5 ms. Chromatographic separation was performed 
using the XBridge Amide column at a flow rate of 0.3 mL/min. The injection volume was 20 µL and the 
column oven temperature was set to 50 °C. The mobile phases consisted of water containing 0.1 % 
FA (v/v) as eluent A and acetonitrile containing 0.1 % FA (v/v) as eluent B. The gradient started with 
90 % eluent B and was decreased to 50 % eluent B within 10 min. Then, the percentage of eluent B 
was decreased to 0 % linearly within 3.1 min and held for 0.9 min. Afterwards eluent B was increased 
again to 90 % within 0.1 min and column was re-equilibrated for 5.9 min at this percentage. In total, 
each run took 20 min taking into account the column equilibration time [108]. 
  
 Chapter III: LC-MS/MS method development for analysis of site-specific core-fucosylation of PSA 
53 
 
2.9.3. Multiple reaction monitoring cubed (MRM³) 
Analysis in MRM³ mode was carried out in positive ionization mode using an ion spray voltage of 
5500 V. The TurboVTM Ion Source was operated at 450 °C. The curtain gas flow was set to 50 psi and 
auxiliary gas 1 and 2 were set to 50 and 70 psi, respectively. The resolution in Q1 was adjusted to 
0.7 ± 0.1 amu full width at half peak height, referred to as unit resolution. The Q3 entry barrier was set 
to 8 V. Linear ion trap (LIT) fill time and excitation time were set to 100 and 25 ms, respectively. 
MS/MS parameters used to fragment 1st precursor ions to 2nd precursor ions in Q2 are described in 
Table 13. Specified 2nd precursor ions were collected, isolated and further fragmented in LIT using 
parameters listed in Table 5. The resulting fragment ions were trapped into LIT prior to being scanned 
out and detected. 
 
Table 5: MRM³ parameters of four surrogate peptides.  
Target Surrogate peptide 1st 
Precursor 
ion [Da] 
2nd 
Precursor 
ion [Da] 
Product 
ion scan 
[Da] 
AF2 start-
stop [V] 
AF3 start-
stop [V] 
EXB start-
stop [V] 
Non-fucosylated 
PSA 
N(GlcNAc)K / 
N(GlcNAc+Fuc)K  
464.2 261.1 60-250 0.12-0.18 2.119-
2.710 
-152.8 
to -145.3 
Fucosylated 
PSA 
N(GlcNAc+Fuc)K  610.3 464.2 200-280 0.06-0.14 2.555-
2.804 
-147.3 
to -144.2 
Total PSA LSEPAELTDAVK 636.8 943.6 400-930 0.1-0.13 3.177-
4.825 
-139.5 
to -118.7 
Total PSA SVILLGR 379.3 579.4 150-550 0.09-0.09 2.399-
3.643 
-149.3 
to -133.6 
AF2 = excitation energy used to fragment isolated 2nd precursor ions in the LIT 
AF3 = trap radio frequency amplitude applied to Q3 when scanning the ions out of the LIT 
EXB = exit barrier used to mass-selectively eject ions from the LIT 
 
2.10. Data acquisition and analysis 
Instrument control, data acquisition, data processing and data analysis were performed using Analyst 
software (Version 1.6.2, AB Sciex). In order to characterize the developed method the dwell time was 
set to 100 ms for each analyte generating sufficient data points per peak (> 25) for accurate 
quantification. The IntelliQuan integration algorithm was used for automatic peak integration and 
MRM spectra were processed with a smoothing width factor of 3 points. In case of inadequate peak 
detection and integration, peaks were integrated manually. Calibration curves were generated by 
plotting peak areas (y) against analyte concentrations (x). In case of samples containing different 
amounts of non-fucosylated and fucosylated PSA the peak area ratio of N(GlcNAc+Fuc)K to 
LSEPAELTDAVK was plotted against the relative amount of fucosylated PSA ranging from 0 to 100 % 
[108].  
  
 Chapter III: LC-MS/MS method development for analysis of site-specific core-fucosylation of PSA 
54 
 
3. Results and discussion 
3.1. Endoglycosidase selection 
Preliminary experiments were performed to find an efficient endoglycosidase which allows partial 
deglycosylation of PSA between the two N-acetylglucosamine (GlcNAc) residues in the 
diacetylchitobiose core of the oligosaccharide linked to Asn-69. The aim was to generate a truncated 
PSA glycoprotein containing one GlcNAc residue with or without fucose (Fuc) that could be easily 
distinguished from PSA forms with complex glycan structures using ESI-MS. Five different 
endoglycosidases were tested including IgGZERO® Endo S from Streptococcus pyogenes AP1, 
GlycINATOR® Endo S2 from Streptococcus pyogenes M49, Remove-iT® Endo S from Streptococcus 
pyogenes, Endo F2 from Elizabethkingia miricola and Endo F3 form Elizabethkingia 
meningosepticum. Endoglycosidase treatment was performed using native PSA as described in 
chapter III section 2.4 and the enzymatic activity was evaluated based on mass spectra which were 
screened for partially deglycosylated PSA and non-deglycosylated PSA. Representative mass spectra 
are shown in Figure 10. Besides five different endoglycosidases, different enzyme mixtures were 
tested. In addition, enzyme amounts and reaction buffers were varied. The results of these 
experiments are summarized in Table 6.  
 
Table 6: Overview of experiments using different endoglycosidases and conditions. 
Experiment 
with 
Sialidase 
Endoglycosidase amount 
per µg PSA [units] 
Efficiency 
IgGZERO® Endo S  8 - 
Remove-iT® Endo S  8 - 
GlycINATOR® Endo S2 (3h incubation)  8 + 
Endo F2  0.01 + 
GlycINATOR® Endo S2  8 ++ 
Remove-iT® Endo S x 200 +++ 
GlycINATOR® Endo S2 x 8 +++ 
Endo F3  0.01 +++++ 
Endo F3 (3 h incubation)  0.01 +++++ 
Endo F3 x 0.01 +++++ 
Endo F3 (3x amount)  0.03 +++++ 
Endo F3 + Endo F2  0.02 +++++ 
Endo F3 in TRIS/HCl at pH 7.8  0.01 ++++ 
 
Taking into account that native PSA possesses five disulfide bonds linking amino acid positions 
31-173, 50-66, 152-219, 184,198 and 209-234, the molecular weight of PSA without glycans, signal 
peptide and propeptide is 26,079 Da. Therefore, native PSA with a GlcNAc residue (+203 Da) or 
GlcNAc+Fuc residue (+349 Da) possesses a molecular weight of 26,282 Da or 26,428 Da, 
respectively. As shown in Figure 10, native PSA treated with IgGZERO® Endo S and 
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Remove-iT® Endo S showed no difference compared to untreated PSA, indicating that these two 
endoglycosidases possess no enzymatic activity on native PSA. The other endoglycosidases 
GlycINATOR® Endo S2, Endo F2 and Endo F3 showed enzymatic activity on native PSA, indicated by 
the generated target peak at m/z 26,428 Da, in which Endo F3 showed superior activity compared to 
all other endoglycosidases tested in this study.  
 
 
Figure 10: Representative mass spectra of partially deglycosylated PSA using different 
endoglycosidases a) no enzyme, b) Remove-iT® Endo S, c) IgGZERO® Endo S, d) Endo F2, 
e) GlycINATOR® Endo S2, f) Endo F3, and g) GlycINATOR® Endo S2 with Sialidase showing the 
target peaks at m/z 26,282 Da and m/z 26,428 Da as well as major peaks of non-deglycosylated PSA 
in the mass range from m/z 27,500 to 29,500 Da. Glycan composition as illustrated is in agreement 
with previously performed in-house N-glycan analysis by LC-MS. 
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Furthermore, Endo F3 was the most efficient enzyme regarding incubation time and required enzyme 
amount per µg PSA (Table 6). The enzyme activity of GlycINATOR® Endo S2 and 
Remove-iT® Endo S could be improved, when PSA was previously treated by sialidase from 
Clostridium perfringens, which specifically removes terminal α(2,3)-, α(2,6)-, or α(2,8)-linked sialic 
acids giving a mass shift of -291 Da per sialic acid molecule. It is known that extended structures on 
glycan chains, such as sulfate, phosphate, poly-N-acetyl-lactosamines or sialic acids can render the 
glycoprotein partially or completely resistant to cleavage by distinct enzymes including 
endoglycosidases which requires removal of each residue before the respective enzyme will 
work [110]. Partial deglycosylation using sialidase followed by GlycINATOR® Endo S2 treatment 
resulted in a PSA species containing one GlcNAc residue (m/z 26,282 Da), which was not detected 
using the other endoglycosidases. However, enzymatic activity regarding the generation of PSA with 
GlcNAc+Fuc modification was significantly lower compared to Endo F3. Native PSA treated by 
sialidase followed by Endo F3 showed no difference to samples exclusively treated by Endo F3. In 
addition, Endo F3 activity was slightly reduced by using a 100 mM TRIS/HCl buffer containing 
10 mM CaCl2 at pH 7.8 which is in agreement with the manufacturer’s documentation specifying the 
pH optimum at 4.5. Residual peaks particularly at m/z 28,285 Da and m/z 28,636 Da showed that 
glycan cleavage of native PSA using Endo F3 is not complete. These two major peaks could be 
assigned to non-fucosylated species by calculation of the m/z difference to native PSA and by 
previously performed in-house MS-based N-glycan analysis indicating low Endo F3 activity on glycan 
structures without Fuc, which is consistent with the literature [111].  
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3.2. Protease and surrogate peptide selection  
3.2.1. In silico digestion of PSA  
For successful quantification of low abundant proteins in complex biosamples, the selection of a 
highly MS-responsive surrogate peptide is a critical step. Normally, every peptide generated by 
digestion of the target protein can be considered as a potential surrogate peptide. In contrast, peptide 
selection for quantification of partially glycosylated PSA is limited to peptides containing the 
N-glycosylation site at Asn-69. In this study, surrogate peptide candidates were initially sought by in 
silico analysis using the PeptideMass tool that predicts fragment peptides on the basis of the protein’s 
amino acid sequence and the proteolytic enzyme specificity. Based upon in silico digestion of PSA 
(Uni-ProtKB P07288) simulated by using different proteases including trypsin, Lys-C, Lys-N, Arg-C, 
Asp-N, Glu-C, chymotrypsin, pepsin, proteinase K, elastase, and thermolysin, enzymes were 
preselected regarding their suitability for usage in laboratory in vitro digestion experiments (Table 7). 
 
Table 7: In silico digestion of PSA (Uni-ProtKB P07288) simulated by using different enzymes. 
Enzyme Sequence of surrogate peptide 
without glycan (Number of 
amino acids)a 
Molecular weight 
(monoisotopic) 
[Da] 
Suitable for usage in 
in vitro digestion 
experiments of PSA 
Trypsin NK (2) 260.1 with restrictions b 
Lys-C HSQPWQVLVASRGRAVCGGVL
VHPQWVLTAAHCIRNK (37) 
4073.2 no 
Lys-N KHSQPWQVLVASRGRAVCGGV
LVHPQWVLTAAHCIRN (37) 
4073.2 no 
Protease Arg-C NKSVILLGR (9) 998.6 yes 
Asp-N IVGGWECEKHSQPWQVLVASR
GRAVCGGVLVHPQWVLTAAHCI
RNKSVILLGRHSLFHPE (60) 
6660.5 no 
Glu-C KHSQPWQVLVASRGRAVCGGV
LVHPQWVLTAAHCIRNKSVILLG
RHSLFHPE (52) 
5787.1 no 
Chymotrypsin TAAHCIRNKSVIL (13) 1424.8 with restrictions c 
Pepsin (pH = 1.3) TAAHCIRNKSVIL (13) 1424.8 with restrictions c 
Proteinase K RNKSV (5) 602.4 with restrictions b 
Elastase RNKS (4) 503.3 with restrictions b 
Thermolysin IRNKS (5) 616.4 with restrictions b 
a N-glycosylation site at asparagine-69 illustrated in bold letter 
b Suitability for usage in in vitro digestion of PSA restricted due to peptide length 
c Suitability for usage in in vitro digestion of PSA restricted due to cysteine containing peptide sequence 
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A general criterion concerning surrogate peptide selection is the peptide length ideally comprising 7 to 
20 amino acids which enhances the probability to obtain a unique and highly MS-responsive 
peptide [112]. Although surrogate peptides of PSA generated by trypsin, proteinase K, elastase and 
thermolysin do not fulfill this recommended criterion, these enzymes were tested in subsequent in 
vitro digestion experiments as the lack of uniqueness may be accomplished by using a highly specific 
anti-PSA antibody later in the workflow. Proteases Lys-C, Lys-N, Asp-N and Glu-C were excluded 
from in vitro experiments as they generate surrogate peptides containing 37, 52, or 60 amino acids 
which is far away from the recommended optimum. Peptides of this length would probably result in 
low MS response due to wide distributed charge states. Furthermore, these peptides contain up to 
three cysteines which may be susceptible to modification in vivo or during sample preparation and 
analysis. Peptides generated by chymotrypsin and pepsin also containing one cysteine were still 
included in in vitro experiments as the peptide length was in the optimal range and the N-glycosylation 
site at Asn-69 was centrally located in the sequence. The latter might be beneficial over sequences 
containing the N-glycosylation site close to the enzymatic cleavage site which could decrease the 
enzyme activity due to hindered enzyme accessibility. The N-terminal cleavage site of the surrogate 
peptide generated by protease Arg-C is next to the N-glycosylation site at Asn-69. However, 
considering the restrictions of the other enzymes mentioned before, protease Arg-C was the preferred 
enzyme for digestion of PSA after evaluation of in silico data.  
 
3.2.2. In vitro digestion of PSA 
In silico digestion was a useful aid for enzyme preselection but its data had to be confirmed by 
laboratory experiments as theoretical digestion did not consider unspecific and missed cleavages. 
The final protease and surrogate peptide selection was based on results generated by in vitro 
digestion of partially deglycosylated PSA prior to peptide mapping by LC-MS/MS as described in 
chapter III section 2.5. In total, seven preselected enzymes were tested including trypsin, elastase, 
proteinase K, thermolysin, protease Arg-C, pepsin and chymotrypsin. Comprehensive lists of 
identified peptides are shown in the appendix. In summary, partially deglycosylated target peptides 
were only detected in samples treated by protease Arg-C and pepsin generating the glycopeptides 
N(GlcNAc+Fuc)KSVILLGR and TAAHCIRN(GlcNAc+Fuc)KSVIL, respectively. Non-fucosylated 
species were not detected which is probably due to low Endo F3 activity on structures without Fuc as 
described before. In samples digested by trypsin and chymotrypsin respective glycopeptides 
N(GlcNAc+Fuc)K and TAAHCIRN(GlcNAc+Fuc)KSVIL were not found, while neighboring peptide 
sequences were detected. The tryptic peptide is a polar dipeptide which was not retained by RPLC 
and thus was not detectable. In subsequent experiments, this peptide could be identified using 
hydrophilic interaction chromatography (HILIC) coupled to MS. Theoretical glycopeptides generated 
by chymotrypsin, elastase, thermolysin and proteinase K digestion could neither be detected by the 
automatic search algorithm of the Proteome DiscovererTM software nor by manual mass search in 
total ion chromatograms, which indicates one or more unspecific cleavages.  
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Trypsin, protease Arg-C and pepsin demonstrated to release partially deglycosylated surrogate 
peptides from PSA which were detectable by MS, although the enzymatic cleavage sites of protease 
Arg-C and trypsin were directly next to the N-glycosylation site. As mentioned before, the surrogate 
peptide generated by pepsin contains one cysteine. Thus, protease Arg-C and trypsin seemed to be 
more suitable in order to generate surrogate peptides for quantification of partially deglycosylated 
PSA. For quantification of total PSA using protease Arg-C, two peptides KWIKDTIVANP and 
PSLYTKVVHYR identified in in vitro experiments were selected as surrogate peptide candidates as 
they fulfill recommended criteria for mass spectrometry-based protein quantification (ideal peptide 
length, no reactive amino acids, uniqueness, observability by MS) [112]. Peptides LSEPAELTDAVK 
and SVILLGR were selected as potential tryptic surrogate peptides for total PSA quantification, which 
are already described in the literature [113, 114]. An overview of selected surrogate peptide 
candidates for quantification of total PSA and partially deglycosylated PSA using protease Arg-C and 
trypsin as digestion enzymes is shown in Table 8. 
 
Table 8: Selected surrogate peptide candidates for quantification of total and partially deglycosylated 
PSA based upon in silico and in vitro digestion using protease Arg-C and trypsin. 
Enzyme Surrogate peptide candidates for 
quantification of total PSA  
Surrogate peptides for quantification 
of partially deglycosylated PSA  
Protease Arg-C KWIKDTIVANP 
PSLYTKVVHYR 
N(GlcNAc+Fuc)KSVILLGR 
N(GlcNAc)KSVILLGR 
Trypsin LSEPAELTDAVK 
SVILLGR 
N(GlcNAc+Fuc)K 
N(GlcNAc)K 
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3.3. Protease Arg-C-based approaches  
3.3.1. Surrogate peptide selection and MRM parameter optimization 
In preliminary experiments potential PSA surrogate peptides generated by protease Arg-C digestion 
were selected. Following, analyte-specific MS parameters including transitions, DP, EP, CE, and CXP 
were optimized. As surrogate peptides generated by protease Arg-C were not available as synthetic, 
pure standard peptides, a systematic procedure based on several LC-MS/MS runs with varying 
parameters was applied to obtain optimal analyte-specific MS parameters. A schematic overview of 
the MRM parameter optimization procedure with or without standard peptides is shown in Figure 11.  
 
 
Figure 11: Systematic procedure for MRM parameter optimization with or without standard peptides. 
Declustering potential = DP, entrance potential = EP, collision energy = CE, and cell exit 
potential = CXP. 
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First, enhanced product ion (EPI) scans of selected precursor ions were performed in order to identify 
sensitive precursor/product ion pairs and their respective CE values (Table 3). For this purpose, MS 
method parameters were held constant except of CE which was initially set to 7 V and increased by 
3 V in each run. The peptides KWIKDTIVANP and PSLYTKVVHYR were selected as surrogate 
peptide candidates for quantification of total PSA (Table 8). As shown in Figure 12 the most sensitive 
transition of peptide KWIKDTIVANP was obtained by measuring the triple charge state 
m/z 428.9 (MH+3) in Q1 and the resulting fragment ion m/z 585.1 (b10+2) in Q3 applying CE of 10 V. 
Using the double charge state m/z 642.9 Da of peptide KWIKDTIVANP as precursor ion resulted in 
less lower signal intensities. For peptide PSLYTKVVHYR the most sensitive precursor/product ion 
pair was m/z 454.9/633.1 (MH+3/y10+2) applying CE of 13 V, while the double charged precursor ion 
m/z 681.9 (MH+2) signal was less intensive. Single charge states of the two peptides were not 
amenable to analysis as they exceed the upper mass range of the MS. Comparison of the most 
sensitive transitions of the two surrogate peptide candidates revealed that transition m/z 428.9/585.1 
of peptide KWIKDTIVANP was more sensitive by a factor of 4 over transition m/z 454.9/633.1 of 
peptide PSLYTKVVHYR. Therefore peptide KWIKDTIVANP was used for final MRM parameter 
optimization.  
 
 
Figure 12: Enhanced product ion (EPI) scans of selected precursor ions of peptides KWIKDTIVANP, 
PSLYTKVVHYR, N(GlcNAc)KSVILLGR and N(GlcNAc+Fuc)KSVILLGR and their most intensive 
product ions at different collision energies (CE). 
 
In-source fragmentation (ISF) is a common phenomenon in MS analysis of glycopeptides in which 
especially the glycosidic bond between GlcNAc and Fuc is labile in dissociation [115]. The most 
intensive precursor/product ion pair of non-fucosylated PSA was m/z 601.9/757.5 (MH+2/y7+1) 
applying CE of 25 V. The precursor ion m/z 601.9 is identical to the double charged ion of fucosylated 
PSA obtained by in source fragmentation when Fuc is lost (1347.8 Da – 146.1 Da = 1201.6 Da; 
MH+2 = m/z 601.9) making differentiation by MS impractical. As chromatographic separation of 
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N(GlcNAc)KSVILLGR and N(GlcNAc+Fuc)KSVILLGR was not achieved by reversed phase liquid 
chromatography (RPLC), in this workflow only the glycopeptide N(GlcNAc+Fuc)KSVILLGR was used 
as surrogate peptide for quantification of core-fucosylated PSA. The most intensive precursor/product 
ion pair was m/z 674.9/601.9 (MH+2/MH+2 minus Fuc) applying CE of 22 V. No signals were detected 
using single and triple charge states of N(GlcNAc+Fuc)KSVILLGR as precursor ions. Most sensitive 
transitions and respective CE values of surrogate peptides generated by protease Arg-C are listed in 
Table 9. Based on these results a multiple reaction monitoring (MRM) method was created. This 
method was run several times but each run one of the initial analyte-specific MS parameters including 
DP, EP, CXP and CE was varied resulting in the final MRM parameters shown in Table 10. 
 
Table 9: Most sensitive transitions and their respective CE values identified in EPI scan experiments. 
Peptide generated by 
protease Arg-C digestion 
Charge 
state 
Precursor ion 
[Da] 
Product ion 
[Da] 
Collision 
energy [V] 
KWIKDTIVANP 3+ 428.9 585.1 10 
PSLYTKVVHYR 3+ 454.9 633.1 13 
N(GlcNAc)KSVILLGR 2+ 601.9 757.5 25 
N(GlcNAc+Fuc)KSVILLGR 2+ 674.9 601.9 22 
 
Table 10: Final MRM parameters of surrogate peptides for quantification of total and core-fucosylated 
PSA using protease Arg-C as digestion enzyme. 
Target Surrogate peptide Charge 
state 
Q1 [Da] Q3 [Da] DP 
[V] 
EP 
[V] 
CE 
[V] 
CXP 
[V] 
Total PSA KWIKDTIVANP 3+ 428.9 585.3 35 7 14 15 
Core-fucosylated PSA N(GlcNAc+Fuc)KSVILLGR 2+ 674.9 601.9 75 9 26 15 
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3.3.2. Overview of the experimental workflow using MSIA tips 
In order to determine total and core-fucosylated PSA in human serum an analytical method was 
developed comprising immunoaffinity enrichment, two enzymatic steps and LC-MS/MS analysis. The 
experimental workflow is illustrated in Figure 13 and described in the experimental section. 
Immunoaffinity enrichment was performed by using biotinylated anti-PSA antibody bound to 
streptavidin-coated MSIA tips to enrich PSA from complex serum matrix. Enriched PSA was eluted 
from the pipette tip and partially deglycosylated in solution using Endo F3 to simplify glycan 
microheterogeneity. Afterwards, surrogate peptides of partially deglycosylated PSA were generated 
by enzymatic treatment using protease Arg-C as digestion enzyme. Selected peptides were 
measured by LC-MS/MS using RPLC without additional up-front clean up.  
 
 
Figure 13: Schematic overview of the experimental workflow for the determination of core-fucosylated 
and total PSA using a MSIA tip-based and protease Arg-C-assisted LC-MS/MS method. 
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3.3.3. Determination of core-fucosylated and total PSA in serum samples  
Analysis of four female serum samples containing different concentrations of core-fucosylated 
(0, 15.6, 31.2, 46.8 ng/mL) and total PSA (0, 20, 40 and 60 ng/mL) was performed in order to 
generate calibration curves by plotting peak areas of peptides N(GlcNAc+Fuc)KSVILLGR and 
KWIKDTIVANP against respective concentrations (Figure 14).  
 
 
Figure 14: Calibration curves and correlation coefficients R² of core-fucosylated (left) and total PSA 
(right) obtained by plotting peak areas of N(GlcNAc+Fuc)KSVILLGR and KWIKDTIVANP against 
respective concentrations, n = 2. 
 
The most sensitive transition of each peptide was selected for quantification, which means Q1/Q3 ion 
pairs were m/z 674.9/601.9 and 428.9/585.3 for core-fucosylated and total PSA, respectively. Each 
concentration was prepared in duplicate followed by analysis as illustrated in Figure 13. Both peptides 
showed poor linearity over the working range with correlation coefficients R² < 0.90. In this study peak 
intensities with a signal-to-noise ratio of 3 and 10 were considered acceptable for determining the 
LLOD and LLOQ, respectively. The LLOD of core-fucosylated PSA was 15.6 ng/mL and the LLOQ 
was 46.8 ng/mL whereas the LLOD and LLOQ of total PSA were much lower than 20 ng/mL. More 
precise values were not determined as it was obviously that core-fucosylated PSA would not meet the 
required LLOQ ≤ 1 ng/mL by applying the described workflow. Representative chromatograms for 
0, 20 and 60 ng/mL total PSA spiked-in female serum are shown in Figure 15. 
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Figure 15: Extracted ion chromatograms of transitions monitored for a) core-fucosylated PSA 
(N(GlcNAc+Fuc)KSVILLGR, m/z 674.9/601.9) and b) total PSA (KWIKDTIVANP, m/z 428.9/585.3) 
derived from 0, 20 and 60 ng/mL total PSA spiked-in female serum samples. 
 
3.3.4. Optimization approaches 
As the described workflow was limited to measure core-fucosylated PSA in the low ng/mL 
concentration range, further approaches were conducted to improve the method’s sensitivity. Crucial 
impacts including the antibody type, the order of digestion steps as well as antibody and enzyme 
amounts were investigated.  
 
3.3.4.1. Antibody type 
Four different biotinylated monoclonal antibody fragments were tested in which PSA30-F(ab’)2 
binding to epitope 1 captures free PSA and PSA10-Fab’ binding to epitope 3a, PSA36-Fab’ binding to 
epitope 6b as well as PSA66-F(ab’)2 binding to epitope 4b capture total PSA [84]. The capture 
efficiencies of PSA10-Fab’ and especially PSA30-F(ab’)2 were lower compared to PSA36-Fab’ and 
PSA66-F(ab’)2 which showed comparable results (Figure 16). These results were supported by data 
obtained from surface plasmon resonance measurements using a streptavidin modified capture chip 
(Table 11). Both PSA36-Fab’ and PSA66-F(ab’)2 showed high affinity to PSA in the subnanomolar 
range. By using PSA66-F(ab’)2 the complex stability expressed as t1/2-dissociation, which is the time 
for a 50 % decline in PSA binding, was superior to the other antibody fragments. The molar ratio 
indicated the stoichiometric integrity of all antibody fragments. As the method sensitivity could not be 
improved by using other antibody fragments, PSA36-Fab’ fragment was kept as antibody for further 
experiments.  
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Figure 16: Workflow capture efficiency of four different antibody fragments tested by monitoring total 
PSA levels (KWIKDTIVANP, m/z 428.9/585.3) using an Endo F3 and protease Arg-C-assisted 
LC-MS/MS method, n = 1. 
 
Table 11: Data obtained by surface plasmon resonance measurements of four different antibody 
fragments. 
Biotinylated antibody fragment KD [nM] t1/2-dissociation [min] Molar ratio (MR) 
PSA30-F(ab’)2 3.0 16 1.5 
PSA10-Fab’ 1.0 5 1.0 
PSA36-Fab’ 0.5 3 0.8 
PSA66-F(ab’)2 0.2 40 1.8 
KD = Affinity constant 
t1/2 dissociation = halftime of complex dissociation 
MR: theoretical F(ab’)2 max. 2.0, Fab’ max. 1.0 
 
3.3.4.2. Antibody and enzyme amount 
Following antibody selection, respective amounts of antibody (0.25 µg, 1.25 µg and 5 µg), Endo F3 
(0.005, 0.01 and 0.02 units) and protease Arg-C (0.28, 1.4, 14, 140 and 500 ng) were tested in 
separate experiments applying a similar MSIA tip-based LC-MS/MS approach as mentioned in 
chapter III section 2.7.1. No influence on peak areas of core-fucosylated and total PSA was observed 
using different Endo F3 and antibody amounts (data not shown). Total PSA monitored by peptide 
KWIKDTIVANP showed increasing peak areas with increasing amounts of protease Arg-C (Figure 17) 
in which the optimum was approximately at 140 ng protease Arg-C. In contrast, the most intensive 
peak of core-fucosylated PSA monitored by glycopeptide N(GlcNAc+Fuc)KSVILLGR was obtained 
using 14 ng protease Arg-C. Both lower and higher enzyme amounts diminished the peak area 
significantly. As mentioned before, protease Arg-C used in this work cleaves at the C-terminus of 
arginine residues but also at the carboxyl side of particular lysines. Using higher amounts of protease 
Arg-C leads to cleavage at the lysine of peptide N(GlcNAc+Fuc)KSVILLGR into smaller peptide 
fragments and thus to the loss of signal intensity. Peptide KWIKDTIVANP also possesses potential 
cleavage sites at two lysine residues but seems to be more stable against trypsin activity. This 
assumption is supported by data of an aqueous tryptic digest of PSA where the intact peptide 
 Chapter III: LC-MS/MS method development for analysis of site-specific core-fucosylation of PSA 
67 
 
KWIKDTIVANP was also detected (Appendix). Furthermore, trypsin activity seems to be an inherent 
issue of protease Arg-C as it was also observed in samples treated by Arg-C proteases from four 
different vendors. 
 
 
Figure 17: Different protease Arg-C amounts tested by monitoring total PSA (KWIKDTIVANP, 
m/z 428.9/585.3, left) and core-fucosylated PSA levels (N(GlcNAc+Fuc)KSVILLGR, m/z 674.9/601.9, 
right) applying a MSIA-based LC-MS/MS approach. Signal intensities are normalized to samples 
treated with 14 ng protease Arg-C and expressed in %, n = 1.   
 
3.3.4.3. Order of digestion and elution steps    
Following MSIA tip-based immunoaffinity enrichment, the described method contains an elution step 
prior to partial deglycosylation in solution using Endo F3 and digestion with protease Arg-C. According 
to the literature, there seems to be no clear consensus on whether or not the target protein should be 
eluted from the immobilized antibody prior to digestion [116]. In order to reach the lowest possible 
limit of quantification for core-fucosylated PSA analysis, several different sample preparation 
procedures with or without elution were applied as summarized in Table 12. Proteolytic digestion and 
deglycosylation were executed in solution, on filter or while PSA was still captured on the tip. 
Furthermore, the order of digestion steps which might also affect the method’s sensitivity was 
investigated.  
 
Deglycosylation of PSA either on filter or immobilized on tip enabled simple buffer exchange prior to 
proteolytic digestion which was required for optimal enzymatic activity. On the other hand, elution is 
often accompanied by vacuum concentration and further sample clean up strategies. An additional 
elution step could be avoided by proteolytic digestion of immobilized PSA as the capture antibody is 
simultaneously cleaved, thus breaking the antibody-PSA interaction. However, this procedure 
generates a complex peptide mixture requiring an effective chromatographic separation prior to MS 
analysis. As shown in Figure 18, filter-based sample preparation procedures were less efficient 
compared to in solution or on tip workflows especially concerning core-fucosylated PSA which might 
be due to hindered accessibility of protease Arg-C or unspecific binding of generated peptides to the 
filter. Comparable results were obtained among workflows conducted in solution or on tip independent 
of whether deglycosylation or proteolytic digestion was performed first.    
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Table 12: Overview of seven sample preparation procedures comprising in solution, on tip or on filter 
digestion and partial deglycosylation.  
Sample 
preparation 
method 
Step 1 Step 2 Step 3 
1 Protease Arg-C on MSIA Wash out Endo F3 in solution 
2 Elution Protease Arg-C on filter Endo F3 in solution 
3 Elution Protease Arg-C in solution Endo F3 in solution 
4 Endo F3 on MSIA Elution Protease Arg-C in solution 
5 Elution Endo F3 on filter Protease Arg-C on filter 
6 Elution EndoF3 in solution Protease Arg-C in solution 
7 Endo F3 on MSIA Protease Arg-C on MSIA Wash out 
 
 
Figure 18: Peak areas of total PSA (KWIKDTIVANP, m/z 428.9/585.3, left) and core-fucosylated PSA 
(N(GlcNAc+Fuc)KSVILLGR, m/z 674.9/601.9, right) obtained by applying seven different sample 
preparation procedures summarized in Table 12, n = 1. 
 
3.3.4.4. Multiple reaction monitoring (MRM) compared to selected ion monitoring (SIM) 
In selected ion monitoring (SIM) analysis, ions of a selected m/z will reach the detector, except for 
those lost in transmission through the quadrupole. In contrast, using multiple reaction monitoring 
(MRM) analysis ions are lost due to transmission through the first and the third quadrupole and due to 
incomplete fragmentation and different fragmentation ways in the collision cell. Consequently, in a 
matrix free environment SIM analysis allows for the detection of more ions representing the analyte, 
and thus can be more sensitive as compared to MRM analysis. As sample preparation in the 
described method comprises several steps including immunoaffinity enrichment, matrix contaminants 
might largely be removed. Therefore, SIM mode was compared to MRM mode using a 427 ng/mL 
total PSA spiked-in female serum sample. As shown in Figure 19, core-fucosylated and total PSA 
could confidently be detected using MRM mode while no specific analyte signals were detected in 
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SIM mode. This was probably due to the high baseline noise and co-eluting species obtained in SIM 
mode indicating that matrix contaminants and other interferences e.g. coming from the streptavidin-
coated MSIA tips were not completely removed despite extensive sample preparation. 
 
 
Figure 19: Comparison of a) SIM mode and b) MRM mode analysis of a 427 ng/mL total PSA spiked-
in female serum sample monitoring total PSA (KWIKDTIVANP, left) and core-fucosylated PSA 
(N(GlcNAc+Fuc)KSVILLGR, right).  
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3.4. From reversed phase to hydrophilic interaction liquid 
chromatography 
The MSIA tip-based workflow using protease Arg-C lacked in sensitivity regarding core-fucosylated 
PSA most likely due to undesired trypsin activity observed with the usage of protease Arg-C. Other 
parameters including the antibody type, the enzyme and antibody amounts and the order of digestion 
steps either had no explicit influence on the method’s sensitivity or were already operated in the 
optimal way. Another disadvantage accompanied with the workflow was that the two glycopeptides 
N(GlcNAc)KSVILLGR and N(GlcNAc+Fuc)KSVILLGR could not be separated by reversed phase 
liquid chromatography (RPLC) column (Acquity UPLC BEH C18, 130 Å, 1.7 µm, 2.1 x 150 mm, 
Waters) used in this workflow. Confident detection of non-fucosylated PSA was impractical due to 
in-source fragmentation (ISF) of glycopeptide N(GlcNAc+Fuc)KSVILLGR loosing Fuc before entering 
the MS. Hence, protease Arg-C was replaced by trypsin identified as a suitable alternative enzyme in 
preliminary experiments.  
 
Two RPLC columns (Acquity UPLC BEH C18, 130 Å, 1.7 µm, 2.1 x 150 mm, Waters and Atlantis® T3, 
3 µm, 2.1 x 100 mm, Waters) were tested but could not retain the polar dipeptides N(GlcNAc)K and 
N(GlcNAc+Fuc)K generated by tryptic digestion of PSA. Elution in the column dead volume adversely 
affects analysis of human samples due to co-eluting endogenous matrix components. Therefore, the 
column selectivity was switched to hydrophilic interaction chromatography (HILIC) which provides the 
possibility to effectively separate polar compounds. Among several commercially available HILIC 
columns XBridge Amide column (130 Å, 3.5 µm, 2.1 x 100 mm, Waters) was selected for further 
experiments as it showed baseline separation of peptides N(GlcNAc)K, N(GlcNAc+Fuc)K, SVILLGR 
and LSEPAELTDAVK (Figure 20). The core-fucosylated peptide N(GlcNAc+Fuc)K eluted 20 s later 
than the related non-fucosylated peptide. This is due to the addition of core-fucose which increases its 
hydrophilicity. Usually, the weak mobile phase component in HILIC is acetonitrile and samples are 
ideally dissolved in solutions with the same acetonitrile composition as the mobile phase starting 
conditions [117]. However, limited solubility of most polar analytes in high organic mixtures is 
challenging. In order to obtain a good balance between analyte solubility, chromatographic behavior 
and MS response, a tryptic digest of partially deglycosylated PSA was diluted in six compositions 
(0-100 %, v/v) of eluent A (H2O with 0.1 % FA) and eluent B (acetonitrile with 0.1 % FA) and peptides 
N(GlcNAc+Fuc)K, SVILLGR and LSEPAELTDAVK were monitored by LC-MS/MS (Figure 22-24). 
Each sample composition was prepared in two concentrations. High concentrations (303 ng/mL PSA) 
were used for injection of low volumes (5 µL) and vice versa low concentrations (75.75 ng/mL PSA) 
were used for injection of high volumes (20 µL) resulting in the same analyte amount on column. 
Samples diluted in 100 % eluent B showed low signals for all three peptides irrespective of the 
injection volume indicating that peptides were not sufficiently solved. Peptide N(GlcNAc+Fuc)K 
showed consistent signal intensity, constant retention time and reproducible peak shape among 
samples containing 80, 60, 40, 20 and 0 % (v/v) eluent B using low injection volumes (Figure 22). 
Peptide LSEPAELTDAVK showed comparable results among samples containing 80, 60 and 
40 % (v/v) eluent B and decreasing peak heights in samples with 20 and 0 % (v/v) eluent B using 5 µL 
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injection volumes (Figure 23). For peptide SVILLGR most intensive peaks were obtained in sample 
compositions with 80 and 60 % (v/v) eluent B using low injection volumes (Figure 24). High injection 
volumes had significantly more impact on peak shapes and signal intensities than low injection 
volumes. Peptides SVILLGR and LSEPAELTDAVK showed the most intensive peaks at 80 % (v/v) 
eluent B, while glycopeptide N(GlcNAc+Fuc)K had its optimum at 60 % (v/v) eluent B. Signal heights 
were clearly reduced and peak shapes of all three peptides were negatively affected caused by 
sample solvents with lower compositions of eluent B. Portions of peptide SVILLGR and 
LSEPAELTDAVK were actually eluted in the column dead volume at sample compositions lower than 
40 % eluent B. 
 
Figure 20: Chromatographic separation of four peptides SVILLGR (3.2 min), LSEPAELTDAVK 
(4.7 min), N(GlcNAc)K (6.9 min) and N(GlcNAc+Fuc)K (7.2 min), generated by tryptic digestion of 
PSA using a HILIC XBridge Amide column. 
 
Besides retention of polar analytes, another benefit of HILIC combined with ESI-MS detection is the 
acetonitrile-rich mobile phase providing favorable conditions for efficient ionization within the MS 
source resulting in improved sensitivity compared to the highly aqueous mobile phases used in RPLC. 
In this work, employing HILIC was 2-3 times more sensitive in measuring peptides N(GlcNAc+Fuc)K, 
SVILLGR and LSEPAELTDAVK compared to RPLC (Figure 21).  
 
 
Figure 21: Comparison of three peptides N(GlcNAc+Fuc)K, SVILLGR and LSEPAELTDAVK 
analyzed by HILIC and RPLC coupled to ESI-MS. 
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Figure 22: Chromatograms of peptide N(GlcNAc+Fuc)K diluted in different compositions of eluent A 
and B using 5 µL (left) and 20 µL (right) injection volume. 
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Figure 23: Chromatograms of peptide LSEPAELTDAVK diluted in different compositions of eluent A 
and B using 5 µL (left) and 20 µL (right) injection volume. 
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Figure 24: Chromatograms of peptide SVILLGR diluted in different compositions of eluent A and B 
using 5 µL (left) and 20 µL (right) injection volume. 
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3.5. Trypsin-based approaches  
3.5.1. Surrogate peptide selection and analyte-specific MS parameter 
optimization 
In the literature peptides LSEPAELTDAVK and SVILLGR are well-described as excellent 
representatives of total PSA in human serum. [113, 114] To verify ionization and fragmentation 
behavior on the instrument used in this work, analyte-specific MS parameters of the two peptides 
were investigated via T-infusion as mentioned in the experimental section using standard peptides 
which were synthesized in-house (Roche Diagnostics GmbH, Penzberg, Germany). Obtained results 
were comparable to that known from the literature [113, 114]. In addition, the same procedure was 
used to analyze the glycopeptides N(GlcNAc)K and N(GlcNAc+Fuc)K serving for quantification of 
partially deglycosylated PSA. The final results of peptide MRM parameter optimization are listed in 
Table 13. The glycopeptide N(GlcNAc+Fuc)K was quantified by measuring transition m/z 464.2/261.1 
where m/z 464.2 in Q1 is referred to the intact single charge state m/z 610.1 of N(GlcNAc+Fuc)K 
without Fuc (146 Da) caused by in-source fragmentation (ISF). As it is shown in Table 13, this is the 
identical transition as the transition used for the non-fucoslyated species N(GlcNAc)K. In practice, 
some degree of ISF is an inherent phenomenon in ESI-MS of glycopeptides, which could not be 
avoided in the study. Therefore, the signal intensity of the in-source fragmented species of 
glycopeptide N(GlcNAc+Fuc)K was maximized by adjusting source parameters, mainly by ion spray 
voltage, declustering potential and temperature. Differentiation of non-fucosylated and fucosylated 
PSA was achieved by chromatographic separation applying HILIC as shown in the previous section 
(Figure 20) [108].  
 
Table 13: Analyte-specific parameters for LC-MS/MS measurement of four surrogate peptides 
generated by tryptic digestion of PSA. Reproduced from [108]. 
Target Surrogate peptide RT 
[min] 
ISF Charge 
state 
Q1 
[Da] 
Q3 
[Da] 
DP 
[V] 
EP 
[V] 
CE 
[V] 
CXP 
[V] 
Non-fucosylated 
PSA 
N(GlcNAc)K 6.8 no 1+ 464.2 261.2 71 10 27 14 
Fucosylated PSA N(GlcNAc+Fuc)K a 7.2 yes 1+ 464.2 261.2 71 10 27 14 
Fucosylated PSA N(GlcNAc+Fuc)K  7.2 no 1+ 610.1 464.2 91 10 33 10 
Total PSA LSEPAELTDAVK 4.7 no 2+ 636.9 943.4 71 10 29 44 
Total PSA SVILLGR 3.2 no 2+ 379.3 571.3 56 10 17 10 
a differentiation of non-fucosylated PSA and fucosylated PSA was achieved by chromatographic separation as 
m/z 464.2 in Q1 is referred to the intact single charge state m/z 464.2 of N(GlcNAc)K as well as to the intact 
single charge state m/z 610.1 of N(GlcNAc+Fuc)K without fucose (146 Da) caused by in-source fragmentation 
(ISF); GlcNAc = N-Acetylglucosamine, Fuc = fucose, RT = retention time, DP = declustering potential, EP = 
entrance potential, CE = collision energy, CXP = cell exit potential. 
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3.5.2. Overview of the experimental workflow using MSIA tips 
The trypsin-based workflow using MSIA tips for PSA enrichment was operated as illustrated in 
Figure 25 and as described in the experimental section. Immunoaffinity enrichment of PSA from 
human serum was performed in the same way as in the RPLC workflow using protease Arg-C 
(Figure 13). In contrast, in this workflow enriched PSA was not eluted from the pipette tip. Partial 
deglycosylation and enzymatic digestion were performed directly on the pipette tip, which allows 
simple buffer exchange required for maximal activity of Endo F3 and trypsin. Digested PSA was 
washed out with eluent B directly into a HPLC micro insert generating optimal chromatographic 
starting conditions. No additional vacuum concentration step was necessary. This procedure was 
more efficient than the in solution workflow presented in Figure 13 when protease Arg-C was replaced 
with trypsin and TRIS/HCl with ABC buffer. Beyond that the order of digestion steps was tested in 
several approaches entailing steps as vacuum concentration, elution and washing which did not lead 
to sensitivity improvements.    
 
 
Figure 25: Schematic overview of the experimental workflow for the determination of core-fucosylated 
and total PSA using a MSIA tip-based and trypsin-assisted LC-MS/MS method. 
 
3.5.3. Determination of partially deglycosylated and total PSA in spiked serum 
samples  
Analysis of six female serum samples containing different concentrations of core-fucosylated (0, 0.78, 
1.56, 3.90, 7.80 and 21.8 ng/mL) and total PSA (0, 1, 2, 5, 10 and 25 ng/mL) was performed in order 
to generate calibration curves by plotting peak areas of peptides N(GlcNAc+Fuc)K (m/z 464.2/261.2), 
LSEPAELTDAVK (m/z 636.9/943.4) and SVILLGR (m/z 379.3/571.3) against respective 
concentrations (Figure 26). Each concentration was prepared six times followed by analysis as 
illustrated in Figure 25. Based on these results the linear range, lower limit of detection (LLOD), lower 
limit of quantification (LLOQ) and precision over the working range expressed as coefficient of 
variation (CV) were evaluated.  
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Peptides N(GlcNAc+Fuc)K and SVILLGR showed poor linearity with correlation coefficients R² < 0.90 
within the working range. In contrast, peptide LSEPAELTDAVK showed good linearity with R² > 0.96 
within 1-25 ng/mL total PSA. As mentioned before, peak intensities with a signal-to-noise ratio of 
3 and 10 were considered acceptable for determining the LLOD and LLOQ, respectively. The LLOD 
value of core-fucosylated PSA monitored by glycopeptide N(GlcNAc+Fuc)K at a retention time of 
7.2 min was 2 ng/mL and the LLOQ value was 5 ng/mL. The LLOD of total PSA monitored by peptide 
LSEPAELTDAVK was lower than 1 ng/mL and the LLOQ was 1 ng/mL. The LLOD of total PSA 
monitored by peptide SVILLGR was 1 ng/mL and the LLOQ was 2 ng/mL. The assay imprecision for 
core-fucosylated PSA expressed as CV of six replicates ranged from 9.6 % to 31.4 % depending on 
the concentration. For total PSA, CVs ranged from 9.1 % to 18.3 % monitored by peptide 
LSEPAELTDAVK and from 14.1 % to 30.2 % monitored by peptide SVILLGR. In samples without 
addition of PSA interfering peaks were detected at the respective retention time of core-fucosylated 
PSA (RT = 7.2 min) and total PSA monitored by SVILLGR (RT = 3.9 min), which impedes robust 
quantification. Significant background noise (up to 500 cps) was present within the retention window 
of total PSA monitored by LSEPAELTDAVK (RT = 4.7 min). Representative chromatograms of serum 
samples containing different concentrations of total PSA are shown in Figure 27. 
 
 
Figure 26: Calibration curves and correlation coefficients R² of core-fucosylated and total PSA 
obtained by plotting peak areas of a) N(GlcNAc+Fuc)K, b) LSEPAELTDAVK, and c) SVILLGR against 
respective concentrations, n = 6. 
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In terms of total PSA quantification, analysis of peptide LSEPAELTDAVK had a clear advantage over 
peptide SVILLGR regarding sensitivity and assay imprecision. Thus, peptide SVILLGR was not 
considered in further experiments. Non-fucosylated PSA monitored by peptide N(GlcNAc)K 
(m/z 464.2/261.2) at a retention time of 6.8 min could not be detected in the highest concentrated total 
PSA spiked-in serum sample (25 ng/mL) containing approximately 22 % non-fucosylated PSA as 
determined by glycan analysis. In a further experiment the LLOD of non-fucosylated PSA was 
determined to be at 13.2 ng/mL analyzing 0 and 60 ng/mL total PSA spiked-in serum samples 
(Figure 28). Further parameters of non-fucosylated PSA including linearity, LLOQ and CVs were not 
performed as the described workflow lacked in sensitivity for non-fucosylated PSA.  
 
 
Figure 27: Extracted ion chromatograms of transitions monitored for a) core-fucosylated PSA 
(N(GlcNAc+Fuc)K, m/z 464.2/261.1), b) total PSA (LSEPAELTDAVK, m/z 636.9/943.4) and c) total 
PSA (SVILLGR, m/z 379.3/571.3) derived from 0, 1, 2, 5, 10 and 25 ng/mL total PSA spiked-in female 
serum samples. 
 
 
Figure 28: Extracted ion chromatograms of non-fucosylated PSA monitored by peptide N(GlcNAc)K 
(m/z 464.2/261.1) derived from 0 and 60 ng/mL total PSA spiked-in female serum samples containing 
22 % non-fucosylated PSA. 
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3.5.4. Feasibility of the method in native serum samples  
In order to demonstrate the feasibility of the method to detect core-fucosylated and total PSA in native 
serum samples a small sample set consisting of three human subjects A, B and C containing 2.35, 
7.20 and 7.30 ng/mL total PSA was analyzed. As shown in Figure 29 signals of core-fucosylated and 
total PSA surrogate peptides were obtained in all three samples. Indeed, core-fucosylated PSA was 
also detected in subject A containing 2.35 ng/mL total PSA, but robust quantification could be 
problematic due to the low S/N ratio in this concentration range.  
 
 
Figure 29: Extracted ion chromatograms of transitions monitored for a) core-fucosylated PSA 
(N(GlcNAc+Fuc)K, m/z 464.2/261.1) and b) total PSA (LSEPAELTDAVK, m/z 636.9/943.4) derived 
from three human specimen with total PSA levels of 2.35, 7.20 and 7.30 ng/mL. Reproduced from 
[108]. 
 
Furthermore, three PSA-free female serum matrices were analyzed to test the existence of interfering 
peaks at respective analyte retention times in native samples derived from different donors. As seen 
before in the female serum pool used for spiking experiments, with the current workflow interfering 
peaks were also detected with varying intensities in three female sera without addition of PSA at the 
respective retention time of core-fucosylated PSA (RT = 7.2 min). In comparison, a PSA-free PBS 
buffer did not show contamination at 7.2 min indicating that interferences come from serum itself 
(Figure 30). At the respective retention time of total PSA monitored by LSEPAELTDAVK 
(RT = 4.7 min), no interfering signals were detected in female sera. As expected, background noise 
was higher in sera than in PBS buffer. To achieve the required limit of quantification of core-
fucosylated PSA further method optimization was performed.  
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Figure 30: Extracted ion chromatograms of transitions monitored for a) core-fucosylated PSA 
(N(GlcNAc+Fuc)K, m/z 464.2/261.1) and b) total PSA (LSEPAELTDAVK, m/z 636.9/943.4) derived 
from PSA-free PBS buffer, three female sera without addition of PSA and a 5 ng/mL PSA spiked-in 
female serum sample.  
 
3.5.5. Optimization approaches  
As the trypsin-based workflow using MSIA tips was still limited to measure partially deglycosylated 
PSA down to 1 ng/mL in human serum and CV values were rather high, further approaches were 
conducted to improve the sensitivity and imprecision of the method.  
 
3.5.5.1. Transitions 
In particular, reliable quantification of core-fucosylated PSA seemed to be challenging due to the 
occurrence of interferences at the respective retention time of core-fucosylated PSA in PSA-free 
human sera. Primary selection of surrogate peptides, charge states and final transitions was 
performed in terms of signal intensity using aqueous tryptic peptide solutions. This procedure does 
not take into account challenges associated with the analysis of human samples including 
chromatographic interferences arising from the serum matrix. Therefore, two samples containing 
0 and 10 ng/mL total PSA spiked-in female serum were prepared and analyzed as illustrated in 
Figure 25. A comprehensive list of different transitions previously obtained by analyte-specific MS 
parameter optimization representing non-fucosylated, core-fucosylated and total PSA was monitored 
with or without consideration of in-source fragmentation (Table 14). Despite the interfering peak at the 
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relevant retention time of core-fucosylated PSA, ion pair m/z 464.2/261.1 was still the favorite 
transition for quantification of core-fucosylated PSA as the signal-to-noise ratio was significantly 
higher compared to other transitions monitored in this experiment. The same applies to total PSA 
monitored by transition m/z 636.9/943.4, which was the most sensitive ion pair among other 
transitions. Non-fucosylated PSA was still untraceable at such low serum concentrations regardless of 
which transition was investigated. This is probably due to lower ionization efficiency of the non-
fucosylated species and less activity of Endo F3 on glycosylation sites without Fuc.  
 
Table 14: Most intensive transitions of non-fucosylated, fucosylated and total PSA obtained by 
analyte-specific MS parameter optimization. 
Target Surrogate peptide RT [min] ISF Charge state Q1 [Da] Q3 [Da] 
Non-fucosylated PSA N(GlcNAc)K 6.8 no 1+ 464.2 84.0 
      126.0 
      129.0 
      209.0 
      226.1 
      261.2 
   no 2+ 232.3 84.0 
      126.0 
      129.0 
      204.0 
      209.0 
      261.2 
   yes 1+ 261.0 a 56.0 
      84.0 
      129.0 
      209.0 
Fucosylated PSA N(GlcNAc+Fuc)K 7.2 no 1+ 610.1 84.0 
      261.1 
      464.2 
   no 2+ 305.3 75.1 
      84.0 
      261.1 
      464.2 
   yes 1+ 464.2 b 84.0 
      126.0 
      129.0 
      209.0 
      261.1 
Total PSA LSEPAELTDAVK 4.7 no 2+ 636.9 69.9 
      84.0 
      183.1 
      312.1 
      472.3 
      943.4 
a m/z 261.0 in Q1 is referred to the intact single charge state m/z 464.2 of N(GlcNAc)K without 
N-Acetylglucosamine (GlcNAc, 203 Da) caused by in-source fragmentation (ISF). 
b m/z 464.2 in Q1 is referred to the intact single charge state m/z 610.1 of N(GlcNAc+Fuc)K without fucose (Fuc, 
146 Da) caused by ISF. 
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3.5.5.2. Differential ion mobility mass spectrometry (DMS) 
Next, differential ion mobility mass spectrometry (DMS) was used by activation of the SelexIon® 
module of the QTRAP 6500 mass spectrometer. DMS offers an additional separation dimension 
which is orthogonal to the LC separation, and thus might help to remove interfering peaks. DMS 
parameters of peptides N(GlcNAc+Fuc)K and LSEPAELTDAVK were optimized manually as 
described in the experimental section and are shown in Table 15. Two samples containing 0 and 
10 ng/mL total PSA spiked-in female serum were analyzed as illustrated in Figure 25 with or without 
additional up-front DMS separation. The application of DMS enabled the reduction of interferences 
and background noise at the respective retention times of core-fucosylated and total PSA by a factor 
of 10. On the other hand, the analyte signal intensity was also considerably lowered (Figure 31). 
Consequently, the S/N ratio of core-fucosylated and total PSA could not be improved by applying up-
front DMS separation. In fact, the DMS module seemed to be susceptible to matrix contamination 
adversely impacting the instruments robustness and making it unsuitable for measurements of large 
numbers of patient samples.  
 
Table 15: Differential ion mobility mass spectrometry (DMS) parameters of peptides N(GlcNAc+Fuc)K 
and LSEPAELTDAVK. 
Target Surrogate peptide RT 
[min] 
ISF Charge 
state 
Q1 
[Da] 
Q3 
[Da] 
COV 
[V] 
DMO 
[V] 
SV  
[V] 
Core-fucosylated PSA N(GlcNAc+Fuc)K 7.2 yes 1+ 464.2 261.2 4.0 5.6 3200 
Total PSA LSEPAELTDAVK 4.7 no 2+ 636.9 943.4 7.5 -10.0 3200 
GlcNAc = N-Acetylglucosamine, Fuc = fucose, RT = retention time, ISF = in-source fragmentation, 
COV =  compensation voltage, DMO = DMS offset, SV = separation voltage. 
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Figure 31: Extracted ion chromatograms of transitions monitored for a) core-fucosylated PSA 
(N(GlcNAc+Fuc)K, m/z 464.2/261.1) and b) total PSA (LSEPAELTDAVK, m/z 636.9/943.4) derived 
from 0 and 10 ng/mL PSA spiked-in female serum samples with and without additional up-front DMS 
separation. 
 
3.5.5.3. Multiple reaction monitoring cubed (MRM³) 
Recently, Fortin et al. demonstrated that a technique using MS3 reconstructed chromatograms on a 
signature of secondary precursor ions, termed multiple reaction monitoring cubed (MRM3), enables 
targeted quantification of protein biomarkers in the low ng/mL range in non-depleted human 
serum [118]. In order to gain sensitivity and selectivity in this work, MRM³ mode was applied to 0 and 
10 ng/mL total PSA spiked-in serum samples. In MRM3 mode secondary precursor ions, previously 
generated by collision induced dissociation (CID) of primary precursor ions in Q2, were collected in 
the Q3 linear ion trap (LIT) and subsequently fragmented to product ions by resonant excitation 
energy as described in the experimental section. Ion chromatograms of core-fucosylated and total 
PSA were reconstructed from specific product ions which were selected among the most intense 
MRM3 transitions (Figure 32). Core-fucosylated and total PSA were monitored by MRM³ transition 
m/z 464.2/261.2/(84.0+129.0+209.0+226.1+244.1) and m/z 636.9/943.4/(494.0+591.1+627.7+680.2 
+779.2), respectively. These were the most intensive and specific transitions identified in MRM³ 
spectra. In comparison to MS/MS analysis, by using MRM³ mode the S/N ratio of total PSA could be 
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enhanced by a factor of 2, while the S/N ratio of core-fucosylated PSA could not be improved. Thus, 
MRM³ mode was not pursued any further in this work.  
 
 
Figure 32: a) MRM³ spectra of core-fucosylated PSA (left) and total PSA (right) and b) reconstructed 
MRM³ ion chromatograms of core-fucosylated PSA (left) and total PSA (right) derived from a 
10 ng/mL total PSA spiked-in serum sample. 
 
3.5.5.4. Derivatization using tandem mass tags (TMT) 
Isobaric mass tags are used for multiplex relative quantification by MS allowing for increased sample 
throughput by generating TMT-labeled analytes which specifically fragment to MS-responsive reporter 
ions. In this work, tandem mass tag label reagent TMT-126 composed of an amine-reactive 
NHS-ester group, a spacer arm and an MS/MS reporter was applied to 0, 10 and 20 ng/mL total PSA 
spiked-in female serum samples in order to overcome chromatographic interferences coming along 
with the analysis of core-fucosylated PSA. In addition, specific fragmentation channels of labelled 
target peptides might improve the method’s sensitivity and imprecision. Analyte-specific MS 
parameters of TMT-labeled peptides were automatically tuned in the same manner as unlabeled 
peptides. The most sensitive transition of TMT-labeled core-fucosylated PSA was m/z 530.8/457.9 in 
which m/z 530.8 in Q1 is referred to the double charged intact peptide N(GlcNAc+Fuc)K labeled with 
two molecules TMT-126 (Figure 33).  
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Figure 33: Derivatization of peptide N(GlcNAc+Fuc)K with two molecules TMT-126 (heavy carbon 
atom indicated by asterisk) at the primary amine residues. 
 
The in-source fragmented species m/z 457.9 where Fuc is lost during the ionization process was 
observed to a much less extent. As shown in Figure 34 derivatization of core-fucosylated PSA 
monitored by peptide N(GlcNAc+Fuc)K + 2xTMT was complete indicated by the disappearance of the 
unlabeled species m/z 464.2/261.1 in 10 and 20 ng/mL total PSA samples. The signal intensity of 
TMT-labeled core-fucosylated PSA increased linearly with increasing total PSA concentrations and 
was twice as high (2.6E+04 cps) as the signal intensity of the unlabeled species (1.3E+04 cps). 
However, in the PSA-free female serum sample interfering peaks were detected at the retention time 
of TMT-labeled core-fucosylated PSA (RT = 5.0 min) resulting in a lower S/N ratio compared to the 
unlabeled species. Hence, the usage of TMT-derivatization of PSA could not improve the method’s 
performance. 
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Figure 34: Extracted ion chromatograms of transitions monitored for core-fucosylated PSA 
(N(GlcNAc+Fuc)K, m/z 464.2/261.1, left) and TMT-labeled core-fucosylated PSA (N(GlcNAc+Fuc)K + 
2xTMT, m/z 530.8/457.9, right) derived from 0, 10 and 20 ng/mL PSA spiked-in female serum 
samples with and without addition of TMT-126.  
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3.5.6. Overview of the experimental workflow using magnet beads 
The trypsin-based workflow using MSIA tips for immunoaffinity enrichment of PSA showed poor 
linearity and lacked in sensitivity regarding the analysis of core-fucosylated PSA. Furthermore, the 
assay imprecision was rather high. Approaches such as DMS, MS³ and TMT-derivatization could not 
improve the method’s performance. A barrier for robust quantification of core-fucosylated PSA in the 
low ng/mL concentration range seemed to be a co-eluting peak derived from a serum compound 
which might be enriched through unspecific binding to MSIA tips. Therefore, another solid support 
material was selected for immobilization of the PSA immunoaffinity complex in order to reduce 
unspecific interaction. A magnetic particle-based workflow was developed and operated as illustrated 
in Figure 35. Starting with 100 µL human serum, immunoaffinity enrichment was performed by using 
biotinylated anti-PSA antibody bound to streptavidin-coated magnetic particles to enrich PSA from 
complex serum matrix. Enriched PSA, still captured by the immunoaffinity complex, was stepwise 
partially deglycosylated in order to simplify glycosylation microheterogeneity and tryptically digested to 
generate surrogate peptides. Following vacuum concentration and reconstitution, appropriate 
peptides were measured by LC-MS/MS without additional up-front SPE clean up. Other procedures 
e.g. involving analyte elution and subsequent in solution digestion were less efficient.  
 
 
Figure 35: Schematic overview of the experimental workflow for the quantitative analysis of core-
fucosylated and total PSA using a magnet bead-based and trypsin-assisted LC-MS/MS method. 
Reproduced from [108]. 
 
3.5.7. Development of the magnet bead-based workflow 
3.5.7.1. Optimization of immunoaffinity enrichment 
Different amounts of anti-PSA antibody PSA36 (0.05, 0.2, 1, and 5 µg) were incubated with constant 
amounts of magnet beads (50 µg). After incubation and washing, human serum containing 5 ng/mL 
PSA was added and incubated. Magnet beads were removed and the residual human serum sample 
was analyzed by ECLIA for PSA which was not bound to the antibody-bead-complex (= unbound 
PSA). The capture efficiency was inversely proportional to unbound PSA which was normalized to the 
initial PSA serum concentration. As shown in Figure 36a using 1 µg anti-PSA antibody showed the 
best capture efficiency. Similar to that procedure, different amounts of magnet beads (10, 50, 100, 
and 250 µg) were incubated with constant amounts of anti-PSA antibody (1 µg) and unbound PSA 
was determined in residual human serum by ECLIA. It was shown that 100 µg magnetic beads 
performed slightly better than 50 µg whereas no significant difference was observed compared to 
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250 µg (Figure 36b). Based on standard conditions applied at the beginning of the method 
development, different parameters concerning incubation steps were varied and tested individually as 
follows. The incubation time was decreased from 30 to 10 min. The incubation temperature was 
decreased from 37 to 25 °C. The stirring rate during incubation was decreased from 1000 to 500 rpm. 
The number of washing steps after antibody-bead incubation was increased from one to four. Results 
in Figure 36c obtained by measuring unbound PSA in residual human serum indicate that the capture 
efficiency is beneficially influenced by a lower incubation temperature whereas a slower stirring rate, a 
shorter incubation time and more wash steps did not show significant changes. In Figure 36d results 
of further approaches which are likely to impact immunoaffinity enrichment are illustrated. For 
example, resuspension of magnet beads could be achieved by vortexing and ultrasound mixing in 
which the latter led to extensive PSA loss after sample incubation. Pretreatment strategies such as 
previous sample dilution with 0.5 % tween in PBS buffer (1:5-dilution, v/v) and sample preincubation 
with antibody followed by magnet bead incubation clearly worsened analyte capturing. The 
simultaneous usage of two different anti-PSA antibodies PSA36 and PSA30 also showed diminished 
PSA enrichment capability compared to the initial workflow. All optimization approaches were 
performed in six replicates.   
 
Figure 36: Optimization of immunoaffinity enrichment by testing of a) different amounts of anti-PSA 
antibody, b) different amounts of magnet beads, c) different incubation and washing conditions and 
d) different approaches such as ultrasound mixing, sample dilution, simultaneous usage of two 
antibodies and sample preincubation with antibody. Unbound PSA was normalized to the initial PSA 
serum concentration. Mean ± standard deviation shown as error bars, n = 6.  
*Standard incubation conditions: temperature = 37 °C, stirring rate = 1000 rpm, time = 30 min, number 
of washing steps after antibody-bead incubation = 1, samples mixed by vortexing.  
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In summary, subsequent conditions were used for immunoaffinity enrichment of PSA: (1) the anti-PSA 
antibody PSA36 amount was 1 µg, (2) the streptavidin-coated magnet bead amount was 100 µg, 
(3) the incubation temperature was 25 °C, (4) the stirring rate during incubation was 1000 rpm, (5) the 
incubation time was 10 min, (6) a single wash step was used after antibody-bead incubation, and 
(7) magnet bead resuspension was achieved by moderate vortexing.  
3.5.7.2. Optimization of partial deglycosylation and tryptic digestion 
The most efficient endoglycosidase was selected in previous experiments (chapter III section 3.1). For 
the current workflow, conditions for partial deglycosylation were reinvestigated including Endo F3 
amount, incubation time, and sample buffer (Figure 37). Each approach was performed in six 
replicates and core-fucosylated and total PSA were analyzed by LC-MS/MS as illustrated in 
Figure 35. Among different Endo F3 amounts (0.5, 2, 10 and 50 milliunits) the optimum for analysis of 
core-fucosylated PSA was 10 milliunits per 100 µL sample evaluated by using 5 ng/mL total PSA 
spiked-in human serum. Usage of higher Endo F3 amounts could not significantly improve signal 
intensity indicated by overlapping error bars. The average signal intensity of core-fucosylated PSA 
was increased after 6 h incubation time compared to 3 h and 25 h incubation time. Due to the large 
error bars obtained for 6 h, this result was not significant. From a practical perspective, an incubation 
time of 3 h was selected, hence shortening the overall workflow duration. The influence of four 
incubation buffers (20 mM and 100 mM sodium acetate pH 4.5, 100 mM sodium acetate pH 6 and 
100 mM ABC buffer pH 8) on partial deglycosylation activity was tested. No significant differences 
could be observed for core-fucosylated PSA. Analysis of total PSA was not affected by variations of 
any of the described parameters indicated by constant total PSA peak areas.  
LC-MS/MS analysis of 5 ng/mL PSA spiked-in serum samples prepared as illustrated in Figure 35 
using various trypsin amounts (0.05, 0.2, 1, 5 and 20 µg) revealed that both core-fucosylated and total 
PSA had maximal intensities between 1 and 20 µg trypsin indicated by the highest signal at 5 µg 
trypsin (Figure 38). Investigation of different 100 mM sample buffers such as ABC (ammonium 
bicarbonate, pH 8), TEAB (triethylammonium bicarbonate, pH 8), HEPES (2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, pH 8.4), TRIS (2-Amino-2-(hydroxymethyl)propane-
1,3-diol, pH 8) buffer clearly showed the predominance of ABC as a buffer substance in mass 
spectrometric applications. TEAB buffer showed decreased signal intensities for core-fucosylated and 
total PSA compared to ABC, while no signals were observed using HEPES and TRIS buffer. This was 
most likely due to ion suppression of the ESI signal and/or extensive adduct formation caused by 
non-volatile electrolytes. 
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Figure 37: Optimization of partial deglycosylation by testing of different Endo F3 amounts, incubation 
times and sample buffers. a) core-fucosylated PSA (N(GlcNAc+Fuc)K, m/z 464.2/261.1) and b) total 
PSA (LSEPAELTDAVK, m/z 636.9/943.4) were analyzed by LC-MS/MS using 5 ng/mL total PSA 
spiked-in serum samples. Mean ± standard deviation shown as error bars, n= 6. 
 
 
Figure 38: Optimization of tryptic digestion by testing of different trypsin amounts and sample buffers. 
a) core-fucosylated PSA (N(GlcNAc+Fuc)K, m/z 464.2/261.1) and b) total PSA (LSEPAELTDAVK, 
m/z 636.9/943.4) were analyzed by LC-MS/MS using 5 ng/mL total PSA spiked-in serum samples, 
n = 6. ABC = ammonium bicarbonate, TEAB = triethylammonium bicarbonate, HEPES = 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, TRIS = 2-Amino-2-(hydroxymethyl)propane-1,3-diol. 
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3.5.8. Comparison of streptavidin-coated solid support materials for 
immunoaffinity enrichment 
Two optimized workflows using different streptavidin-coated solid support materials, MSIA tips and 
magnetic particles were evaluated. The MSIA tip-based and the magnet bead-based workflow were 
executed as shown in Figure 25 and Figure 35, respectively. Comparison of the two solid support 
materials was based on the analysis of 0 and 5 ng/mL total PSA-spiked in serum aliquots. Each 
aliquot was prepared six times with both workflows followed by LC-MS/MS measurement. In average, 
the S/N ratio of core-fucosylated PSA obtained by the magnet bead-based workflow was 7 times 
higher than the S/N ratio obtained by the MSIA tip-based workflow. This was mainly due to high 
chromatographic interferences observed in PSA-free serum samples prepared by the MSIA tip-based 
workflow as seen in the representative chromatogram of core-fucosylated PSA (Figure 39). The 
magnet bead-based workflow was more sensitive by a factor of 3 regarding total PSA quantification. 
Moreover, the assay imprecision could be improved by using magnetic beads revealed by CV values 
of respective analyte peak areas obtained by analysis of six 5 ng/mL total PSA spiked-in serum 
samples. CV values of core-fucosylated PSA were 13.4 % using magnetic beads and 23.2 % using 
MSIA tips. CV values of total PSA were 8.8 % using magnetic beads and 10.2 % using MSIA tips. 
 
Figure 39: Extracted ion chromatograms of transitions monitored for a) core-fucosylated PSA 
(N(GlcNAc+Fuc)K, m/z 464.2/261.1) and b) total PSA (LSEPAELTDAVK, m/z 636.9/943.4) derived 
from 0 and 5 ng/mL PSA spiked-in serum samples prepared with MSIA tips or magnetic particles, 
respectively.  
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3.5.9. Characterization of the final workflow using magnet beads 
3.5.9.1. Linearity, LLOD, LLOQ and imprecision of the magnet bead-based workflow 
LC-MS/MS analysis of female serum samples containing different concentrations of core-fucosylated 
PSA (0, 0.4, 0.8, 1.6, 3.9, 7.8, 23.4 and 46.8 ng/mL) and total PSA (0, 0.5, 1, 2, 5, 10, 30 and 
60 ng/mL) was performed using analyte-specific MS parameters as shown in Table 13. The most 
sensitive transition of each of the two peptides was selected for quantification, which means Q1/Q3 
ion pairs were m/z 464.2/261.2 and m/z 636.9/943.4 for core-fucosylated and total PSA, respectively. 
Each concentration was prepared in triplicate on two different days followed by analysis as illustrated 
in Figure 35. Calibration curves were obtained by plotting peak areas of peptides N(GlcNAc+Fuc)K or 
LSEPAELTDAVK against respective concentrations (Figure 40). Based on these results the linear 
range, lower limit of detection (LLOD), lower limit of quantification (LLOQ) and precision over the 
working range expressed as CV were evaluated. Both peptides showed good linearity within 
0.4-46.8 ng/mL for core-fucosylated PSA and 0.5-60 ng/mL for total PSA, respectively. Calibration 
curves were obtained at two different days (n = 3 at each day) with average correlation coefficient 
R2 > 0.99 for the core-fucosylated PSA peptide N(GlcNAc+Fuc)K and R2 > 0.98 for the total PSA 
peptide LSEPAELTDAVK at both days (Figure 40) [108].  
 
 
Figure 40: Calibration curves and correlation coefficients R2 of core-fucosylated (left) and total PSA 
(right) obtained by plotting peak areas of N(GlcNAc+Fuc)K and LSEPAELTDAVK against respective 
concentrations at day one (top) and day two (bottom), n = 3 at each day. Reproduced from [108]. 
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Combining results of day one and two (n = 6) gave calibration curves with average correlation 
coefficient R2 > 0.94 for the core-fucosylated PSA peptide N(GlcNAc+Fuc)K and R2 > 0.98 for the 
total PSA peptide LSEPAELTDAVK. In this work, peak intensities with a signal-to-noise ratio of 3 and 
10 were considered acceptable for determining the LLOD and LLOQ, respectively. The LLOD value of 
core-fucosylated PSA was 0.4 ng/mL and the LLOQ value was 1 ng/mL whereas the LLOD and LLOQ 
of total PSA were lower than 0.5 ng/mL. Compared to intact glycopeptide analysis, a major advantage 
of the method is the increased ionization efficiency of partially deglycosylated peptides. In addition, 
the sensitivity of the assay was improved due to stacking effects of identical glycopeptides and data 
analysis was greatly simplified. Even though the method was not optimized for total PSA 
quantification, total PSA concentrations lower than 0.5 ng/mL could be quantified, which is more 
sensitive than similar approaches described in the current literature using immunoaffinity enrichment 
coupled to mass spectrometry [113, 119, 120]. However, as this method emphasizes the 
quantification of core-fucosylated PSA, it cannot compete with high-sensitive methods focusing on 
total PSA quantification only such as the PRISM-SRM workflow introduced by Shi et al [121]. Without 
addition of PSA, no peaks were detected at the respective retention times of core-fucosylated PSA 
(RT = 7.2 min) and total PSA (RT = 4.7 min) indicating the high specificity of the workflow. 
Representative chromatograms for 0, 0.5 and 1 ng/mL total PSA spiked-in serum sample are shown 
in Figure 41 [108].  
 
   
Figure 41: Extracted ion chromatograms of transitions monitored for a) core-fucosylated PSA 
(N(GlcNAc+Fuc)K, m/z 464.2/261.1) and b) total PSA (LSEPAELTDAVK, m/z 636.9/943.4) derived 
from 0, 0.5 and 1 ng/mL total PSA spiked-in female serum samples. Reproduced from [108]. 
 
Intra-day precision calculated by using three replicates of each concentration expressed as the CV 
ranged from 3.1 % to 10.5 % for core-fucosylated PSA and from 2.1 % to 9.8 % for total PSA at day 
one and from 2.1 % to 17.0 % for core-fucosylated PSA and from 4.1 % to 26.9 % for total PSA at day 
two depending on the relative concentration. Inter-day precision combining results of day one and two 
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ranged from 9.7 % to 23.2 % for core-fucosylated PSA and from 10.3 % to 18.3 % for total PSA. The 
average peak area ratio of core-fucosylated PSA to total PSA in the interesting concentration range of 
1-10 ng/mL was 0.26 with a CV value of 20.8 % over two days (n = 6). Approaches for protein 
quantification often benefit from the usage of stable-isotope labeled (SIL) proteins, peptides or 
analogues thereof as internal standards, thereby positively impacting the imprecision of the 
method [122]. Thus, it should be possible to improve CV values of the described method by using SIL 
PSA, which is not commercially available yet. As an alternative, the usage of more easily accessible 
SIL peptides of PSA could improve the assay imprecision, although this strategy cannot reflect the 
whole sample preparation workflow. Still the imprecision of the method is acceptable, regarding the 
intended use e.g. as support for biomarker refinement studies, and data could be strengthened by 
measuring of larger patient cohorts or performing repetitive sample analysis [108]. 
 
3.5.9.2. Analysis of serum samples containing different amounts of fucosylated PSA 
Applying LCA lectin chromatography, PSA from Scripps Laboratories was separated into two fractions 
consisting of non-fucosylated or fucosylated PSA. The fucosylation degree of these two fractions was 
determined by N-glycan analysis demonstrating the effectiveness of the LCA separation step because 
almost no fucosylated glycans could be detected in the non-fucosylated fraction whereas Fuc was 
bound to nearly all glycan structures in the fucosylated fraction. Finally, serum samples were 
prepared containing five different ratios of non-fucosylated to fucosylated PSA (100:0, 75:25, 50:50, 
25:75 and 0:100) at total PSA concentrations of 10 ng/mL as determined by ECLIA. Each of the five 
ratio samples was processed six times as illustrated in Figure 35 (n = 6) resulting in six calibration 
curves with an average correlation coefficient R2 > 0.97 (Figure 42). CV values of the peak area ratio 
of core-fucosylated PSA to total PSA ranged from 4.1 % to 8.6 %. This proof-of-concept experiment 
revealed the method’s feasibilty to distinguish between different relative core-fucosylation degrees 
[108]. 
 
 
Figure 42: Calibration curve of serum samples containing different ratios of non-fucosylated to 
fucosylated PSA by plotting the peak area ratio of N(GlcNAc+Fuc)K to LSEPAELTDAVK against the 
relative amount of fucosylated PSA ranging from 0 to 100 % (n = 6, R2 > 0.97). Reproduced from 
[108]. 
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3.5.9.3. Analysis of human specimens 
The described method was applied to quantify core-fucosylated and total PSA in native serum 
samples. For this purpose, three human serum specimens with total PSA levels of 2.03 ng/mL 
(subject A), 6.06 ng/mL (subject B) and 9.95 ng/mL (subject C) were prepared in triplicate at different 
days as illustrated in Figure 35 and quantitated by external calibration using five calibrators with 
different concentrations of core-fucosylated PSA (0.78, 2.34. 4.68, 7.02 and 9.36 ng/mL) and total 
PSA (1, 3, 6, 9 and 12 ng/mL). Representative chromatograms in Figure 43 demonstrate that the 
method is able to detect core-fucosylated and total PSA in native human specimens covering the 
critical grey area in PCa diagnosis. CV values of subject A, B and C were 22.4 %, 17.0 % and 27.3 % 
for core-fucosylated PSA, 16.6 %, 5.6 % and 13.1 % for total PSA, and 10.4, 12.8 and 21.5 for the 
ratio of core-fucosylated to total PSA (Table 16). These CVs were comparable to CVs obtained under 
artificial conditions of PSA spiked-in serum samples [108].  
 
 
Figure 43: Extracted ion chromatograms of transitions monitored for a) core-fucosylated PSA 
(N(GlcNAc+Fuc)K, m/z 464.2/261.1) and b) total PSA (LSEPAELTDAVK, m/z 636.9/943.4) derived 
from three human specimen with total PSA levels of 2.03, 6.06 and 9.95 ng/mL. Reproduced from 
[108]. 
 
Table 16: Results of the analysis of three anonymized human specimens by ECLIA (n = 1) and LC-
MS/MS (n = 3) expressed as mean ± standard deviation. 
Human 
Specimen 
total PSA 
determined by 
LC-MS/MS [ng/mL] 
core-fucosylated PSA 
determined by 
LC-MS/MS [ng/mL] 
ratio of core-
fucosylated PSA to 
total PSA determined 
by LC-MS/MS [%] 
total PSA 
determined by 
ECLIA [ng/mL] 
Patient A 1.93 ± 0.32 1.90 ± 0.43 100.7 ± 10.5 2.03 
Patient B 6.43 ± 0.36 4.75 ± 0.81 73.6 ± 9.4 6.06 
Patient C 10.95 ± 1.43 9.73 ± 2.66 88.4 ± 19.0 9.95 
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4. Conclusions 
In this chapter, a sensitive endoglycosidase-assisted LC-MS/MS assay based on immunoaffinity 
enrichment using magnet beads, consecutive two-step on bead partial deglycosylation and tryptic 
digestion followed by LC-MS/MS analysis was developed allowing for the multiplex quantification of 
core-fucosylated PSA down to 1 ng/mL and total PSA lower than 0.5 ng/mL in human serum. The 
method was shown to be linear from 0.5 to 60 ng/mL total PSA, clearly covering the critical grey area 
in PCa diagnosis. The imprecision of the method ranged from 9.7 % to 23.2 % for core-fucosylated 
PSA and 10.3 % to 18.3 % for total PSA depending on the PSA level, which is acceptable for the 
intended use in a biomarker refinement study. To meet the critical requirements as mass 
spectrometric application in the clinical routine, the imprecision of the method would have to be 
optimized as CV values are still too high. This could be achieved by internal standardization. As 
stable-isotope labeled (SIL) forms of PSA are at present commercially not available, the preparation 
of such standards could be a future task for the scientific community [108]. 
 
The feasibility of the method to detect core-fucosylated and total PSA in native samples was shown 
using three human specimens with low ng/mL total PSA concentrations. As there is little information 
about how large serum levels of core-fucosylated PSA differ in prostate cancer compared to benign 
conditions, the described method could be used in comprehensive patient cohorts to study the 
potential value of core-fucosylated PSA as a biomarker for discrimination between BPH and PCa or 
for identification of high aggressive PCa in the critical grey area ranging from 4 to 10 ng/mL. 
Moreover, by exchanging the total PSA antibody employed in this study, core-fucosylation analysis of 
free PSA is also feasible using a specific antibody against free PSA. As specific and sensitive 
methods for the simultaneous quantification of low-concentrated glycoproteins and its core-
fucosylated subpopulations are rare, the described strategy could also be used for the analysis of 
other low-concentrated glycoproteins in human serum to monitor their potential changes in 
site-specific core-fucosylation in different diseases [108].  
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Chapter IV: A case study: Is core-fucosylated prostate-specific 
antigen (PSA) a refined biomarker for differentiation of benign 
prostate hyperplasia (BPH) and prostate cancer of different 
aggressiveness? 
 
1. Introduction 
Prostate cancer (PCa) is the second most frequently diagnosed cancer and the fifth leading cause of 
cancer death in men, representing a major public health concern worldwide. In 2012, globally 
1.1 million estimated new cases were reported and approximately 307,500 men died from PCa [123]. 
These counts are expected to increase to nearly 1.7 million new PCa cases and 500,000 deaths until 
2030 [124]. Incidence rates of PCa vary by more than 25-fold worldwide, in which approximately 75 % 
of the registered cases occur in developed countries, largely due to the broad use of prostate-speciﬁc 
antigen (PSA) testing and subsequent biopsy in those regions. [125] The risk to develop PCa 
increases with advanced age, black race, familial predisposition and certain genetic changes [125].  
 
First indications of PCa can be obtained by digital rectal examination (DRE) and screening of PSA 
serum levels. The increase of total PSA representing abnormalities in prostate gland structure and 
vascularization has been associated with PCa since the mid-1980s [126]. Today, PSA serum levels 
are known to be elevated as well in situations including benign prostate hyperplasia (BPH), prostatitis 
or extrinsic manipulations of the prostate e.g. by bicycling or catheterization [127]. As a consequence, 
PSA testing lacks in specificity and results in an alarming number of false positive readings, especially 
when PSA values fall within the critical “grey area” ranging from 4 – 10 ng/mL leading to the risk of 
overdiagnosis and overtreatment with adverse side effects [4]. On the other hand, low non-diagnostic 
PSA serum concentrations were detected in men with aggressive PCa [128]. Several authors actually 
proposed to lower the PSA cut-offs to 1.5 or 2.6 – 4 ng/mL to enhance the likelihood for early 
detection of curable PCa (Early Warning PSA-zone, EWP Zone) [129-131]. Still, there is no clear PSA 
cut-off with simultaneous high sensitivity and high specificity for differentiation of benign from 
cancerous conditions nor non-aggressive from aggressive PCa forms [132]. Only aggressive PCa 
need immediate treatment, while observation might be sufficient for patients with non-aggressive 
PCa. Thus, new or refined biomarkers detecting clinically significant and aggressive PCa are highly 
demanded.   
 
In the past, numerous approaches have been proposed in order to tackle the limitations of PSA 
testing such as using of age-specific PSA cut-offs, normalizing PSA to the prostate volume (PSA 
density), and monitoring PSA kinetics in serum including PSA velocity (PSAV) and PSA doubling time 
(PSA-DT) [133-135]. However, only small improvements in predictive value have been found among 
these efforts. Improvements in the analysis of various molecular forms of PSA in serum have allowed 
the measurement of free PSA and its distinct cleavage isoforms pro-PSA and BPH-associated PSA 
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(BPSA) [120, 136, 137]. Other forms include complexed PSA which is bound to serum proteins, 
mainly to α1-antichymotrypsin and α2-macroglobulin [93]. The ratio of free PSA to total PSA (%-free 
PSA), which was shown by Catalona et al. to be decreased in PCa compared to BPH, has been 
approved by the FDA as an adjunct to total PSA in men with total PSA serum concentrations between 
4 and 10 ng/mL [138]. Although, %-free PSA slightly improved the ability to distinguish between PCa 
and BPH the most appropriate %-free PSA cut-off value remains debatable and the identification of 
non-aggressive and aggressive PCa is still not feasible. From a medical point of view it means that 
the final decision in PCa diagnosis still necessitates histopathological verification of adenocarcinoma 
in prostate cores derived from transrectal ultrasound (TRUS)-guided biopsy or in specimens obtained 
from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement 
[139]. These techniques are invasive and cause embarrassment or discomfort to patients [124]. An 
important part of the decision-making process concerning the need for active treatment or 
surveillance alone is the Gleason score (GS) grading system in which GS ≤ 6 are regarded as low risk 
cancer and GS > 6 as intermediate/high risk cancer [140]. However, early-stage PCa detection is 
challenging as the majority of prostatic cancers are slow growing and asymptomatic [141]. Besides 
GS, the reproducibility of which is not optimal, and PSA testing, a few new prognostic tests are now 
commercially available for PCa management [142, 143]. An urinary assay for Prostate Cancer 
Antigen 3 (PCA3), a prostate-specific, non-coding mRNA biomarker obtained after prostatic massage 
during DRE, appears to be useful for detection in men with elevated PSA but its usefulness for 
differentiation between non-aggressive and aggressive PCa is uncertain [144, 145]. The Prostate 
Health Index (PHI) test combines free, total and the (-2)pro-PSA into a single score. The 4Kscore test 
measures a panel of four kallikreins (free PSA, total PSA, intact PSA and kallikrein-like 
peptidase 2 [hK2]). Both tests are intended to reduce the number of unnecessary prostate biopsies in 
PSA tested men and demonstrated to outperform PCa detection by %-free PSA [146, 147]. These 
examples reveal that new markers in combination with conventional PSA are providing promise to aid 
in PCa diagnosis.  
 
The focus in the research community has currently been on discovering non-invasive markers derived 
from proteins, tumor cells or nucleic acids in the blood or urine of patients with prostate 
cancer [141, 148-152]. Among these targets, glycosylated proteins play an emerging role as it was 
shown that altered glycosylation patterns can be linked to oncologic malignancies such as breast, 
liver, colon or prostate cancer [153-156]. PSA also known as human kallikrein 3 (KLK3) is a 
28-32 kDa glycoprotein approximately containing 8 % (m/m) carbohydrates attached to a single 
N-glycosylation site at asparagine-69 [3, 157]. Changes in glycosylation of PSA associated with PCa 
development and progression have been analyzed in several foundational studies focusing on human 
samples of different origin including prostate tissue, cell lines, seminal fluid, urine and 
serum [2, 98, 158-160]. These studies span the breadth from whole glycoform profiling to targeted 
analysis of single glycan modifications such as terminal sialylation or site-specific 
core-fucosylation [4, 161]. With regard to the evaluation of glycosylation changes of PSA in human 
serum as prognostic and diagnostic marker for prostate cancer, some of these assays lack in 
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sensitivity for usage in the critical grey area or have not been tested using statistically significant 
sample numbers. In summary, currently there is no non-invasive diagnostic tool that can distinguish 
non-aggressive from aggressive tumors which would be of particular importance as recently shown by 
Wilt et al. after 20 years follow-up for PIVOT (Prostate Cancer Intervention versus Observation 
Trial) [158, 162]. Among men with localized PCa of different risk, surgery did not demonstrate 
significantly higher overall or PCa survival than observation, but was associated with higher frequency 
of adverse side-effects such as urinary incontinence and erectile dysfunction.  
 
The aim of this case study is to assess the potential diagnostic value of core-fucosylated PSA 
(fuc-PSA) as biomarker for differentiation of BPH and PCa and for identification of aggressive PCa. 
For this purpose a comprehensive patient cohort was used comprising 150 samples categorized into 
three groups: (1) BPH, (2) non-aggressive PCa (GS ≤ 6), and (3) aggressive PCa (GS > 6). In order 
to analyze the above specimens a previously developed endoglycosidase-assisted LC-MS/MS-based 
strategy was applied for the analysis of fuc-PSA in the low ng/mL range in human serum which is 
described in chapter III [108]. 
  
 Chapter IV: A case study: Is core-fucosylated PSA a refined biomarker in PCa diagnosis? 
101 
 
2. Experimental section 
2.1. Reagents and materials 
Streptavidin-coated magnetic particles (Ref. 11641786001), biotinylated monoclonal antibody PSA36 
against total PSA (= free + complexed PSA) binding to epitope 6b [84], total PSA CalSet II (Ref. 
04485220190) and PC TM1 control solution of the PreciControl Tumor Marker set (Ref. 
11776452122) were obtained from Roche Diagnostics GmbH (Mannheim, Germany). Phosphate 
buffered saline (PBS), trypsin from porcine pancreas, tween 20 and ammonium bicarbonate (ABC) 
were purchased from Sigma-Aldrich (St. Louis, USA). Endoglycosidase F3 (Endo F3) from 
Elizabethkingia meningosepticum was obtained from Ludger Ltd (Oxfordshire, UK). Anhydrous 
sodium acetate and glacial acetic acid were from Merck (Darmstadt, Germany). Acetonitrile (ACN) 
and formic acid (FA) both ULC/MS grade were purchased from Biosolve (Dieuze, France).  
 
2.2. Preparation of calibrators and control samples 
Calibrator solutions were prepared by using total PSA CalSet II, which contains calibrator 1 and 2 
consisting of human PSA in female serum matrix at 0 ng/mL and 60 ng/mL total PSA, respectively. 
The fucosylation degree of PSA spiked in calibrator 2 was determined to be 78 % by in-house LC-MS 
N-glycan analysis at Roche Diagnostics GmbH (Penzberg, Germany). Based on the two stock 
calibrators 1 and 2, five calibrator solutions Cal A, B, C, D and E were prepared at total PSA 
concentrations of 1, 3, 6, 9 and 12 ng/mL. Taking the fucosylation degree of 78 % into account, the 
fuc-PSA concentrations of Cal A-E were calculated to 0.78, 2.34, 4.67, 7.02 and 9.36 ng/mL. The PC 
TM1 control solution of the PreciControl Tumor Marker set served as a control sample during the 
entire study. Both calibrator solutions and the control sample were aliquoted and stored at -20 °C until 
analysis. 
 
2.3. Patient samples 
Serum samples were obtained from 50 BPH patients and 100 PCa patients provided by the HELIOS 
Klinikum Berlin-Buch, Charité Berlin, Urologische Klinik and Klinikum Ludwigshafen (all located in 
Germany), following the standard operating procedures of their Ethics Committee. Informed written 
consent was obtained from all subjects participating in the study. Total PSA serum levels of all 
samples were between 2 and 10 ng/mL. Serum samples were collected before any diagnostic 
procedure was started and stored at -80 °C until analysis. Repeated freezing and thawing was 
avoided. PCa diagnosis was verified using transrectal ultrasound-guided biopsy and/or 
adenomectomy/radical prostatectomy followed by histopathological analysis. 
 
BPH patients (age range 47-80 years) had total PSA serum levels ranging from 2.03-9.13 ng/mL 
(average of 5.12 ng/mL) and free PSA serum levels ranging from 0.18-2.52 ng/mL (average of 
1.03 ng/mL) (Table 17). PCa patients were classified according to the Gleason score (GS) grading 
system following the general guidelines of the European Association of Urology. GS were used from 
pathological examination or if not available from biopsy. Patients with GS ≤ 6 were assigned to the 
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non-aggressive PCa group and patients with GS > 6 were assigned to the aggressive PCa group as 
reported previously [163]. Hence, out of the 100 PCa patients, 50 patients (age range 49-78) were 
classified as non-aggressive PCa with total PSA serum levels ranging from 2.49-9.95 ng/mL (average 
of 5.82 ng/mL) and free PSA serum levels ranging from 0.28-1.86 ng/mL (average of 0.80 ng/mL) and 
50 patients (age range 52-75) were classified as aggressive PCa with total PSA serum levels ranging 
from 2.90-9.92 ng/mL (average of 5.86 ng/mL) and free PSA serum levels ranging from 
0.21-1.95 ng/mL (average of 0.76 ng/mL). In 9 patients of the non-aggressive PCa group (n = 50) and 
in 6 patients of the aggressive PCa group (n = 50) cell patterns associated with both BPH and PCa 
were observed in tissue samples derived from different regions of the prostate.  
 
2.4. Quantification of total and free PSA by ECLIA 
Total and free PSA levels of patient samples, calibrator solutions and the control sample were 
measured using commercially available Elecsys® total PSA electrochemiluminescence immunoassay 
(ECLIA) on the cobas e 601 analyzer at Roche Diagnostics GmbH (Penzberg, Germany) as 
described previously [59].  
 
2.5. LC-MS/MS-based analysis of total PSA and core-fucosylated PSA 
The method used for quantification of total PSA and its core-fucosylated subpopulation applying 
immunoaffinity enrichment, two enzymatic steps and LC-MS/MS analysis is described in detail in the 
previous chapter and a related manuscript [108]. Briefly, biotinylated anti-PSA antibody PSA36 was 
bound to streptavidin-coated magnetic particles. Afterwards, 100 µL serum sample were added to the 
antibody-bound magnetic particles to enrich total PSA from the complex serum matrix. By means of a 
magnet separator (DynaMag™-2 Magnet), the supernatant was removed and magnetic particles were 
washed to remove unspecific bound serum contaminants. Enriched PSA, still captured by the 
immunoaffinity complex, was partially deglycosylated using Endo F3 in order to simplify glycosylation 
complexity followed by tryptic digestion to generate surrogate peptides. The supernatant was 
transferred to a new vial, dried in a vacuum concentrator (Eppendorf concentrator 5301) and 
re-dissolved for LC-MS/MS analysis. Finally, total PSA and fuc-PSA were analyzed by measuring 
peptide LSEPAELTDAVK and glycopeptide N(GlcNAc+Fuc)K, respectively, using an Infinity 1290 
UHPLC from Agilent Technologies (Santa Clara, USA) connected to a QTRAP 6500 MS instrument 
equipped with TurboVTM Ion Source from AB Sciex (Darmstadt, Germany).  
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2.6. Study design 
In this study, up to 36 samples were analyzed per day, including calibrator solutions, control samples 
and patient samples. On each of the 19 study days samples were measured in the following 
sequence order: two blanks (acetonitrile containing 0.1 % FA), sample for system suitability pre-test 
(neat PSA-derived peptide solution), blank, calibrator solutions Cal A-D, control sample, patient 
samples, calibrator solutions Cal A-D, control sample, blank, sample for system suitability post-test, 
two blanks. Three replicates of each patient sample were randomly distributed on the 19 study days 
and individually analyzed. In total, 678 single measurements consisting of 190 calibrator solutions, 
38 control samples and 450 patient samples were performed.  
 
2.7. Data analysis and statistics 
Total PSA and fuc-PSA were analyzed by peak integration of their respective surrogate peptides 
LSEPAELTDAVK and N(GlcNAc+Fuc)K using Analyst software (Version 1.6.2, AB Sciex). Automatic 
peak integration was performed by the IntelliQuant integration algorithm. Peaks were integrated 
manually, if peak assignment was incorrect or peak integration was inadequate. Using calibrator 
solutions Cal A-E, calibration curves for total PSA and fuc-PSA were generated by plotting peak areas 
of their respective surrogate peptides LSEPAELTDAVK and N(GlcNAc+Fuc)K (y) against respective 
analyte concentrations (x). As described before, on each study day one set of calibrator solutions 
Cal A-E was analyzed at the beginning and one set at the end of a LC-MS/MS sequence (calibrator 
bracketing) giving two calibration curves for total PSA and two for fuc-PSA. Both calibrator sets were 
taken together, resulting in average calibration curves for total and fuc-PSA, which were used for 
calculation of total and fuc-PSA concentrations of patient samples and control samples. Method 
comparison using total PSA serum levels measured by LC-MS/MS and ECLIA was performed by 
Deming Regression using software JMP 12.1.0. The %-core-fucosylated PSA of each patient was 
calculated as the median of fuc-PSA serum levels divided by the median of total PSA serum levels 
obtained from three LC-MS/MS replicates (%-fuc-PSA-MS). The median of fuc-PSA serum levels 
obtained by LC-MS/MS analysis was also standardized to total PSA serum levels measured by ECLIA 
(%-fuc-PSA-ECLIA). Patients were divided into three groups: (1) BPH, (2) non-aggressive PCa, and 
(3) aggressive PCa. Receiver operating characteristic (ROC) curves and box plot diagrams were 
prepared using the free software R 3.2.2 available at https://www.R-project.org in order to evaluate 
the diagnostic value of fuc-PSA for differentiation of PCa patients from participants with BPH. ROC 
curves were also used to investigate the diagnostic value of fuc-PSA with regards to the 
aggressiveness of PCa according to the GS which were used as the boundary between non-
aggressive (GS ≤ 6) and aggressive PCa (GS > 6). Standardized (%-fuc- PSA) and non-standardized 
core-fucosylated PSA (fuc-PSA) were compared to free PSA, total PSA and %-free PSA (= free PSA 
standardized to total PSA). Differences in clinical groups were tested using the Wilcoxon rank sum 
test. Confidence levels for the area under the ROC curve were calculated by the DeLong method 
[164]. 
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3. Results 
A previously described LC-MS/MS-based method was applied on a patient cohort consisting of 
150 specimens in order to evaluate the potential value of core-fucosylated PSA (fuc-PSA) as 
biomarker for discrimination between BPH and PCa or for identification of aggressive PCa in the low 
ng/mL concentration range. Total PSA serum levels of patient samples ranged from 2-10 ng/mL 
clearly covering the critical grey area in PCa diagnosis. Each patient sample was measured in 
triplicate resulting in average coefficients of variation (CV) of 13.9 % for fuc-PSA and 8.7 % for total 
PSA. CV values > 20 % were observed in 21 out of 150 patient samples for fuc-PSA and in 7 out of 
150 patient samples for total PSA. The median of fuc-PSA and total PSA were used for data analysis 
which showed good robustness to outliers.   
 
As mentioned before, all LC-MS/MS measurements were monitored by a control sample which was 
analyzed in duplicate on each of the 19 study days. The average fuc-PSA concentration over all study 
days was 3.41 ng/mL with a CV value of 11.4 % and the average total PSA concentration was 
4.77 ng/mL with a CV value of 7.0 %. The measured total PSA concentration was in excellent 
accordance with results previously determined by ECLIA giving a total PSA concentration of 
4.72 ng/mL. The average %-fuc-PSA-MS was 71.4 % with a CV value of 9.8 %. Comparison of total 
PSA concentrations of 150 patient samples measured by LC-MS/MS and ECLIA performing a 
Bland-Altman analysis showed a good agreement between the two methods with a mean bias of 
1.9 % and a 2S agreement range of ± 16.1 % (Figure 44). Method comparison using the Deming 
Regression procedure assuming equal error variances resulted in a regression equation of 
y = 0.88 x + 0.52. The Spearman’s rank correlation coefficient ρ was 0.98 (Figure 45). As shown in 
control charts of fuc-PSA, total PSA and %-fuc-PSA-MS, no specific trends could be observed within 
the 19 study days (Figure 46). 
 
 
Figure 44: Relative Bland Altman plot for the comparison of total PSA serum concentrations of 150 
patients measured by ECLIA and LC-MS/MS. The comparison of results showed a good agreement 
between the two methods with a mean bias of - 1.9 % and a 2S agreement range of ± 16.1 %. 
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Figure 45: Method comparison using Deming Regression assuming equal error variances obtained 
by quantitative ECLIA and LC-MS/MS analysis of total PSA serum concentrations of 150 patient 
samples. The Spearman’s rank correlation coefficient ρ was 0.98. 
 
Figure 46: Control charts of serum levels of a) core-fucosylated PSA (fuc-PSA), b) total PSA and c) 
%-core-fucosylated PSA standardized by total PSA from LC-MS/MS (%-fuc-PSA-MS) obtained by 
repetitive analysis of a control sample at 19 study days. Blue line = mean. 
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ROC curve analysis was performed using all 150 patient samples in order to investigate the 
diagnostic value of fuc-PSA for differentiation of BPH (n = 50) from PCa (n = 100) (Figure 47, 
Table 18). Initially, ROC curve analysis was performed using several serum parameters including 
non-standardized fuc-PSA (AUC = 0.58) and standardized %-fuc-PSA-MS (AUC = 0.54) or 
%-fuc-PSA-ECLIA (AUC = 0.51). These results were compared to the AUC values of free PSA 
(AUC = 0.63), total PSA (AUC = 0.60) and %-free PSA (AUC = 0.74) measured by ECLIA and 
revealed that both non-standardized and standardized fuc-PSA had no diagnostic value for 
differentiation of BPH from PCa compared to conventional diagnostic PCa markers. ROC curves were 
also used to investigate the predictive power of fuc-PSA in the identification of aggressive PCa 
(Table 19). The GS was used as a cut-off point between non-aggressive PCa (GS ≤ 6) and 
aggressive PCa (GS > 6). Results from serum samples of 100 patients diagnosed with PCa showed a 
slight diagnostic value for %-fuc-PSA-MS (AUC = 0.57) and a more meaningful value for 
%-fuc-PSA-ECLIA (AUC = 0.60). The AUC values of non-standardized fuc-PSA (AUC = 0.53), free 
PSA (AUC = 0.52), total PSA (AUC = 0.52) and %-free PSA (AUC = 0.55) were slightly inferior to 
AUC values obtained by using %-fuc-PSA (Figure 47). As shown in Figure 48, the aggressive PCa 
group showed decreased %-fuc-PSA values (Q1-Q3: 71-84 %) than non-aggressive PCa patients 
(Q1-Q3: 74-90 %). The PSA core-fucosylation ratio did not correlate with their total PSA levels and 
was therefore independent of the total PSA level in each of the patient groups (Figure 49). 
 
Table 18: AUC values obtained by ROC curve analysis of 50 BPH and 100 PCa patients. 
Acronym Biomarker (platform) Standard (platform) AUC (95%-CI) 
fuc-PSA core-fucosylated PSA (MS) none 0.58 (0.48-0.68) 
%-fuc-PSA-MS core-fucosylated PSA (MS) total PSA (MS) 0.54 (0.43-0.64) 
%-fuc-PSA-ECLIA core-fucosylated PSA (MS) total PSA (ECLIA) 0.51 (0.41-0.62) 
free PSA free PSA (ECLIA) none 0.63 (0.53-0.73) 
total PSA total PSA (ECLIA) none 0.60 (0.50-0.70) 
%-free PSA free PSA (ECLIA) total PSA (ECLIA) 0.74 (0.65-0.83) 
CI: Confidence intervals 
 
Table 19: AUC values obtained by ROC curve analysis of 50 non-aggressive PCa (GS ≤ 6) and 50 
aggressive PCa (GS > 6) patients. 
Acronym Biomarker (platform) Standard (platform) AUC (95%-CI) 
fuc-PSA core-fucosylated PSA (MS) none 0.53 (0.42-0.65) 
%-fuc-PSA-MS core-fucosylated PSA (MS) total PSA (MS) 0.57 (0.45-0.68) 
%-fuc-PSA-ECLIA core-fucosylated PSA (MS) total PSA (ECLIA) 0.60 (0.49-0.71) 
free PSA free PSA (ECLIA) none 0.52 (0.41-0.64) 
total PSA total PSA (ECLIA) none 0.52 (0.40-0.63) 
%-free PSA free PSA (ECLIA) total PSA (ECLIA) 0.55 (0.43-0.66) 
CI: Confidence intervals 
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Figure 47: Comparison of ROC curves for free PSA, total PSA, %-free PSA, %-core-fucosylated PSA 
standardized to total PSA determined by ECLIA (%-fuc-PSA-ECLIA). The %-fuc-PSA-ECLIA gave the 
highest AUC value (AUC = 0.60) for differentiation of non-aggressive (GS ≤ 6) and aggressive PCa 
(GS > 6).  
 
Figure 48: Box-plot of %-core-fucosylated PSA standardized by total PSA from ECLIA (%-fuc-PSA-
ECLIA) used for differentiation of non-aggressive (GS ≤ 6) and aggressive PCa (GS > 6). The center 
line represents the median. The bottom (Q1) and the top (Q3) of the box represent the 25th and 75th 
percentiles, respectively. 
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Figure 49: Scatter plot of %-core-fucosylated PSA standardized by total PSA from ECLIA (%-fuc-
PSA-ECLIA) against total PSA serum levels measured by ECLIA (n = 150). The PSA core-
fucosylation ratio did not correlate with their total PSA levels in none of the patient groups (BPH, non-
aggressive PCa and aggressive PCa).   
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4. Discussion 
In a cohort of 150 patient samples, measurement of fuc-PSA showed a slightly improved diagnostic 
differentiation between aggressive and non-aggressive PCa in comparison to standard free- and total 
PSA tests. Several studies, mostly based on enzyme-linked lectin assays (ELLA), have been applied 
to assess whether differences in terminal or core-fucosylation of PSA either in urine, seminal fluid, 
blood or tissue enable discrimination of BPH from PCa or identification of aggressive 
PCa [93, 99, 160, 165]. These lectin immunoassays have the same basic format as a standard 
enzyme-linked immunosorbent assay (ELISA), in which one antibody is replaced by a lectin 
recognizing carbohydrate moieties. However, reports with contradictory results have been described 
which might be due to the use of different sample matrices or different lectins (Table 20). For 
example, a significant decrease of core-fucosylated PSA with an AUC = 0.94 was recently reported by 
Llop et al. in GS > 6 PCa serum samples using Pholiota squarossa lectin (PhoSL), while Li et al. 
found an increase in PSA core-fucosylation in serum of high-risk PCa patients with an AUC = 0.86 
using Aleuria aurantia lectin (AAL) [4, 163].  
In order to expand the field, the present work describes an LC-MS/MS-based study for evaluation of 
site-specific core-fucosylation changes of PSA in human sera derived from patients diagnosed with 
BPH and PCa of different degrees of aggressiveness. Total PSA serum concentrations of patient 
samples ranged from 2-10 ng/mL and thus, did not exceed the critical grey area of PCa diagnosis. In 
former lectin-based studies, patient samples with higher serum concentrations (up to 110 ng/mL) or 
urine samples with very high total PSA levels by nature (µg/mL range) were analyzed [4, 160, 165]. 
This is largely because of the lack in sensitivity of these assays as lectins possess 100-10,000-fold 
lower binding affinities than antibodies [166]. In addition, low specificity of lectins towards glycan 
structures and their unspecific binding to glycoproteins from human matrix is an inherent problem of 
lectins resulting in high background signals obscuring the analyte signal of interest and worsening the 
limit of detection. Considering the low amount of core-fucosylated PSA in the critical grey area 
compared to the immense amount of other glycoproteins in blood, analysis of serum or plasma 
samples by lectin-based assays is challenging. In this study, these limitations could be tackled by 
combining the sensitivity of immunoassays with the specificity of mass spectrometric detection [108]. 
Patient samples (n = 150) used in this study were equally distributed into three groups (1) BPH, 
(2) non-aggressive PCa (GS ≤ 6), and (3) aggressive PCa (GS > 6) in which classification was 
performed according to the GS as reported previously [163]. Method comparison showed a good 
agreement between total PSA levels obtained by LC-MS/MS and ECLIA with approximately 10 % bias 
which seems to be correctable by proper calibration. The %-core-fucosylated PSA variation 
(%-fuc-PSA-MS) in a control sample monitored over all 19 study days was lower than 10 % indicating 
the feasibility of the applied method for measuring fuc-PSA in the critical grey area. 
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Table 20: Overview of previous case studies on terminal and core-fucosylated PSA in different 
sample matrices using ELLA-type approaches. 
First author 
[Reference] 
Target Sample 
matrix 
Lectin 
used in 
ELLA 
Number of cases 
(total serum PSA in 
ng/mL) 
Fucosylation 
degree of PSA in 
PCa 
Llop et al.[4] core-
fucosylated 
PSA 
serum PhoSL BPH: 20 (7.8-18.2)  
PCa (GS 7-10): 20  
(8.7-109.7) 
decreased 
(AUC=0.94, 
Sens. 90 %, 
Spec. 95 %) 
Barrabés et 
al. [160] 
core-
fucosylated 
PSA 
urine PhoSL benign: 18 (1.4-9.2) 
PCa: 35 (2.3-1400) 
no significant 
differences 
Kekki et al. 
[165] 
core-
fucosylated 
PSA 
urine AAL BPH: 15 (n/a) 
PCa: 16 (n/a) 
increased (p=0.030) 
Li et al. [163] core-
fucosylated 
PSA 
serum AAL PCa (GS 6-9): 47  
(1.9-54.5) 
increased in  
GS > 7 (AUC=0.86) 
GS > 6 (AUC=0.77) 
Dwek et al. 
[93] 
terminal 
fucosylated 
PSA 
serum UEA-1 BPH: 13 (1.9-9.1)  
PCa: 13 (3.4-10.7) 
increased  
(Sens. 92 %, 
Spec. 69 %) 
Fukushima et 
al. [99] 
terminal 
fucosylated 
PSA 
serum TJA-II BPH: 20 (n/a) 
PCa: 20 (n/a) 
increased (p<0.05) 
PhoSL: Pholiota squarossa lectin (recognizes core α(1,6)-linked fucoses) 
UEA-1: Ulex europaeus agglutinin (recognizes terminal α(1,2)-linked fucoses) 
AAL: Aleuria aurantia lectin (recognizes core α(1,6)- and α(1,3)-linked fucoses)   
TJA-II: Trichosanthes japonica agglutinin-II (recognizes terminal α(1,2)-linked fucoses and β-N-
acetylglucosamine residues) 
GS: Gleason score 
n/a: not applicable 
 
 
The diagnostic power of fuc-PSA was assessed by ROC curve analysis and revealed two major 
findings. First, fuc-PSA (AUC = 0.58), %-fuc-PSA-MS (AUC = 0.54), and %-fuc-PSA-ECLIA 
(AUC = 0.51) had no diagnostic value for differentiation of BPH from PCa compared to conventional 
diagnostic PCa markers in which %-free PSA gave the highest AUC value (AUC = 0.74). Decreased 
%-free PSA serum levels in PCa compared to BPH patients have been also reported in a 
comprehensive study including 773 men [138]. Second, the highest AUC for differentiation of 
non-aggressive and aggressive PCa was obtained using %-fuc-PSA standardized by total PSA 
determined by ECLIA (%-fuc-PSA-ECLIA, AUC = 0.60) which was slightly better than standardization 
to total PSA obtained by LC-MS/MS (%-fuc-PSA-MS, AUC = 0.57). This could probably be due to the 
higher imprecision of the LC-MS/MS method compared to the routinely used ECLIA workflow. Both 
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%-fuc-PSA values performed better than conventional markers such as free, total and %-free PSA (all 
AUC ≤ 0.55). The %-fuc-PSA-ECLIA was found to be slightly decreased in the aggressive PCa group 
which is in agreement with reported results from serum, seminal fluid and urine [3, 4, 167, 168]. 
However, the obtained results were not as powerful as stated in previous studies which might be for 
different reasons. First, a subset of patient samples was used in this study which might possess only 
small differences in core-fucosylation degree of serum PSA. These changes would not be detectable 
by the method applied in this study. At present, there is little information about how pronounced 
differences in native serum samples actually are. Second, in previous studies patient samples with 
higher total PSA serum levels ranging from 8 to 110 ng/mL or 2 to 55 ng/mL were analyzed and total 
PSA values alone already identified high-risk PCa with AUC values of 0.89 or 0.81, 
respectively [4, 163]. Finally, selected patient panels in those studies were rather small (40 and 47 
samples), which why larger scale studies might be necessary to further validate these findings. 
Although, it was the first time such a high number of patient samples (n = 150) was used for studying 
site-specific core-fucosylation changes of serum PSA, increasing number of patient samples could 
help to consolidate the obtained results as well. As shown in this and previous studies, a single 
biomarker (e.g. core-fucosylated PSA alone) might only unlikely possess diagnostic strength to 
indicate the likelihood of aggressive PCa. On the other hand, a combination of several complimentary 
biomarkers (e.g. ratio of core-fucosylated PSA to total PSA) may have potential for improvement of 
both clinical sensitivity and specificity.  
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5. Conclusions  
In summary, a previously developed endoglycosidase-assisted LC-MS/MS-based approach was used 
to analyze serum core-fucosylated PSA from BPH and PCa patients of different degrees of 
aggressiveness (n = 150). The data revealed that %-fuc-PSA standardized to total PSA was slightly 
decreased in GS > 6 patient samples representing aggressive PCa and had better diagnostic power 
than conventional total PSA. However, on the basis of these findings it is still uncertain if %-fuc-PSA 
could be used clinically to improve and facilitate the differentiation of non-aggressive from aggressive 
tumors. Further validation in larger patient cohorts or the usage of improved methods regarding assay 
imprecision will be required to confirm obtained results of this study.  
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Identified peptides of reduced and alkylated prostate-specific antigen (PSA, Uni-ProtKB P07288) after 
partial deglycosylation and subsequent proteolytic digestion are shown for the following enzymes: 
 
Trypsin 
Sequence Modifications z [M+H]+ MC 
VVHYR  1 673.3781 0 
DTIVANP  2 729.3774 0 
SVILLGR  2 757.4927 0 
FMLcAGR C4(CAM) 2 854.4010 0 
FmLcAGR M2(OX); C4(CAM) 2 870.3959 0 
IVGGWEcEK C7(CAM) 2 1077.5034 0 
WIKDTIVANP  2 1156.6361 1 
LSEPAELTDAVK  2 1272.6679 0 
KWIKDTIVANP  2 1284.7304 2 
HSQPWQVLVASR  2 1407.7491 0 
FLRPGDDSSHDLMLLR  3 1871.9447 0 
FLRPGDDSSHDLmLLR M13(OX) 3 1887.9394 0 
NRFLRPGDDSSHDLMLLR  3 2142.0872 1 
NRFLRPGDDSSHDLmLLR M15(OX) 3 2158.0820 1 
AVcGGVLVHPQWVLTAAHcIR C3(CAM); C19(CAM) 3 2344.2183 0 
LQcVDLHVISNDVcAQVHPQK C3(CAM); C14(CAM) 3 2460.2135 0 
IVGGWEcEKHSQPWQVLVASR C7(CAM) 3 2466.2346 1 
KLQcVDLHVISNDVcAQVHPQK C4(CAM); C15(CAM) 2 2588.3060 1 
LQcVDLHVISNDVcAQVHPQKVTK C3(CAM); C14(CAM) 3 2788.4243 1 
KLQcVDLHVISNDVcAQVHPQKVTK C4(CAM); C15(CAM) 3 2916.5225 2 
HSLFHPEDTGQVFQVSHSFPHPLYDMSLLK  4 3493.7055 0 
HSLFHPEDTGQVFQVSHSFPHPLYDmSLLK M26(OX) 3 3509.6979 0 
VmDLPTQEPALGTTcYASGWGSIEPEEFLTPK M2(OX); C15(CAM) 3 3540.6566 0 
 
Elastase 
Sequence Modifications z [M+H]+ MC 
DLHVI  1 596.3399 2 
TKFML  2 639.3533 0 
SEPAEL  1 645.3087 1 
ELTDAV  1 647.3243 2 
RLSEPA  1 672.3674 1 
YDMSLL  1 741.3489 1 
QVHPQKV  2 835.4779 1 
cNGVLQGI C1(CAM) 1 860.4292 2 
QcVDLHV C2(CAM) 2 870.4135 2 
TKFMLcA C6(CAM) 2 870.4211 1 
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TKFmLcA M4(OX); C6(CAM) 2 886.4163 1 
RLSEPAEL  1 914.4941 2 
SHSFPHPL  2 921.4573 0 
MDLPTQEPA  2 1001.4605 0 
mDLPTQEPA M1(OX) 2 1017.4555 0 
KVMDLPTQEPA  2 1228.6249 1 
HYRKWIKDTI  2 1359.7535 1 
VHYRKWIKDTI  2 1458.8218 2 
GRHSLFHPEDTGQV  2 1579.7621 1 
SHSFPHPLYDMSLL  2 1643.7918 2 
SHSFPHPLYDmSLL M11(OX) 2 1659.7882 2 
SGWGSIEPEEFLTPKKL  2 1917.9954 2 
IVGGWEcEKHSQPWQV C7(CAM) 2 1939.9130 2 
VGGWEcEKHSQPWQVL C6(CAM) 2 1939.9130 2 
GGWEcEKHSQPWQVLV C5(CAM) 2 1939.9130 2 
GRHSLFHPEDTGQVFQV  2 1953.9589 2 
TSWGSEPcALPERPSLYTKV C8(CAM) 2 2278.1184 2 
 
Proteinase K 
Sequence Modifications z [M+H]+ MC 
cGGVL C1(CAM) 1 505.24385 1 
FHPE  1 529.24042 1 
IVGGW  1 531.29175 2 
QEPAL  1 557.29305 2 
GSIEPE  1 631.29304 2 
DTGQVF  1 666.30908 2 
RLSEPA  1 672.36708 2 
cSGDSGGPL C1(CAM) 1 849.34072 0 
SHSFPHPL  2 921.45754 1 
PHPLYDmSL M7(OX) 2 1088.51122 2 
LRPGDDSSHDL  2 1211.56523 1 
KNRFLRPGDDSSHDL  2 1756.87355 2 
 
Thermolysin 
Sequence Modifications z [M+H]+ MC 
VLQG  1 416.2503 1 
VTKF  1 494.2972 1 
IVANP  1 513.3030 2 
VISND  1 547.2722 1 
VcGGVL C2(CAM) 1 604.3123 1 
LYTKV  2 623.3759 1 
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LYDMS  1 628.2647 1 
LQcVD C3(CAM) 1 634.2864 1 
LSEPAE  1 645.3088 1 
LTDAVK  2 646.3768 2 
LLGRHS  2 682.3993 0 
LGRHSL  2 682.3993 0 
LGTTcY C5(CAM) 1 714.3124 0 
LYDMSL  1 741.3484 1 
LYDmSL M4(OX) 1 757.3436 1 
IEPEEF  2 763.3509 1 
VHPQWV  2 765.4043 0 
ALPERPS  1 769.4202 1 
LLKNRF  2 790.4931 1 
LQcVDLH C3(CAM) 2 884.4292 1 
VSHSFPHP  2 907.4419 1 
LRLSEPAE  2 914.4938 1 
FHPEDTGQ  2 930.3946 0 
MDLPTQEPA  2 1001.4611 2 
mDLPTQEPA M1(OX) 2 1017.4559 2 
FHPEDTGQV  2 1029.4633 1 
LFHPEDTGQ  2 1043.4784 1 
LRPGDDSSHD  2 1098.4805 0 
LFHPEDTGQV  2 1142.5478 2 
LRPGDDSSHDL  2 1211.5652 0 
FLRPGDDSSHD  2 1245.5500 1 
FHPEDTGQVFQ  2 1304.5896 1 
IEPEEFLTPKK  2 1330.7257 2 
LRPGDDSSHDLM  2 1342.6051 1 
LRPGDDSSHDLm M12(OX) 2 1358.6005 1 
VLQGITSWGSEPc C13(CAM) 2 1433.6699 2 
ITSWGSEPcALPERPS C9(CAM) 2 1786.8433 2 
AGRWTGGKSTcSGDSGGPL C11(CAM) 2 1850.8465 1 
LcAGRWTGGKSTcSGDSGGPL C2(CAM); C13(CAM) 2 2123.9599 1 
AGRWTGGKSTcSGDSGGPLVcNG C11(CAM); C21(CAM) 2 2281.0072 2 
 
Protease Arg-C 
Sequence Modifications z [M+H]+ MC 
KWIKDTIVANP  2 1284.7314 0 
nKSVILLGR N1(HexNAc-dHex) 2 1348.7683 0 
PSLYTKVVHYR  2 1362.7527 0 
PGDDSSHDLMLLR  2 1455.6905 0 
PGDDSSHDLmLLR M10(OX) 2 1471.6857 0 
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FLRPGDDSSHDLMLLR  3 1871.9442 1 
FLRPGDDSSHDLmLLR M13(OX) 3 1887.9399 1 
AVcGGVLVHPQWVLTAAHcIR C3(CAM); C19(CAM) 3 2344.2185 0 
IVGGWEcEKHSQPWQVLVASR C7(CAM) 3 2466.2340 0 
WTGGKSTcSGDSGGPLVcNGVLQGITSWGSE
PcALPER 
C8(CAM); C18(CAM); 
C33(CAM) 
3 3977.8152 0 
 
Pepsin (pH = 1.3) 
Sequence Modifications z [M+H]+ MC 
VcNGVL C2(CAM) 1 661.3334 0 
PERPSL  2 698.3830 0 
GSEPcAL C5(CAM) 1 733.3189 0 
PTQEPAL  1 755.3937 0 
LGRHSLF  2 829.4678 2 
VHPQWVL  2 878.4886 1 
GSIEPEEF  1 907.4048 0 
RLSEPAEL  2 914.4939 1 
TDAVKVMDL  2 991.5134 0 
LRLSEPAEL  1 1027.5785 2 
HPEDTGQVF  2 1029.4636 0 
FHPEDTGQVF  2 1176.5314 1 
VASRGRAVcGGVL C9(CAM) 2 1301.7098 0 
LTPKKLQcVDL C8(CAM) 2 1314.7444 2 
LRPGDDSSHDLML  2 1455.6906 2 
RPGDDSSHDLMLL  2 1455.6906 2 
LRPGDDSSHDLmL M12(OX) 2 1471.6848 2 
RPGDDSSHDLmLL M11(OX) 2 1471.6848 2 
EcEKHSQPWQVL C2(CAM) 2 1540.7221 1 
TAAHcIRnKSVIL C5(CAM); N8(HexNAc) 2 1685.9016 0 
TDAVKVMDLPTQEPAL  2 1727.8901 1 
TDAVKVmDLPTQEPAL M7(OX) 2 1743.8865 1 
TGGKSTcSGDSGGPLVcNGVL C7(CAM); C17(CAM) 2 2022.9214 1 
IVGGWEcEKHSQPWQVL C7(CAM) 2 2052.9985 2 
QGITSWGSEPcALPERPSL C11(CAM) 2 2084.9873 2 
HVISNDVcAQVHPQKVTKF C8(CAM) 2 2207.1409 0 
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Chymotrypsin 
Sequence Modifications z [M+H]+ MC 
DmSLL M2(OX) 1 594.2803 2 
QcVDL C2(CAM) 1 634.2862 0 
VcNGVL C2(CAM) 1 661.3333 0 
KNRFL  1 677.4089 1 
LKNRF  1 677.4089 1 
LTPKKL  2 699.4763 1 
GRHSLF  2 716.3837 1 
TKVVHY  2 746.4192 0 
TDAVKVM  2 763.4017 0 
TDAVKVm M7(OX) 1 779.3970 0 
LGRHSLF  1 829.4679 2 
VHPQWVL  2 878.4887 1 
GSIEPEEF  2 907.4042 0 
RLSEPAEL  2 914.4942 1 
IKDTIVANP  2 970.5566 0 
LRLSEPAEL  2 1027.5782 2 
HPEDTGQVF  2 1029.4632 0 
QVSHSFPHPL  2 1148.5843 0 
FHPEDTGQVF  2 1176.5318 1 
EcEKHSQPW C2(CAM) 2 1200.5102 0 
LRPGDDSSHDL  2 1211.5656 1 
RPGDDSSHDLM  2 1229.5215 1 
RPGDDSSHDLm M11(OX) 2 1245.5170 1 
VASRGRAVcGGVL C9(CAM) 2 1301.7101 0 
QVSHSFPHPLY  2 1311.6471 1 
RPGDDSSHDLML  2 1342.6053 2 
LRPGDDSSHDLM  2 1342.6054 2 
LRPGDDSSHDLm M12(OX) 2 1358.6002 2 
RPGDDSSHDLmL M11(OX) 2 1358.6011 2 
TGGKSTcSGDSGGPL C7(CAM) 2 1380.6059 0 
SEPAELTDAVKVm M13(OX) 2 1405.6888 1 
RKWIKDTIVANP  2 1440.8316 1 
DLPTQEPALGTTcY C13(CAM) 2 1565.7165 1 
GSEPcALPERPSLY C5(CAM) 2 1575.7484 1 
RLSEPAELTDAVKVM  3 1658.8795 2 
RLSEPAELTDAVKVm M15(OX) 3 1674.8752 2 
IVGGWEcEKHSQPW C7(CAM) 2 1712.7871 1 
GRHSLFHPEDTGQVF  3 1726.8292 2 
TGGKSTcSGDSGGPLVcNGVL C7(CAM); C17(CAM) 2 2022.9213 1 
VASRGRAVcGGVLVHPQWVL C9(CAM) 3 2161.1831 2 
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TDAVKVMDLPTQEPALGTTcY C20(CAM) 2 2310.1043 2 
QcVDLHVISNDVcAQVHPQKVTKF C2(CAM); C13(CAM) 3 2822.4099 1 
QcVDLHVISNDVcAQVHPQKVTKFM C2(CAM); C13(CAM) 4 2953.4406 2 
 
CAM = Carbamidomethylation (+57.021 Da) 
OX = Oxidation (+15.995 Da)  
HexNAc = N-glycosylation with GlcNAc (+203.079 Da) 
HexNAc-dHex = N-glycosylation with GlcNAc + Fuc (+349.137 Da) 
z = Charge state 
MC = Missed cleavage 
